2.2　SP0961 試験［発作コントロールが得られていない強直間代発作を有するてんかん患者を対象とするラコサミド併用療法における安全性を検討する非盲検、パイロット試験］（5.3.5.2.2：参考資料）

治験方法の概略（表 2.2-1）及び結果の要約を示した。

表 2.2-1　試験方法の概略

項目	内容
標題	発作コントロールが得られていない強直間代発作を有するてんかん患者を対象に、併用療法としてラコサミドを経口投与した時の安全性を評価する非盲検、パイロット試験
開発の相	第 II 相
目的	発作コントロールが得られていない強直間代発作を有するてんかん患者を対象に、併用療法としてラコサミドを経口投与した時の安全性を評価する
治験デザイン	多施設共同、非盲検
治験方法	試験デザインの概要を図 2.2-1 に示した。 本治験は、Prospective ベースライン期間（4 週間）、増量期間（3 週間）、維持期間（6 週間）及び治験終了期間（3 週間）から構成された。また、Prospective ベースライン期間前の 12 週間を Historical ベースライン期間とし、2 つを合わせた期間を Combined ベースライン期間（16 週間）とした。増量期間と維持期間を合わせた期間を治療期間（9 週間）とした。 Prospective ベースライン期間の第 1 回来院（第 0 週）時に被験者の適格性を確認した。発作回数及び発作型分類の適格性は、Historical ベースライン期間で収集された発作記録（例：発作日誌）で確認した。また、第 1 回来院の 2 週間後に電話調査で継続的な適格性を確認した。第 2 回来院（第 4 週の終わり）前日の朝から第 2 回来院まで、被験者にポータブル 24 時間脳波検査を実施した。脳波検査は、治験薬の初回投与前に完了した。Prospective ベースライン期間を完了した被験者は、増量期間に移行した。 増量期間では、第 2 回来院時に適格性が認められた被験者に治験薬の投与を開始した。開始用量を 100 mg/日とし、1 週間継続後、臨床的に問題がないと判断された場合は、第 3 回来院（第 5 週の終わり）時、第 4 回来院（第 6 週の終わり）時及び第 5 回来院（第 7 週の終わり）時にそれぞれ 200、300 及び 400 mg/日に増量した。増量期間を完了した被験者は、維持期間に移行した。 維持期間では、増量期間完了時の用量を継続して投与した。第 6 回来院（第 8 週の終わり）前日の朝から第 6 回来院まで、被験者にポータブル 24 時間脳波検査を実施した。第 7 回来院（第 13 週の終わり、最終の規定来院）時に維持期間を完了し、継続投与試験の SP0962 試験への参加を希望した被験者は、第 7 回来院を SP0962 試験の第 1 回来院とした。SP0962 試験への参加を希望しない被験者又は参加基準を満たさない被験者は、治験終了期間に移行した。 なお、増量期間及び維持期間を通じて、忍容性に問題がある場合は、1 回のみ 1 段階（100 mg/日）の減量を可能とした。減量した場合は、再度増量することは不可とし、

表 2.2-1 試験方法の概略（続き）

項目	内容
治験方法（続き）	減量後も忍容性に問題がある場合は、治験を中止した。治験の中止について、治験責任医師は可能な限りメディカルモニターに相談した上で決定した。 治験終了期間では、維持期間に 300 又は 400 mg/日を投与された被験者には、毎週 200 mg/日ずつ減量することを推奨した。これらの被験者には、第 14 週の終わりに減量完了来院を、最終投与 2 週間後（第 16 週の終わり）に治験終了来院を実施した。また、維持期間に 100 又は 200 mg/日を投与された被験者は、減量せずに第 7 回来院で治験薬の投与を終了した。これらの被験者には、減量完了来院を実施せず、最終投与 3 週間後（第 16 週の終わり）に治験終了来院を実施した。
併用薬及び併用療法	併用抗てんかん薬： 1～3 剤の抗てんかん薬の併用を可能とした。第 1 回来院の 28 日以上前から一定の用法・用量で使用し、Prospective ベースライン期間中の変更は不可とした。てんかんの治療を目的としたベンゾジアゼピン系薬剤は、併用抗てんかん薬 1 剤としてカウントした。 なお、治験期間中に併用抗てんかん薬の変更が必要な場合は、治験責任医師は治験の中止について可能な限りメディカルモニターに相談した上で決定した。 併用制限薬及び併用制限療法： 迷走神経刺激療法（VNS）：組入れの 6 ヵ月以上前に取り付けており、第 1 回来院の 28 日以上前から設定が一定に保たれていた場合は、併用を可能とした。 Prospective ベースライン期間中の変更は不可とした。 ベンゾジアゼピン系薬剤：てんかん以外の治療を目的とし、用法・用量を変更せずに使用する場合は、併用を可能とした。なお、てんかん以外の治療を目的としても併用抗てんかん薬 1 剤としてカウントした。 緊急処置薬： ベンゾジアゼピン系薬剤の頓用使用は、てんかんに対する緊急処置を目的とし、1 ヵ月に 2 回の頻度で使用する場合のみ可能とした。治験期間中のてんかん以外の治療を目的とした頓用使用は、不可とした。
被験者数	計画例数：45 例 登録例数：49 例、完了例数：40 例 安全性解析対象集団（SS）：49 例、 治験実施計画書に適合した薬物動態解析対象集団（PK-PPS）：41 例 【被験者数設定の根拠】 本治験では統計的仮説に基づいた被験者数の算出は行わなかった。
対象	発作コントロールが得られていない強直間代発作を有するてんかん患者
主な選択/除外基準	選択基準： 1) 16 歳以上 65 歳以下の男性又は女性 2) 国際抗てんかん連盟による「てんかん発作の臨床・脳波分類（1981）」に従って強直間代発作を有するコントロールが不十分なてんかん及び「てんかん、てんかん症候群および関連発作性疾患の分類（1989）」に従ってんかんと診断された患者。既往歴及び第 1 回来院の 5 年以内に測定された脳波検査で棘徐波放電が認められ、確定診断されていること

表 2.2-1　試験方法の概略（続き）

項目	内容
主な選択/除外基準（続き）	3) 第 1 回来院前 12 週間以内に 1 回以上の強直間代発作が認められた患者 4) VNS 併用の有無に関わらず、一定の用法・用量で 1～3 剤の抗てんかん薬による治療を受けている患者。抗てんかん薬は第 1 回来院の 28 日以上前から及び Prospective ベースライン期間中に用法・用量が一定に保たれていること。VNS は組入れの 6 ヵ月以上前に取り付けており、第 1 回来院の 28 日以上前から及び Prospective ベースライン期間中に設定が一定に保たれていること。なお、ベンゾジアゼピン系薬剤は抗てんかん薬に含まれる 除外基準： 1) 過去に本治験に参加したことがある、又は過去にラコサミドの別の治験で治療群に割り付けられたことがある患者 2) 部分発作の既往がある、又は部分発作と一致する脳波所見のある患者 3) 第 1 回来院前 5 年以内にてんかん重積状態の既往がある患者 4) 現在又は過去に、偽発作、転換性障害若しくはてんかん発作と混同されることがある他の非てんかん性発作を有する患者 5) 自殺企図の既往がある患者、自殺念慮のためカウンセリングを受けたことがある、又は現在自殺念慮が認められる患者 6) 急性又は亜急性の進行性の中枢神経系疾患が認められる患者 7) BMI が 40 以上の患者 8) ALT、AST 若しくは総ビリルビンが基準範囲上限値の 2 倍以上、又は ALP が基準範囲上限値の 3 倍以上の患者 9) 第 1 回来院時に腎機能障害が認められる患者（以下の計算式で CL_{CR} が 30 mL/min 未満） 成人男性：CL_{CR} = (140 −年齢) ×体重[kg] / (72 ×血清クレアチニン[mg/dL]) 成人女性：CL_{CR} = {(140 −年齢) ×体重[kg] / (72 ×血清クレアチニン[mg/dL])} × 0.85 10) ペースメーカー非使用時に洞不全症候群が認められる、又は第二度若しくは第三度房室ブロックが認められる患者 11) 過去 3 ヵ月以内に心筋梗塞の既往がある患者 12) ニューヨーク心臓協会のクラス III 又は IV に分類される心不全が認められる患者 13) ケトン食療法を受けていた患者 14) ブルガダ症候群等のナトリウムチャネロパチーが判明している患者
治験薬、投与量及び投与方法	治験薬： ラコサミド 50 mg 錠：バッチ番号 BX1003849 ラコサミド 100 mg 錠：バッチ番号 BX1003848 ラコサミド 150 mg 錠：バッチ番号 BX1003847 ラコサミド 200 mg 錠：バッチ番号 BX1003845 投与量及び投与方法： 治験薬は、朝・夕 1 日 2 回経口投与した。

表 2.2-1　試験方法の概略（続き）


項目	内容
治験薬、投与量及び投与方法（続き）	1)　増量期間 第 2 回来院時に適格性が認められた被験者に治験薬の投与を開始した。開始用量を 100 mg/日（50 mg を約 12 時間間隔で 1 日 2 回）とし、1 週間継続後、臨床的に問題がないと判断された場合は、第 3 回来院（第 5 週の終わり）時、第 4 回来院（第 6 週の終わり）時及び第 5 回来院（第 7 週の終わり）時にそれぞれ 200、300 及び 400 mg/日に増量した。 2)　維持期間 増量期間完了時の用量を継続して投与した。臨床的に重要な増悪、又はミオクロニー発作若しくは欠神発作が新たに発現した場合は、48 時間以内に来院し、減量又は治験中止を判断した。 <u>治験薬の減量</u> · 増量期間若しくは維持期間に臨床的に重要な増悪、又はミオクロニー発作若しくは欠神発作が新たに発現した場合は、1 段階（100 mg/日）の減量を可能とした · 維持期間に目標用量の 400 mg/日で忍容性に問題がある場合は、1 段階の減量を可能とした。ただし、400 mg/日（200 mg を 1 日 2 回）を 4 日間以上投与した被験者のみ、減量を可能とした いずれの理由でも治験期間中の減量は 1 回のみとし、減量した場合は、再度増量することは不可とした。減量が必要な場合は、治験責任医師が可能な限りメディカルモニターに相談した上で来院時（規定来院又は規定外来院）に減量した。減量後も治験薬の継続が困難な場合、又はミオクロニー発作若しくは欠神発作が持続した場合は、治験を中止した。 第 7 回来院（第 13 週の終わり、最終の規定来院）時に維持期間を完了し、SP0962 試験への参加を希望した被験者は、維持期間完了時と同じ用量で SP0962 試験へ移行した。SP0962 試験への参加を希望しない被験者又は参加基準を満たさない被験者は、治験終了期間に移行した。 治験を早期中止した被験者は、早期中止来院を実施し、必要に応じて治験薬を減量した。 3)　治験終了期間 維持期間に 300 又は 400 mg/日を投与された被験者には、毎週 200 mg/日ずつ減量することを推奨した。医療上必要な場合は、より緩やかな減量（毎週 100 mg/日ずつの減量）を可能とした。緊急時には、治験責任医師は可能な限りメディカルモニターに相談した上でより速やかな減量も可能とした。 維持期間に 100 又は 200 mg/日を投与された被験者は、減量せずに第 7 回来院で治験薬の投与を終了した。

表 2.2-1　試験方法の概略（続き）

項目		内容
投与期間		最長投与期間約 12 週間 · 増量期間 3 週間 · 維持期間 6 週間 · 治験終了期間 3 週間
評価項目	安全性	主要評価項目 · Prospective ベースライン期間に対する維持期間の 28 日あたりの欠神発作発現日数の変化量 · Prospective ベースライン期間に対する維持期間の 28 日あたりのミオクロニー発作発現日数の変化量 副次評価項目 · ポータブル 24 時間脳波検査で測定された、第 2 回来院に対する第 6 回来院の全般性棘徐波放電回数の変化量 · ポータブル 24 時間脳波検査で計測された、第 2 回来院に対する第 6 回来院の 3 Hz 棘徐波放電回数（覚醒時）の変化量 · 被験者及び／又は介護者の自発的報告又は治験責任医師の観察により報告された有害事象 · 有害事象による中止例 その他の評価項目 · Prospective ベースライン期間及び Combined ベースライン期間に対する増量期間、維持期間及び治療期間の 28 日あたりの強直間代発作回数の変化率 · 維持期間完了時又は早期中止来院時の臨床全般評価の変化 · 維持期間完了時又は早期中止来院時の被験者による全般評価の変化 · 臨床検査値（血液学的検査、血液生化学検査、尿検査）の変化 · 12 誘導心電図の変化 · バイタルサイン（血圧、脈拍数、体温）、体重及び身体所見（神経学的検査を含む）の変化
	薬物動態	血漿中ラコサミド濃度
統計解析方法		解析対象集団の定義： SS：本治験に登録され、治験薬を 1 回以上投与された被験者 PK-PPS : SS のうち、評価可能な血漿中薬物濃度の測定結果を 1 回以上得られた被験者 安全性の解析は SS、薬物動態の解析は PK-PPS を対象とした。

表 2.2-1　試験方法の概略（続き）

項目	内容
統計解析方法（続き）	安全性： Prospective ベースライン期間、増量期間、維持期間及び治療期間の 28 日あたりの欠神発作及びミオクロニー発作発現日数、並びに Prospective ベースライン期間に対する各期間の変化量の記述統計量を求めた。また、部分集団解析も同様に行った。 ポータブル 24 時間脳波検査の評価可能なデータを用いて、全般性棘徐波放電回数及び 3 Hz 棘徐波放電回数（覚醒時）、並びに各項目について第 2 回来院に対する第 6 回来院の変化量の記述統計量を求めた。また、各項目について第 2 回来院に対する第 6 回来院の変化率が 30%以上及び 50%以上増加又は減少した被験者数と割合を求めた。 治験薬投与開始後に認められた有害事象について発現例数及び発現率を求めた。 治験薬投与開始後に認められた有害事象は、本治験の治験薬初回投与日から最終投与 30 日後までに認められた事象、又は悪化した事象と定義した。 Combined ベースライン期間、増量期間、維持期間及び治療期間の 28 日あたりの強直間代発作回数、Combined ベースライン期間に対する各期間の変化量及び変化率を求めた。また、Prospective ベースライン期間に対する各期間の変化率を求めた。 維持期間完了時及び早期中止来院時の臨床全般評価の変化及び被験者による全般評価の変化をカテゴリー別に集計した。 臨床検査値、バイタルサイン及び体重について、測定値及び Prospective ベースライン期間からの変化量の記述統計量を来院時別に求めた。 12 誘導心電図の所見及び身体所見（神経学的検査を含む）について、各来院時の被験者数及び割合をカテゴリー別に集計した。 薬物動態： 血漿中ラコサミド濃度の記述統計量を来院時別に求めた。
治験責任医師	20 名
治験実施医療機関	19 医療機関（米国）
公表文献	なし
治験実施期間	2010 年 5 月 [redacted] 日～2011 年 8 月 [redacted] 日



EOTV：減量完了来院、FCV：治験終了来院、LCM：ラコサミド、TC：電話調査、V：来院

a 第 7 回来院から減量完了来院までの用量は、維持期間に 400 mg/日を投与された被験者では 200 mg/日、300 mg/日を投与された被験者では 100 mg/日とした

b 維持期間に 100 又は 200 mg/日を投与された被験者は、減量せずに第 7 回来院（第 13 週の終わり）で投与を終了し、最終投与 3 週間後（第 16 週の終わり）に治験終了来院を実施した

c 維持期間に 300 及び 400 mg/日を投与された被験者は、第 14 週の終わりに減量完了来院を、最終投与 2 週間後（第 16 週の終わり）に治験終了来院を実施した

SP0961 試験総括報告書（5.3.5.2.2）Figure 3-1

図 2.2-1 試験デザインの概要

2.2.1 被験者の内訳

本治験の SS での被験者の内訳及び中止理由を期間別に表 2.2-2 に示した。

本治験では 49 例が登録された。このうち、40 例（81.6%）が本治験を完了し、9 例（18.4%）が本治験を中止した。中止理由は、有害事象（5 例、10.2%）及び同意撤回（4 例、8.2%）であった。

表 2.2-2　被験者の内訳及び中止理由：SS

Table 1.4.1
Subject Disposition by Phase
Population: Safety Set

Disposition	N = 49 n (%)
Completed Study	40 (81.6)
Discontinued	9 (18.4)
Reason for Discontinuation	
ADVERSE EVENT	5 (10.2)
CONSENT WITHDRAWN	4 (8.2)
LACK OF EFFICACY	0
PROTOCOL VIOLATION	0
LOST TO FOLLOW-UP	0
OTHER	0
Completed Titration Phase	44 (89.8)
Discontinued from Titration Phase	5 (10.2)
Reason for Discontinuation	
ADVERSE EVENT	3 (6.1)
CONSENT WITHDRAWN	2 (4.1)
LACK OF EFFICACY	0
PROTOCOL VIOLATION	0
LOST TO FOLLOW-UP	0
OTHER	0

Reference: Subject Data Listings 1.5.1, 1.7.1

表 2.2-2　被験者の内訳及び中止理由：SS（続き）

Table 1.4.1
Subject Disposition by Phase
Population: Safety Set

Disposition	N = 49 n (%)
Entered the Maintenance Phase	44 (89.8)
Completed Maintenance Phase	40 (81.6)
Discontinued from Maintenance Phase	4 (8.2)
Reason for Discontinuation	
ADVERSE EVENT	2 (4.1)
CONSENT WITHDRAWN	2 (4.1)
LACK OF EFFICACY	0
PROTOCOL VIOLATION	0
LOST TO FOLLOW-UP	0
OTHER	0

Reference: Subject Data Listings 1.5.1, 1.7.1

2.2.2 被験者背景

2.2.2.1 人口統計学的特性及び疾患特性

本治験の SS での人口統計学的特性及びベースラインの疾患特性を表 2.2-3 に示した。

表 2.2-3　人口統計学的特性及びベースラインの疾患特性：SS

Table 3.1.1
Demographics and Baseline Characteristics Summary
Population: Safety Set

Parameter	Statistic	N = 49
Age (years)	n	49
	Mean	29.7
	SD	10.1
	Median	28.0
	Min	17
	Max	55
Age category (years)		
16-20	n (%)	8 (16.3)
>20-25	n (%)	15 (30.6)
>25-40	n (%)	19 (38.8)
>40	n (%)	7 (14.3)
<18	n (%)	3 (6.1)
18-<65	n (%)	46 (93.9)
>=65	n (%)	0
Gender		
Male	n (%)	13 (26.5)
Female	n (%)	36 (73.5)
Race		
American Indian/Alaskan Native	n (%)	0
Asian	n (%)	0
Black	n (%)	8 (16.3)
Native Hawaiian/Other Pacific Islander	n (%)	0
White	n (%)	40 (81.6)
Other/Mixed	n (%)	1 (2.0)

[1] Subjects may have more than one ILAE classification.

Reference: Subject Data Listings 2.1.1, 2.2.1, 2.3.1, 2.12.1, 2.13.1

表 2.2-3　人口統計学的特性及びベースラインの疾患特性：SS（続き）

Table 3.1.1

Demographics and Baseline Characteristics Summary

Population: Safety Set

Parameter	Statistic	N = 49
Ethnicity		
Hispanic or Latino	n (%)	3 (6.1)
Not Hispanic or Latino	n (%)	46 (93.9)
Height (cm)	n	49
	Mean	168.08
	SD	9.32
	Median	167.40
	Min	152.4
	Max	197.5
Weight (kg)	n	49
	Mean	77.90
	SD	19.80
	Median	74.40
	Min	40.6
	Max	124.3
BMI (kg/m2)	n	49
	Mean	27.50
	SD	6.33
	Median	26.40
	Min	15.4
	Max	39.2

[1] Subjects may have more than one ILAE classification.

Reference: Subject Data Listings 2.1.1, 2.2.1, 2.3.1, 2.12.1, 2.13.1

表 2.2-3　人口統計学的特性及びベースラインの疾患特性：SS（続き）

Table 3.1.1

Demographics and Baseline Characteristics Summary

Population: Safety Set

Parameter	Statistic	N = 49
BMI Category		
<18.5	n (%)	2 (4.1)
18.5-<25	n (%)	19 (38.8)
25-<30	n (%)	9 (18.4)
>=30	n (%)	19 (38.8)
Missing	n (%)	0
Time Since Diagnosis (years)	n	49
	Mean	17.64
	SD	11.73
	Median	13.85
	Min	3.1
	Max	51.4
Age at Onset of the Diagnosis (years)	n	49
	Mean	12.1
	SD	6.9
	Median	12.0
	Min	0
	Max	43

[1] Subjects may have more than one ILAE classification.

Reference: Subject Data Listings 2.1.1, 2.2.1, 2.3.1, 2.12.1, 2.13.1

表 2.2-3　人口統計学的特性及びベースラインの疾患特性：SS（続き）

Table 3.1.1

Demographics and Baseline Characteristics Summary

Population: Safety Set

Parameter	Statistic	N = 49
ILAE Classification History		
Partial Onset Seizures	n (%)	0
Simple partial	n (%)	0
Complex partial	n (%)	0
Partial evolving to secondary generalized	n (%)	0
Generalized Seizures	n (%)	49 (100)
Absence	n (%)	34 (69.4)
Myoclonic	n (%)	27 (55.1)
Clonic	n (%)	0
Tonic	n (%)	2 (4.1)
Tonic-clonic	n (%)	49 (100)
Atonic	n (%)	2 (4.1)
Unclassified epileptic seizures	n (%)	0

[1] Subjects may have more than one ILAE classification.

Reference: Subject Data Listings 2.1.1, 2.2.1, 2.3.1, 2.12.1, 2.13.1

表 2.2-3　人口統計学的特性及びベースラインの疾患特性：SS（続き）

Table 3.1.1
Demographics and Baseline Characteristics Summary
Population: Safety Set

Parameter	Statistic	N = 49
ILAE Epilepsy Syndrome Classification		
Generalized Idiopathic		
No	n (%)	2 (4.1)
Yes	n (%)	47 (95.9)
Childhood absence epilepsy		
Yes	n (%)	4 (8.2)
No	n (%)	33 (67.3)
Unknown	n (%)	10 (20.4)
Epilepsy with grand mal seizures on awakening		
Yes	n (%)	0
No	n (%)	35 (71.4)
Unknown	n (%)	12 (24.5)
Epilepsies with seizures precipitated by specific modes of activation		
Yes	n (%)	0
No	n (%)	34 (69.4)
Unknown	n (%)	13 (26.5)
Juvenile absence epilepsy		
Yes	n (%)	3 (6.1)
No	n (%)	35 (71.4)
Unknown	n (%)	11 (22.4)
Juvenile myoclonic epilepsy		
Yes	n (%)	16 (32.7)
No	n (%)	22 (44.9)
Unknown	n (%)	9 (18.4)
Other generalized idiopathic epilepsies not defined above		
Yes	n (%)	20 (40.8)
No	n (%)	15 (30.6)
Unknown	n (%)	12 (24.5)

[1] Subjects may have more than one ILAE classification.

Reference: Subject Data Listings 2.1.1, 2.2.1, 2.3.1, 2.12.1, 2.13.1

表 2.2-3　人口統計学的特性及びベースラインの疾患特性：SS（続き）

Table 3.1.1
Demographics and Baseline Characteristics Summary
Population: Safety Set

Parameter	Statistic	N = 49
Twelve-Month ILAE Classification History [1]		
Screening to 6 Months		
Absence	n (%)	8 (16.3)
Myoclonic	n (%)	4 (8.2)
Clonic	n (%)	3 (6.1)
Tonic	n (%)	5 (10.2)
Tonic-clonic	n (%)	42 (85.7)
Atonic	n (%)	3 (6.1)
6 Months to 12 Months		
Absence	n (%)	4 (8.2)
Myoclonic	n (%)	3 (6.1)
Clonic	n (%)	3 (6.1)
Tonic	n (%)	3 (6.1)
Tonic-clonic	n (%)	23 (46.9)
Atonic	n (%)	3 (6.1)
Number of Concomitant AEDs		
1	n (%)	15 (30.6)
2	n (%)	25 (51.0)
3	n (%)	9 (18.4)
Missing	n (%)	0

[1] Subjects may have more than one ILAE classification.

Reference: Subject Data Listings 2.1.1, 2.2.1, 2.3.1, 2.12.1, 2.13.1

2.2.2.2 抗てんかん薬

本治験の SS での治験期間（増量期間+維持期間）中に併用していた抗てんかん薬を表 2.2-4 に示した。

表 2.2-4　治験期間中の併用抗てんかん薬：SS

Table 5.2.1
Concomitant AED Use Summary
Population: Safety Set

Level 4 ATC Class Medication Name	N = 49 n (%)
Number of subjects with at least one medication	49 (100)
ANTIEPILEPTICS	1 (2.0)
VIMPAT [1]	1 (2.0)
BENZODIAZEPINE DERIVATIVES	18 (36.7)
LORAZEPAM	11 (22.4)
CLONAZEPAM	7 (14.3)
DIAZEPAM	1 (2.0)
CARBOXAMIDE DERIVATIVES	1 (2.0)
RUFINAMIDE	1 (2.0)
FATTY ACID DERIVATIVES	12 (24.5)
VALPROATE	12 (24.5)
HYDANTOIN DERIVATIVES	5 (10.2)
PHENYTOIN	5 (10.2)

Note: [1] The investigator text of 'VIMPAT' is displayed instead of the WHO Preferred Term of 'ANTIEPILEPTICS'.
Note: Subjects reporting the same class more than once are counted once per class.
Note: Phenytoin use includes phenytoin, phenytoin sodium, ethotoin, fosphenytoin, fosphenytoin sodium, and zentronal. Valproate use includes valproic acid, valproate semisodium, valproate sodium, ergenyl chrono, and valpromide.

Reference: Subject Data Listing 2.8.1

表 2.2-4　治験期間中の併用抗てんかん薬：SS（続き）

Table 5.2.1
Concomitant AED Use Summary
Population: Safety Set

Level 4 ATC Class Medication Name	N = 49 n (%)
OTHER ANTIEPILEPTICS	42 (85.7)
LEVETIRACETAM	25 (51.0)
LAMOTRIGINE	24 (49.0)
TOPIRAMATE	11 (22.4)
ZONISAMIDE	10 (20.4)
SUCCINIMIDE DERIVATIVES	1 (2.0)
ETHOSUXIMIDE	1 (2.0)

Note: [1] The investigator text of 'VIMPAT' is displayed instead of the WHO Preferred Term of 'ANTIEPILEPTICS'.
Note: Subjects reporting the same class more than once are counted once per class.
Note: Phenytoin use includes phenytoin, phenytoin sodium, ethotoin, fosphenytoin, fosphenytoin sodium, and zentronal. Valproate use includes valproic acid, valproate semisodium, valproate sodium, ergenyl chrono, and valpromide.

Reference: Subject Data Listing 2.8.1

2.2.3 安全性

2.2.3.1 曝露状況

本治験での治験薬の曝露期間及び平均投与量を期間別に表 2.2-5 に示した。また、治験薬の曝露期間別の曝露状況を表 2.2-6 に示した。

表 2.2-5　治験薬の曝露期間及び平均投与量：SS

Table 6.1.1
Total Duration of LCM Exposure and Mean Daily Dose
Population: Safety Set

Study Phase Parameter	LCM Exposure N = 49 n	Mean	SD	Median	Min	Max
Titration Phase						
Total duration of LCM Exposure (days)	49	20.6	3.5	21.0	1	30
Mean Daily Dose (mg/day)	48	189.2	24.5	192.9	50	216
Maintenance Phase						
Total duration of LCM Exposure (days)	44	40.8	7.9	42.5	7	56
Mean Daily Dose (mg/day)	44	375.0	35.2	394.0	283	409
Treatment Phase						
Total duration of LCM Exposure (days)	49	57.2	16.5	64.0	1	77
Mean Daily Dose (mg/day)	48	295.2	57.7	325.6	50	342

Note: Total duration of LCM exposure (days) is calculated as the date of last dose of LCM minus the date of the first dose of LCM plus one day.
Note: Subject [redacted] had an unknown dose during the Titration Phase so their mean daily dose is considered unknown for the Titration and Treatment Phases.

Reference: Subject Data Listing 4.3.1

表 2.2-6　治験薬の曝露期間別の曝露状況：SS

Table 6.2.1
Extent of Exposure
Population: Safety Set

Number of days of LCM exposure	N = 49 n (%)
<= 21	2 (4.1)
>21 - 42	5 (10.2)
>42 - 63	16 (32.7)
>63	26 (53.1)

Note: Total duration of exposure (days) is calculated as the date of last dose of LCM minus the date of the first dose of LCM plus one day.

Reference: Subject Data Listing 4.3.1

2.2.3.2 主要評価項目

2.2.3.2.1 欠神発作発現日数の変化量

本治験の SS での治療期間（増量期間+維持期間）における 28 日あたりの欠神発作発現日数及び Prospective ベースライン期間に対する変化量を部分集団別及び期間別に表 2.2-7 に示した。

28 日あたりの欠神発作発現日数の平均値 ± 標準偏差は、Prospective ベースライン期間の 4.65 ± 8.48 日に対して、維持期間では 4.54 ± 9.13 日と減少した。Prospective ベースライン期間に対する維持期間の 28 日あたりの欠神発作発現日数の変化量は、平均値 ± 標準偏差が−0.37 ± 4.80 日で、中央値が 0.00 日であった。

年齢別又は併用抗てんかん薬別の部分集団では、Prospective ベースライン期間に対する維持期間の欠神発作発現日数の変化量に、臨床的に意味のある結果は認められなかった。

表 2.2-7　治療期間における 28 日あたりの欠神発作発現日数及び Prospective ベースライン期間に対する変化量：SS

Table 7.3.1

Change in the Number of Days with Absence Seizures per 28 Days by Subgroup and Phase During the Treatment Phase

Population: Safety Set

Subgroup / Phase	Actual Value n	Actual Value Mean	Actual Value SD	Actual Value Med	Actual Value Min	Actual Value Max	Change From Baseline n	Change From Baseline Mean	Change From Baseline SD	Change From Baseline Med	Change From Baseline Min	Change From Baseline Max
All Subjects												
Baseline	49	4.65	8.48	0.00	0.0	28.0						
Titration	49	4.91	8.42	0.00	0.0	28.0	49	0.26	3.67	0.00	-12.1	12.7
Maintenance	44	4.54	9.13	0.00	0.0	28.0	44	-0.37	4.80	0.00	-13.0	17.6
Treatment	49	4.89	8.60	0.00	0.0	28.0	49	0.25	4.26	0.00	-10.4	12.7
Age At Onset Of The Diagnosis: <2 years												
Baseline	2	7.00	8.58	7.00	0.9	13.1						
Titration	2	2.67	3.77	2.67	0.0	5.3	2	-4.33	4.81	-4.33	-7.7	-0.9
Maintenance	2	1.35	0.99	1.35	0.7	2.0	2	-5.65	7.59	-5.65	-11.0	-0.3
Treatment	2	1.80	1.92	1.80	0.4	3.2	2	-5.20	6.66	-5.20	-9.9	-0.5
Age At Onset Of The Diagnosis: 2 - <5 years												
Baseline	4	6.60	8.35	4.52	0.0	17.4						
Titration	4	6.32	7.68	4.87	0.0	15.6	4	-0.28	5.79	0.00	-7.6	6.5
Maintenance	4	8.03	12.69	2.73	0.0	26.7	4	1.43	12.18	0.00	-11.9	17.6
Treatment	4	7.13	10.15	3.50	0.0	21.5	4	0.53	9.36	0.00	-10.4	12.5

Note: Other AEDs includes all anti-epileptic drugs except Valproate and Lamotrigine.

Reference: Subject Data Listing 8.4.1

表 2.2-7　治療期間における 28 日あたりの欠神発作発現日数及び Prospective ベースライン期間に対する変化量：SS（続き）

Table 7.3.1

Change in the Number of Days with Absence Seizures per 28 Days by Subgroup and Phase During the Treatment Phase

Population: Safety Set

Subgroup / Phase	Actual Value n	Actual Value Mean	Actual Value SD	Actual Value Med	Actual Value Min	Actual Value Max	Change From Baseline n	Change From Baseline Mean	Change From Baseline SD	Change From Baseline Med	Change From Baseline Min	Change From Baseline Max
Age At Onset Of The Diagnosis: 5 - <10 years												
Baseline	9	4.95	9.41	0.00	0.0	27.0						
Titration	9	4.43	9.22	0.00	0.0	28.0	9	-0.52	4.59	0.00	-12.1	4.0
Maintenance	8	4.93	9.86	0.00	0.0	28.0	8	-0.64	1.63	0.00	-4.1	1.0
Treatment	9	4.41	9.16	0.00	0.0	28.0	9	-0.53	2.39	0.00	-6.8	1.0
Age At Onset Of The Diagnosis: 10 - <15 years												
Baseline	22	5.85	9.94	0.00	0.0	28.0						
Titration	22	6.94	9.87	0.64	0.0	28.0	22	1.09	3.68	0.00	-5.7	12.7
Maintenance	18	5.56	9.91	0.00	0.0	28.0	18	-0.93	3.89	0.00	-13.0	3.7
Treatment	22	6.58	9.52	1.21	0.0	28.0	22	0.73	4.28	0.00	-7.6	12.7
Age At Onset Of The Diagnosis: 15 - <20 years												
Baseline	8	1.75	4.95	0.00	0.0	14.0						
Titration	8	2.17	5.61	0.00	0.0	16.0	8	0.42	0.79	0.00	0.0	2.0
Maintenance	8	3.17	8.96	0.00	0.0	25.3	8	1.42	4.01	0.00	0.0	11.3
Treatment	8	2.90	7.81	0.00	0.0	22.2	8	1.15	2.88	0.00	0.0	8.2

Note: Other AEDs includes all anti-epileptic drugs except Valproate and Lamotrigine.

Reference: Subject Data Listing 8.4.1

表 2.2-7　治療期間における 28 日あたりの欠神発作発現日数及び Prospective ベースライン期間に対する変化量：SS（続き）

Table 7.3.1

Change in the Number of Days with Absence Seizures per 28 Days by Subgroup and Phase During the Treatment Phase

Population: Safety Set

Subgroup / Phase	Actual Value n	Actual Value Mean	Actual Value SD	Actual Value Med	Actual Value Min	Actual Value Max	Change From Baseline n	Change From Baseline Mean	Change From Baseline SD	Change From Baseline Med	Change From Baseline Min	Change From Baseline Max
Age At Onset Of The Diagnosis: >=20 years												
Baseline	4	0.00	0.00	0.00	0.0	0.0						
Titration	4	0.00	0.00	0.00	0.0	0.0	4	0.00	0.00	0.00	0.0	0.0
Maintenance	4	0.00	0.00	0.00	0.0	0.0	4	0.00	0.00	0.00	0.0	0.0
Treatment	4	0.00	0.00	0.00	0.0	0.0	4	0.00	0.00	0.00	0.0	0.0
Childhood Absence Epilepsy: Yes												
Baseline	4	3.50	7.00	0.00	0.0	14.0						
Titration	4	4.00	8.00	0.00	0.0	16.0	4	0.50	1.00	0.00	0.0	2.0
Maintenance	4	6.33	12.67	0.00	0.0	25.3	4	2.83	5.67	0.00	0.0	11.3
Treatment	4	5.56	11.11	0.00	0.0	22.2	4	2.06	4.11	0.00	0.0	8.2
Childhood Absence Epilepsy: No												
Baseline	33	5.24	9.67	0.00	0.0	28.0						
Titration	33	4.96	8.93	0.00	0.0	28.0	33	-0.27	3.98	0.00	-12.1	12.7
Maintenance	30	4.85	9.15	0.00	0.0	28.0	30	-0.91	3.49	0.00	-11.9	3.7
Treatment	33	5.03	8.81	0.00	0.0	28.0	33	-0.20	4.04	0.00	-10.4	12.7

Note: Other AEDs includes all anti-epileptic drugs except Valproate and Lamotrigine.

Reference: Subject Data Listing 8.4.1

表 2.2-7　治療期間における 28 日あたりの欠神発作発現日数及び Prospective ベースライン期間に対する変化量：SS（続き）

Table 7.3.1

Change in the Number of Days with Absence Seizures per 28 Days by Subgroup and Phase During the Treatment Phase

Population: Safety Set

Subgroup / Phase	Actual Value n	Actual Value Mean	Actual Value SD	Actual Value Med	Actual Value Min	Actual Value Max	Change From Baseline n	Change From Baseline Mean	Change From Baseline SD	Change From Baseline Med	Change From Baseline Min	Change From Baseline Max
Epilepsy With Grand Mal Seizures On Awakening: Yes												
Baseline	0											
Titration	0						0					
Maintenance	0						0					
Treatment	0						0					
Epilepsy With Grand Mal Seizures On Awakening: No												
Baseline	35	4.94	9.46	0.00	0.0	28.0						
Titration	35	4.68	8.74	0.00	0.0	28.0	35	-0.26	3.86	0.00	-12.1	12.7
Maintenance	32	4.55	8.93	0.00	0.0	28.0	32	-0.85	3.38	0.00	-11.9	3.7
Treatment	35	4.75	8.62	0.00	0.0	28.0	35	-0.19	3.92	0.00	-10.4	12.7
Epilepsies With Seizures Precipitated By Specific Modes Of Activation: Yes												
Baseline	0											
Titration	0						0					
Maintenance	0						0					
Treatment	0						0					

Note: Other AEDs includes all anti-epileptic drugs except Valproate and Lamotrigine.

Reference: Subject Data Listing 8.4.1

表 2.2-7　治療期間における 28 日あたりの欠神発作発現日数及び Prospective ベースライン期間に対する変化量：SS（続き）

Table 7.3.1

Change in the Number of Days with Absence Seizures per 28 Days by Subgroup and Phase During the Treatment Phase

Population: Safety Set

Subgroup / Phase	Actual Value n	Actual Value Mean	Actual Value SD	Actual Value Med	Actual Value Min	Actual Value Max	Change From Baseline n	Change From Baseline Mean	Change From Baseline SD	Change From Baseline Med	Change From Baseline Min	Change From Baseline Max
Epilepsies With Seizures Precipitated By Specific Modes Of Activation: No												
Baseline	34	5.08	9.56	0.00	0.0	28.0						
Titration	34	4.81	8.84	0.00	0.0	28.0	34	-0.27	3.92	0.00	-12.1	12.7
Maintenance	31	4.69	9.04	0.00	0.0	28.0	31	-0.88	3.43	0.00	-11.9	3.7
Treatment	34	4.88	8.71	0.00	0.0	28.0	34	-0.20	3.98	0.00	-10.4	12.7
Juvenile Absence Epilepsy: Yes												
Baseline	3	0.00	0.00	0.00	0.0	0.0						
Titration	3	4.24	7.35	0.00	0.0	12.7	3	4.24	7.35	0.00	0.0	12.7
Maintenance	2	0.00	0.00	0.00	0.0	0.0	2	0.00	0.00	0.00	0.0	0.0
Treatment	3	4.24	7.35	0.00	0.0	12.7	3	4.24	7.35	0.00	0.0	12.7
Juvenile Absence Epilepsy: No												
Baseline	35	5.45	9.50	0.00	0.0	28.0						
Titration	35	5.00	8.82	0.00	0.0	28.0	35	-0.45	3.26	0.00	-12.1	5.9
Maintenance	33	5.24	9.47	0.00	0.0	28.0	33	-0.54	3.95	0.00	-11.9	11.3
Treatment	35	5.13	8.98	0.00	0.0	28.0	35	-0.32	3.54	0.00	-10.4	8.2

Note: Other AEDs includes all anti-epileptic drugs except Valproate and Lamotrigine.

Reference: Subject Data Listing 8.4.1

表 2.2-7　治療期間における 28 日あたりの欠神発作発現日数及び Prospective ベースライン期間に対する変化量：SS（続き）

Table 7.3.1

Change in the Number of Days with Absence Seizures per 28 Days by Subgroup and Phase During the Treatment Phase

Population: Safety Set

Subgroup / Phase	n	Actual Value Mean	SD	Med	Min	Max	n	Change From Baseline Mean	SD	Med	Min	Max
Juvenile Myoclonic Epilepsy: Yes												
Baseline	16	2.06	6.99	0.00	0.0	28.0						
Titration	16	2.38	7.13	0.00	0.0	28.0	16	0.32	1.13	0.00	-0.9	4.0
Maintenance	15	2.05	7.20	0.00	0.0	28.0	15	-0.15	0.49	0.00	-1.9	0.0
Treatment	16	2.16	6.98	0.00	0.0	28.0	16	0.10	0.52	0.00	-0.5	2.0
Juvenile Myoclonic Epilepsy: No												
Baseline	22	6.54	10.16	0.00	0.0	28.0						
Titration	22	6.08	9.16	1.33	0.0	28.0	22	-0.46	4.88	0.00	-12.1	12.7
Maintenance	20	5.84	9.36	0.00	0.0	28.0	20	-1.35	4.24	0.00	-11.9	3.7
Treatment	22	6.17	8.98	1.71	0.0	28.0	22	-0.37	4.96	0.00	-10.4	12.7
Other Generalized Idiopathic Epilepsies Not Defined Above: Yes												
Baseline	20	7.19	10.45	0.00	0.0	28.0						
Titration	20	6.05	9.41	1.33	0.0	28.0	20	-1.14	4.09	0.00	-12.1	5.9
Maintenance	19	6.15	9.51	0.00	0.0	28.0	19	-1.42	4.34	0.00	-11.9	3.7
Treatment	20	6.15	9.21	1.71	0.0	28.0	20	-1.05	4.20	0.00	-10.4	5.9

Note: Other AEDs includes all anti-epileptic drugs except Valproate and Lamotrigine.

Reference: Subject Data Listing 8.4.1

表 2.2-7　治療期間における 28 日あたりの欠神発作発現日数及び Prospective ベースライン期間に対する変化量：SS（続き）

Table 7.3.1

Change in the Number of Days with Absence Seizures per 28 Days by Subgroup and Phase During the Treatment Phase

Population: Safety Set

Subgroup / Phase	Actual Value n	Actual Value Mean	Actual Value SD	Actual Value Med	Actual Value Min	Actual Value Max	Change From Baseline n	Change From Baseline Mean	Change From Baseline SD	Change From Baseline Med	Change From Baseline Min	Change From Baseline Max
Other Generalized Idiopathic Epilepsies Not Defined Above: No												
Baseline	15	1.93	7.22	0.00	0.0	28.0						
Titration	15	2.85	7.69	0.00	0.0	28.0	15	0.92	3.32	0.00	-0.9	12.7
Maintenance	13	2.20	7.75	0.00	0.0	28.0	13	-0.02	0.08	0.00	-0.3	0.0
Treatment	15	2.88	7.68	0.00	0.0	28.0	15	0.95	3.30	0.00	-0.5	12.7
Use Of Valproate: Yes												
Baseline	12	1.08	3.75	0.00	0.0	13.0						
Titration	12	1.50	4.60	0.00	0.0	16.0	12	0.42	1.00	0.00	0.0	3.0
Maintenance	11	0.33	1.11	0.00	0.0	3.7	11	-0.85	4.18	0.00	-13.0	3.7
Treatment	12	0.82	1.68	0.00	0.0	5.4	12	-0.26	2.46	0.00	-7.6	2.4
Use Of Valproate: No												
Baseline	37	5.80	9.27	0.00	0.0	28.0						
Titration	37	6.01	9.11	0.00	0.0	28.0	37	0.21	4.20	0.00	-12.1	12.7
Maintenance	33	5.94	10.17	0.00	0.0	28.0	33	-0.21	5.04	0.00	-11.9	17.6
Treatment	37	6.22	9.51	0.42	0.0	28.0	37	0.41	4.72	0.00	-10.4	12.7

Note: Other AEDs includes all anti-epileptic drugs except Valproate and Lamotrigine.

Reference: Subject Data Listing 8.4.1

表 2.2-7　治療期間における 28 日あたりの欠神発作発現日数及び Prospective ベースライン期間に対する変化量：SS（続き）

Table 7.3.1

Change in the Number of Days with Absence Seizures per 28 Days by Subgroup and Phase During the Treatment Phase

Population: Safety Set

Subgroup / Phase	Actual Value n	Actual Value Mean	Actual Value SD	Actual Value Med	Actual Value Min	Actual Value Max	Change From Baseline n	Change From Baseline Mean	Change From Baseline SD	Change From Baseline Med	Change From Baseline Min	Change From Baseline Max
Use Of Lamotrigine: Yes												
Baseline	24	4.66	8.43	0.00	0.0	28.0						
Titration	24	5.50	8.67	0.00	0.0	28.0	24	0.84	2.81	0.00	-5.7	8.0
Maintenance	22	5.36	10.07	0.00	0.0	28.0	22	0.82	4.96	0.00	-8.6	17.6
Treatment	24	5.79	9.38	0.00	0.0	28.0	24	1.13	3.96	0.00	-7.6	12.5
Use Of Lamotrigine: No												
Baseline	25	4.63	8.70	0.00	0.0	28.0						
Titration	25	4.34	8.31	0.00	0.0	28.0	25	-0.29	4.32	0.00	-12.1	12.7
Maintenance	22	3.72	8.24	0.00	0.0	28.0	22	-1.55	4.44	0.00	-13.0	3.7
Treatment	25	4.03	7.87	0.00	0.0	28.0	25	-0.60	4.45	0.00	-10.4	12.7
Use Of Other AEDs: Yes												
Baseline	43	5.30	8.87	0.00	0.0	28.0						
Titration	43	5.55	8.81	0.00	0.0	28.0	43	0.25	3.91	0.00	-12.1	12.7
Maintenance	39	5.12	9.55	0.00	0.0	28.0	39	-0.41	5.11	0.00	-13.0	17.6
Treatment	43	5.53	9.00	0.00	0.0	28.0	43	0.24	4.55	0.00	-10.4	12.7

Note: Other AEDs includes all anti-epileptic drugs except Valproate and Lamotrigine.

Reference: Subject Data Listing 8.4.1

表 2.2-7　治療期間における 28 日あたりの欠神発作発現日数及び Prospective ベースライン期間に対する変化量：SS（続き）

Table 7.3.1

Change in the Number of Days with Absence Seizures per 28 Days by Subgroup and Phase During the Treatment Phase

Population: Safety Set

Subgroup / Phase	Actual Value n	Actual Value Mean	Actual Value SD	Actual Value Med	Actual Value Min	Actual Value Max	Change From Baseline n	Change From Baseline Mean	Change From Baseline SD	Change From Baseline Med	Change From Baseline Min	Change From Baseline Max
Use Of Other AEDs: No												
Baseline	6	0.00	0.00	0.00	0.0	0.0						
Titration	6	0.33	0.82	0.00	0.0	2.0	6	0.33	0.82	0.00	0.0	2.0
Maintenance	5	0.00	0.00	0.00	0.0	0.0	5	0.00	0.00	0.00	0.0	0.0
Treatment	6	0.33	0.82	0.00	0.0	2.0	6	0.33	0.82	0.00	0.0	2.0

Note: Other AEDs includes all anti-epileptic drugs except Valproate and Lamotrigine.

Reference: Subject Data Listing 8.4.1

2.2.3.2.2 ミオクロニー発作発現日数の変化量

本治験の SS での治療期間（増量期間+維持期間）における 28 日あたりのミオクロニー発作発現日数及び Prospective ベースライン期間に対する変化量を部分集団別及び期間別に表 2.2-8 に示した。

28 日あたりのミオクロニー発作発現日数の平均値 ± 標準偏差は、Prospective ベースライン期間の 4.66 ± 7.98 日に対して、維持期間では 1.70 ± 5.08 日と減少した。Prospective ベースライン期間に対する維持期間の 28 日あたりのミオクロニー発作発現日数の変化量は、平均値 ± 標準偏差が−2.19 ± 5.80 日で、中央値が 0.00 日であった。

年齢別又は併用抗てんかん薬別の部分集団では、Prospective ベースライン期間に対する維持期間のミオクロニー発作発現日数の変化量に、臨床的に意味のある結果は認められなかった。

表 2.2-8　治療期間における 28 日あたりのミオクロニー発作発現日数及び Prospective ベースライン期間に対する変化量：SS

Table 7.4.1

Change in the Number of Days with Myoclonic Seizures per 28 Days by Subgroup and Phase During the Treatment Phase

Population: Safety Set

Subgroup / Phase	Actual Value n	Actual Value Mean	Actual Value SD	Actual Value Med	Actual Value Min	Actual Value Max	Change From Baseline n	Change From Baseline Mean	Change From Baseline SD	Change From Baseline Med	Change From Baseline Min	Change From Baseline Max
All Subjects												
Baseline	49	4.66	7.98	0.00	0.0	27.0						
Titration	49	3.37	7.00	0.00	0.0	28.0	49	-1.29	6.26	0.00	-23.9	10.3
Maintenance	44	1.70	5.08	0.00	0.0	28.0	44	-2.19	5.80	0.00	-26.3	4.0
Treatment	49	2.75	6.25	0.00	0.0	27.6	49	-1.91	6.34	0.00	-25.2	8.0
Age At Onset Of The Diagnosis: <2 years												
Baseline	2	15.87	2.64	15.87	14.0	17.7						
Titration	2	18.67	13.20	18.67	9.3	28.0	2	2.80	10.56	2.80	-4.7	10.3
Maintenance	2	10.17	9.56	10.17	3.4	16.9	2	-5.69	6.92	-5.69	-10.6	-0.8
Treatment	2	12.93	10.62	12.93	5.4	20.4	2	-2.93	7.98	-2.93	-8.6	2.7
Age At Onset Of The Diagnosis: 2 - <5 years												
Baseline	4	6.93	11.44	1.85	0.0	24.0						
Titration	4	7.33	12.95	1.33	0.0	26.7	4	0.41	2.35	0.83	-2.7	2.7
Maintenance	4	7.67	13.61	1.33	0.0	28.0	4	0.74	2.82	0.83	-2.7	4.0
Treatment	4	7.56	13.39	1.33	0.0	27.6	4	0.63	2.66	0.83	-2.7	3.6

Note: Other AEDs includes all anti-epileptic drugs except Valproate and Lamotrigine.

Reference: Subject Data Listing 8.4.1

表 2.2-8　治療期間における 28 日あたりのミオクロニー発作発現日数及び Prospective ベースライン期間に対する変化量：SS（続き）

Table 7.4.1

Change in the Number of Days with Myoclonic Seizures per 28 Days by Subgroup and Phase During the Treatment Phase

Population: Safety Set

Subgroup / Phase	Actual Value n	Actual Value Mean	Actual Value SD	Actual Value Med	Actual Value Min	Actual Value Max	Change From Baseline n	Change From Baseline Mean	Change From Baseline SD	Change From Baseline Med	Change From Baseline Min	Change From Baseline Max
Age At Onset Of The Diagnosis: 5 - <10 years												
Baseline	9	4.00	9.12	0.00	0.0	27.0						
Titration	9	1.68	4.00	0.00	0.0	12.0	9	-2.32	8.15	0.00	-23.9	3.0
Maintenance	8	1.14	3.22	0.00	0.0	9.1	8	0.01	0.04	0.00	0.0	0.1
Treatment	9	1.47	3.40	0.00	0.0	10.1	9	-2.53	8.02	0.00	-23.9	1.1
Age At Onset Of The Diagnosis: 10 - <15 years												
Baseline	22	5.90	8.29	0.00	0.0	27.0						
Titration	22	3.36	6.42	0.00	0.0	20.0	22	-2.54	7.17	0.00	-23.2	8.0
Maintenance	18	0.69	1.70	0.00	0.0	5.9	18	-4.85	8.03	0.00	-26.3	0.0
Treatment	22	2.77	5.94	0.00	0.0	20.0	22	-3.13	7.60	0.00	-25.2	8.0
Age At Onset Of The Diagnosis: 15 - <20 years												
Baseline	8	0.38	1.06	0.00	0.0	3.0						
Titration	8	0.98	2.33	0.00	0.0	6.7	8	0.60	1.30	0.00	0.0	3.7
Maintenance	8	0.25	0.71	0.00	0.0	2.0	8	-0.13	0.35	0.00	-1.0	0.0
Treatment	8	0.50	1.24	0.00	0.0	3.6	8	0.12	0.23	0.00	0.0	0.6

Note: Other AEDs includes all anti-epileptic drugs except Valproate and Lamotrigine.

Reference: Subject Data Listing 8.4.1

表 2.2-8　治療期間における 28 日あたりのミオクロニー発作発現日数及び Prospective ベースライン期間に対する変化量：SS（続き）

Table 7.4.1

Change in the Number of Days with Myoclonic Seizures per 28 Days by Subgroup and Phase During the Treatment Phase

Population: Safety Set

Subgroup / Phase	Actual Value n	Actual Value Mean	Actual Value SD	Actual Value Med	Actual Value Min	Actual Value Max	Change From Baseline n	Change From Baseline Mean	Change From Baseline SD	Change From Baseline Med	Change From Baseline Min	Change From Baseline Max
Age At Onset Of The Diagnosis: >=20 years												
Baseline	4	0.00	0.00	0.00	0.0	0.0						
Titration	4	0.37	0.74	0.00	0.0	1.5	4	0.37	0.74	0.00	0.0	1.5
Maintenance	4	0.00	0.00	0.00	0.0	0.0	4	0.00	0.00	0.00	0.0	0.0
Treatment	4	0.11	0.23	0.00	0.0	0.5	4	0.11	0.23	0.00	0.0	0.5
Childhood Absence Epilepsy: Yes												
Baseline	4	0.00	0.00	0.00	0.0	0.0						
Titration	4	0.00	0.00	0.00	0.0	0.0	4	0.00	0.00	0.00	0.0	0.0
Maintenance	4	0.00	0.00	0.00	0.0	0.0	4	0.00	0.00	0.00	0.0	0.0
Treatment	4	0.00	0.00	0.00	0.0	0.0	4	0.00	0.00	0.00	0.0	0.0
Childhood Absence Epilepsy: No												
Baseline	33	4.17	7.47	0.00	0.0	27.0						
Titration	33	2.89	6.45	0.00	0.0	28.0	33	-1.28	6.01	0.00	-23.2	10.3
Maintenance	30	1.16	3.32	0.00	0.0	16.9	30	-2.82	6.35	0.00	-26.3	0.0
Treatment	33	2.10	5.06	0.00	0.0	20.4	33	-2.07	5.95	0.00	-25.2	3.7

Note: Other AEDs includes all anti-epileptic drugs except Valproate and Lamotrigine.

Reference: Subject Data Listing 8.4.1

表 2.2-8　治療期間における 28 日あたりのミオクロニー発作発現日数及び Prospective ベースライン期間に対する変化量：SS（続き）

Table 7.4.1

Change in the Number of Days with Myoclonic Seizures per 28 Days by Subgroup and Phase During the Treatment Phase

Population: Safety Set

Subgroup / Phase	Actual Value n	Actual Value Mean	Actual Value SD	Actual Value Med	Actual Value Min	Actual Value Max	Change From Baseline n	Change From Baseline Mean	Change From Baseline SD	Change From Baseline Med	Change From Baseline Min	Change From Baseline Max
Epilepsy With Grand Mal Seizures On Awakening: Yes												
Baseline	0											
Titration	0						0					
Maintenance	0						0					
Treatment	0						0					
Epilepsy With Grand Mal Seizures On Awakening: No												
Baseline	35	3.93	7.31	0.00	0.0	27.0						
Titration	35	2.72	6.29	0.00	0.0	28.0	35	-1.21	5.84	0.00	-23.2	10.3
Maintenance	32	1.09	3.22	0.00	0.0	16.9	32	-2.64	6.18	0.00	-26.3	0.0
Treatment	35	1.98	4.94	0.00	0.0	20.4	35	-1.95	5.79	0.00	-25.2	3.7
Epilepsies With Seizures Precipitated By Specific Modes Of Activation: Yes												
Baseline	0											
Titration	0						0					
Maintenance	0						0					
Treatment	0						0					

Note: Other AEDs includes all anti-epileptic drugs except Valproate and Lamotrigine.

Reference: Subject Data Listing 8.4.1

表 2.2-8　治療期間における 28 日あたりのミオクロニー発作発現日数及び Prospective ベースライン期間に対する変化量：SS（続き）

Table 7.4.1

Change in the Number of Days with Myoclonic Seizures per 28 Days by Subgroup and Phase During the Treatment Phase

Population: Safety Set

Subgroup / Phase	Actual Value n	Actual Value Mean	Actual Value SD	Actual Value Med	Actual Value Min	Actual Value Max	Change From Baseline n	Change From Baseline Mean	Change From Baseline SD	Change From Baseline Med	Change From Baseline Min	Change From Baseline Max
Epilepsies With Seizures Precipitated By Specific Modes Of Activation: No												
Baseline	34	4.05	7.39	0.00	0.0	27.0						
Titration	34	2.80	6.37	0.00	0.0	28.0	34	-1.24	5.92	0.00	-23.2	10.3
Maintenance	31	1.12	3.27	0.00	0.0	16.9	31	-2.73	6.26	0.00	-26.3	0.0
Treatment	34	2.04	5.00	0.00	0.0	20.4	34	-2.00	5.87	0.00	-25.2	3.7
Juvenile Absence Epilepsy: Yes												
Baseline	3	0.00	0.00	0.00	0.0	0.0						
Titration	3	0.00	0.00	0.00	0.0	0.0	3	0.00	0.00	0.00	0.0	0.0
Maintenance	2	0.00	0.00	0.00	0.0	0.0	2	0.00	0.00	0.00	0.0	0.0
Treatment	3	0.00	0.00	0.00	0.0	0.0	3	0.00	0.00	0.00	0.0	0.0
Juvenile Absence Epilepsy: No												
Baseline	35	3.96	7.30	0.00	0.0	27.0						
Titration	35	3.03	6.46	0.00	0.0	28.0	35	-0.93	5.86	0.00	-23.2	10.3
Maintenance	33	1.41	3.47	0.00	0.0	16.9	33	-2.24	6.03	0.00	-26.3	1.7
Treatment	35	2.31	5.11	0.00	0.0	20.4	35	-1.65	5.75	0.00	-25.2	3.7

Note: Other AEDs includes all anti-epileptic drugs except Valproate and Lamotrigine.

Reference: Subject Data Listing 8.4.1

表 2.2-8　治療期間における 28 日あたりのミオクロニー発作発現日数及び Prospective ベースライン期間に対する変化量：SS（続き）

Table 7.4.1

Change in the Number of Days with Myoclonic Seizures per 28 Days by Subgroup and Phase During the Treatment Phase

Population: Safety Set

Subgroup / Phase	Actual Value n	Actual Value Mean	Actual Value SD	Actual Value Med	Actual Value Min	Actual Value Max	Change From Baseline n	Change From Baseline Mean	Change From Baseline SD	Change From Baseline Med	Change From Baseline Min	Change From Baseline Max
Juvenile Myoclonic Epilepsy: Yes												
Baseline	16	6.80	9.09	2.00	0.0	27.0						
Titration	16	5.16	8.17	2.07	0.0	28.0	16	-1.63	8.18	0.00	-23.2	10.3
Maintenance	15	2.18	4.72	0.00	0.0	16.9	15	-3.98	8.37	0.00	-26.3	1.7
Treatment	16	3.91	6.86	0.89	0.0	20.4	16	-2.89	8.13	0.00	-25.2	3.7
Juvenile Myoclonic Epilepsy: No												
Baseline	22	1.76	4.33	0.00	0.0	14.0						
Titration	22	1.24	3.74	0.00	0.0	15.4	22	-0.52	2.83	0.00	-11.6	4.0
Maintenance	20	0.69	1.74	0.00	0.0	5.9	20	-1.15	2.95	0.00	-10.6	0.0
Treatment	22	0.89	2.27	0.00	0.0	9.2	22	-0.87	2.52	0.00	-8.6	0.4
Other Generalized Idiopathic Epilepsies Not Defined Above: Yes												
Baseline	20	1.94	4.52	0.00	0.0	14.0						
Titration	20	1.37	3.91	0.00	0.0	15.4	20	-0.57	2.97	0.00	-11.6	4.0
Maintenance	19	0.73	1.78	0.00	0.0	5.9	19	-1.22	3.01	0.00	-10.6	0.0
Treatment	20	0.98	2.37	0.00	0.0	9.2	20	-0.96	2.64	0.00	-8.6	0.4

Note: Other AEDs includes all anti-epileptic drugs except Valproate and Lamotrigine.

Reference: Subject Data Listing 8.4.1

表 2.2-8　治療期間における 28 日あたりのミオクロニー発作発現日数及び Prospective ベースライン期間に対する変化量：SS（続き）

Table 7.4.1

Change in the Number of Days with Myoclonic Seizures per 28 Days by Subgroup and Phase During the Treatment Phase

Population: Safety Set

Subgroup / Phase	n	Actual Value Mean	SD	Med	Min	Max	n	Change From Baseline Mean	SD	Med	Min	Max
Other Generalized Idiopathic Epilepsies Not Defined Above: No												
Baseline	15	6.58	9.43	0.00	0.0	27.0						
Titration	15	4.53	8.32	0.00	0.0	28.0	15	-2.05	8.33	0.00	-23.2	10.3
Maintenance	13	1.61	4.65	0.00	0.0	16.9	13	-4.73	8.78	0.00	-26.3	0.0
Treatment	15	3.32	6.95	0.00	0.0	20.4	15	-3.26	8.29	0.00	-25.2	3.7
Use Of Valproate: Yes												
Baseline	12	5.86	8.51	0.00	0.0	24.0						
Titration	12	5.71	9.47	0.00	0.0	26.7	12	-0.15	3.64	0.00	-9.7	4.0
Maintenance	11	3.08	8.45	0.00	0.0	28.0	11	-1.84	4.98	0.00	-15.0	4.0
Treatment	12	4.91	9.33	0.00	0.0	27.6	12	-0.95	4.36	0.00	-13.2	3.7
Use Of Valproate: No												
Baseline	37	4.27	7.89	0.00	0.0	27.0						
Titration	37	2.61	5.95	0.00	0.0	28.0	37	-1.66	6.90	0.00	-23.9	10.3
Maintenance	33	1.23	3.38	0.00	0.0	16.9	33	-2.31	6.12	0.00	-26.3	1.7
Treatment	37	2.05	4.85	0.00	0.0	20.4	37	-2.22	6.88	0.00	-25.2	8.0

Note: Other AEDs includes all anti-epileptic drugs except Valproate and Lamotrigine.

Reference: Subject Data Listing 8.4.1

表 2.2-8　治療期間における 28 日あたりのミオクロニー発作発現日数及び Prospective ベースライン期間に対する変化量：SS（続き）

Table 7.4.1

Change in the Number of Days with Myoclonic Seizures per 28 Days by Subgroup and Phase During the Treatment Phase

Population: Safety Set

Subgroup / Phase	Actual Value n	Actual Value Mean	Actual Value SD	Actual Value Med	Actual Value Min	Actual Value Max	Change From Baseline n	Change From Baseline Mean	Change From Baseline SD	Change From Baseline Med	Change From Baseline Min	Change From Baseline Max
Use Of Lamotrigine: Yes												
Baseline	24	3.13	6.79	0.00	0.0	27.0						
Titration	24	2.89	7.08	0.00	0.0	28.0	24	-0.23	5.68	0.00	-23.2	10.3
Maintenance	22	1.34	4.01	0.00	0.0	16.9	22	-1.45	5.65	0.00	-26.3	1.7
Treatment	24	2.37	5.89	0.00	0.0	20.4	24	-0.76	5.59	0.00	-25.2	8.0
Use Of Lamotrigine: No												
Baseline	25	6.13	8.87	0.00	0.0	27.0						
Titration	25	3.83	7.03	0.00	0.0	26.7	25	-2.30	6.74	0.00	-23.9	4.0
Maintenance	22	2.05	6.03	0.00	0.0	28.0	22	-2.94	5.98	0.00	-20.7	4.0
Treatment	25	3.11	6.69	0.00	0.0	27.6	25	-3.02	6.90	0.00	-23.9	3.7
Use Of Other AEDs: Yes												
Baseline	43	4.29	7.68	0.00	0.0	27.0						
Titration	43	2.73	5.92	0.00	0.0	28.0	43	-1.56	6.59	0.00	-23.9	10.3
Maintenance	39	1.19	3.22	0.00	0.0	16.9	39	-2.48	6.04	0.00	-26.3	1.7
Treatment	43	2.01	4.66	0.00	0.0	20.4	43	-2.27	6.62	0.00	-25.2	8.0

Note: Other AEDs includes all anti-epileptic drugs except Valproate and Lamotrigine.

Reference: Subject Data Listing 8.4.1

表 2.2-8　治療期間における 28 日あたりのミオクロニー発作発現日数及び Prospective ベースライン期間に対する変化量：SS（続き）

Table 7.4.1

Change in the Number of Days with Myoclonic Seizures per 28 Days by Subgroup and Phase During the Treatment Phase

Population: Safety Set

Subgroup / Phase	Actual Value n	Actual Value Mean	Actual Value SD	Actual Value Med	Actual Value Min	Actual Value Max	Change From Baseline n	Change From Baseline Mean	Change From Baseline SD	Change From Baseline Med	Change From Baseline Min	Change From Baseline Max
Use Of Other AEDs: No												
Baseline	6	7.33	10.31	1.87	0.0	24.0						
Titration	6	7.97	12.09	0.58	0.0	26.7	6	0.64	2.61	0.58	-3.7	3.7
Maintenance	5	5.60	12.52	0.00	0.0	28.0	5	0.05	2.74	0.00	-3.7	4.0
Treatment	6	8.00	12.46	0.22	0.0	27.6	6	0.67	2.76	0.22	-3.7	3.7

Note: Other AEDs includes all anti-epileptic drugs except Valproate and Lamotrigine.

Reference: Subject Data Listing 8.4.1

2.2.3.3 副次評価項目

2.2.3.3.1 全般性棘徐波放電回数／3 Hz 棘徐波放電回数

本治験の SS でのポータブル 24 時間脳波検査における第 2 回来院及び第 6 回来院の結果、並びに第 2 回来院に対する第 6 回来院の変化量を表 2.2-9 に示した。また、第 2 回来院に対する第 6 回来院の変化率が 30%以上及び 50%以上増加した被験者数及び割合を表 2.2-10 に、30%以上及び 50%以上減少した被験者数及び割合を表 2.2-11 に示した。

全般性棘徐波放電回数及び 3 Hz 棘徐波放電回数が 30%以上及び 50%以上増加又は減少した被験者の割合は、いずれも同程度であった。覚醒時の 3 Hz 棘徐波放電回数が 30%以上増加した被験者と欠神発作発現日数が増加した被験者に、明らかな関連性は認められなかった。なお、Prospective ベースライン期間中に欠神発作を発現せず、治療期間中に欠神発作を発現した被験者、及び／又は欠神発作の有害事象を発現した被験者が 8 例認められた。このうち、2 例のみに 3 Hz 棘徐波放電回数の増加と関連性が認められた。

表 2.2-9　ポータブル 24 時間脳波検査の結果及び第 2 回来院に対する第 6 回来院の変化量：SS

Table 8.2.1
24 Hours EEG Evaluation
Population: Safety Set

Parameter / Visit	Visit Values n	Mean	SD	Med	Min	Max	Change from Visit 2 n	Mean	SD	Med	Min	Max
Sleep Hours [h]												
VISIT 2	46	7.87	1.51	7.92	4.3	11.4						
VISIT 2 with VISIT 6	40	7.93	1.54	8.03	4.3	11.4						
VISIT 6	42	8.34	1.64	8.10	4.5	12.6	40	0.41	2.14	0.02	-5.1	6.5
Awake Hours [h]												
VISIT 2	46	15.90	1.78	15.63	12.5	20.7						
VISIT 2 with VISIT 6	40	15.89	1.84	15.63	12.5	20.7						
VISIT 6	42	15.59	1.84	15.84	11.6	20.5	40	-0.31	2.25	0.03	-4.4	6.0
Interpretable Hours [h]												
VISIT 2	46	23.77	1.35	24.03	19.9	28.2						
VISIT 2 with VISIT 6	40	23.82	1.43	24.03	19.9	28.2						
VISIT 6	42	23.93	0.92	24.07	20.9	26.4	40	0.10	1.36	-0.03	-3.5	4.5

Note: Only subjects with an evaluable EEG measurement at the respective visit are included in summaries (ie, >19 interpretable hours).

Reference: Subject Data Listing 8.2.1

表 2.2-9　ポータブル 24 時間脳波検査の結果及び第 2 回来院に対する第 6 回来院の変化量：SS（続き）

Table 8.2.1
24 Hours EEG Evaluation
Population: Safety Set

Parameter / Visit	Visit Values n	Mean	SD	Med	Min	Max	Change from Visit 2 n	Mean	SD	Med	Min	Max
Sleep Hours / Interpretable Hours												
VISIT 2	46	0.33	0.06	0.34	0.2	0.5						
VISIT 2 with VISIT 6	40	0.33	0.06	0.34	0.2	0.5						
VISIT 6	42	0.35	0.07	0.34	0.2	0.5	40	0.02	0.09	0.00	-0.2	0.2
Awake Hours / Interpretable Hours												
VISIT 2	46	0.67	0.06	0.66	0.5	0.8						
VISIT 2 with VISIT 6	40	0.67	0.06	0.66	0.5	0.8						
VISIT 6	42	0.65	0.07	0.66	0.5	0.8	40	-0.02	0.09	-0.00	-0.2	0.2
General Spike Wave Discharges / Interpretable Hours [1/h]												
VISIT 2	46	55.32	119.01	11.02	0.0	582.3						
VISIT 2 with VISIT 6	40	53.15	124.67	8.35	0.0	582.3						
VISIT 6	42	51.60	97.18	8.57	0.0	522.3	40	-3.47	55.85	0.00	-255.5	104.4

Note: Only subjects with an evaluable EEG measurement at the respective visit are included in summaries (ie, >19 interpretable hours).

Reference: Subject Data Listing 8.2.1

表 2.2-9　ポータブル 24 時間脳波検査の結果及び第 2 回来院に対する第 6 回来院の変化量：SS（続き）

Table 8.2.1
24 Hours EEG Evaluation
Population: Safety Set

Parameter / Visit	Visit Values n	Mean	SD	Med	Min	Max	Change from Visit 2 n	Mean	SD	Med	Min	Max
3 Hz Spike Wave Discharges / Awake Hours [1/h]												
VISIT 2	46	0.71	1.63	0.00	0.0	7.6						
VISIT 2 with VISIT 6	40	0.55	1.54	0.00	0.0	7.6						
VISIT 6	42	0.96	2.51	0.00	0.0	11.6	40	0.13	2.17	0.00	-6.9	8.6

Note: Only subjects with an evaluable EEG measurement at the respective visit are included in summaries (ie, >19 interpretable hours).

Reference: Subject Data Listing 8.2.1

表 2.2-10　ポータブル 24 時間脳波検査で第 2 回来院に対する第 6 回来院の変化率が 30%以上及び 50%以上増加した被験者数と割合：SS

Table 8.4.1

24 Hours EEG Evaluation - Frequency Table of 30% and 50% Increases

Population: Safety Set

Parameter Category	N = 49 n (%)
Evaluable EEG measurements at both Visit 2 and Visit 6	40 (81.6)
Sleep Hours [h]	
>=30% Increase at Visit 6 compared to Visit 2	9 (22.5)
>=50% Increase at Visit 6 compared to Visit 2	4 (10.0)
Awake Hours [h]	
>=30% Increase at Visit 6 compared to Visit 2	1 (2.5)
>=50% Increase at Visit 6 compared to Visit 2	0
Interpretable Hours [h]	
>=30% Increase at Visit 6 compared to Visit 2	0
>=50% Increase at Visit 6 compared to Visit 2	0
Sleep Hours / Interpretable Hours	
>=30% Increase at Visit 6 compared to Visit 2	10 (25.0)
>=50% Increase at Visit 6 compared to Visit 2	5 (12.5)
Awake Hours / Interpretable Hours	
>=30% Increase at Visit 6 compared to Visit 2	1 (2.5)
>=50% Increase at Visit 6 compared to Visit 2	0

Note: Percentage for evaluable EEG measurements is calculated based on the number of subjects in the Safety Set. All other percentages are calculated based on the number of subjects with evaluable EEG measurements at both Visit 2 and Visit 6 (ie, >19 interpretable hours).

Reference: Subject Data Listing 8.2.1

表 2.2-10　ポータブル 24 時間脳波検査で第 2 回来院に対する第 6 回来院の変化率が 30%以上及び 50%以上増加した被験者数と割合:SS(続き)

Table 8.4.1

24 Hours EEG Evaluation - Frequency Table of 30% and 50% Increases

Population: Safety Set

Parameter Category	N = 49 n (%)
General Spike Wave Discharges / Interpretable Hours [1/h]	
>=30% Increase at Visit 6 compared to Visit 2	11 (27.5)
>=50% Increase at Visit 6 compared to Visit 2	10 (25.0)
3 Hz Spike Wave Discharges / Awake Hours [1/h]	
>=30% Increase at Visit 6 compared to Visit 2	2 (5.0)
>=50% Increase at Visit 6 compared to Visit 2	2 (5.0)

Note: Percentage for evaluable EEG measurements is calculated based on the number of subjects in the Safety Set. All other percentages are calculated based on the number of subjects with evaluable EEG measurements at both Visit 2 and Visit 6 (ie, >19 interpretable hours).

Reference: Subject Data Listing 8.2.1

表 2.2-11　ポータブル 24 時間脳波検査で第 2 回来院に対する第 6 回来院の変化率が 30%以上及び 50%以上減少した被験者数と割合：SS

Table 8.5.1

24 Hours EEG Evaluation - Frequency Table of 30% and 50% Decreases

Population: Safety Set

Parameter Category	N = 49 n (%)
Evaluable EEG measurements at both Visit 2 and Visit 6	40 (81.6)
Sleep Hours [h]	
>=30% Decrease at Visit 6 compared to Visit 2	2 (5.0)
>=50% Decrease at Visit 6 compared to Visit 2	1 (2.5)
Awake Hours [h]	
>=30% Decrease at Visit 6 compared to Visit 2	0
>=50% Decrease at Visit 6 compared to Visit 2	0
Interpretable Hours [h]	
>=30% Decrease at Visit 6 compared to Visit 2	0
>=50% Decrease at Visit 6 compared to Visit 2	0
Sleep Hours / Interpretable Hours	
>=30% Decrease at Visit 6 compared to Visit 2	2 (5.0)
>=50% Decrease at Visit 6 compared to Visit 2	1 (2.5)
Awake Hours / Interpretable Hours	
>=30% Decrease at Visit 6 compared to Visit 2	1 (2.5)
>=50% Decrease at Visit 6 compared to Visit 2	0

Note: Percentage for evaluable EEG measurements is calculated based on the number of subjects in the Safety Set. All other percentages are calculated based on the number of subjects with evaluable EEG measurements at both Visit 2 and Visit 6 (ie, >19 interpretable hours).

Reference: Subject Data Listing 8.2.1

表 2.2-11　ポータブル 24 時間脳波検査で第 2 回来院に対する第 6 回来院の変化率が 30%以上及び 50%以上減少した被験者数と割合:SS(続き)

Table 8.5.1

24 Hours EEG Evaluation - Frequency Table of 30% and 50% Decreases

Population: Safety Set

Parameter Category	N = 49 n (%)
General Spike Wave Discharges / Interpretable Hours [1/h]	
>=30% Decrease at Visit 6 compared to Visit 2	13 (32.5)
>=50% Decrease at Visit 6 compared to Visit 2	11 (27.5)
3 Hz Spike Wave Discharges / Awake Hours [1/h]	
>=30% Decrease at Visit 6 compared to Visit 2	4 (10.0)
>=50% Decrease at Visit 6 compared to Visit 2	3 (7.5)

Note: Percentage for evaluable EEG measurements is calculated based on the number of subjects in the Safety Set. All other percentages are calculated based on the number of subjects with evaluable EEG measurements at both Visit 2 and Visit 6 (ie, >19 interpretable hours).

Reference: Subject Data Listing 8.2.1

2.2.3.4 その他の評価項目

2.2.3.4.1 強直間代発作回数の変化量及び変化率

本治験の SS での治療期間（増量期間+維持期間）における 28 日あたりの強直間代発作回数及び Combined ベースライン期間に対する変化量を部分集団別及び期間別に表 2.2-12 に示し、Combined ベースライン期間に対する治療期間（増量期間+維持期間）の 28 日あたりの強直間代発作回数の変化率を部分集団別及び期間別に表 2.2-13 に示した。また、Prospective ベースライン期間に対する治療期間（増量期間+維持期間）の 28 日あたりの強直間代発作回数の変化率を部分集団別及び期間別に表 2.2-14 に示した。

Combined ベースライン期間に対する 28 日あたりの強直間代発作回数の変化量の平均値 ± 標準偏差は、維持期間が−0.27 ± 1.05 回で、治療期間が 0.04 ± 2.40 回であった。また、変化量の中央値は、維持期間が−0.35 回で、治療期間が−0.25 回であった。

Combined ベースライン期間に対する 28 日あたりの強直間代発作回数の変化率の平均値 ± 標準偏差は、維持期間が−26.37 ± 156.16%で、治療期間が−25.37 ± 106.67%であった。また、変化率の中央値は、維持期間が−100%で、治療期間が−65.00%であった。Prospective ベースライン期間に対する 28 日あたりの強直間代発作回数の変化率の中央値は、維持期間が−100%で、治療期間が−68.23%であった。なお、29 例（59.2%）は Combined ベースライン期間に強直間代発作を発現したが、維持期間では発現しなかった。

表 2.2-12　治療期間における 28 日あたりの強直間代発作回数及び Combined ベースライン期間に対する変化量：SS

Table 7.7.1

Change in the Number of PGTC Seizures per 28 Days by Subgroup and Phase During the Treatment Phase

Population: Safety Set

Subgroup / Phase	Actual Value n	Actual Value Mean	Actual Value SD	Actual Value Med	Actual Value Min	Actual Value Max	Change From Baseline n	Change From Baseline Mean	Change From Baseline SD	Change From Baseline Med	Change From Baseline Min	Change From Baseline Max
All Subjects												
Baseline	49	0.94	0.74	0.75	0.3	3.5						
Titration	49	1.03	2.83	0.00	0.0	19.1	49	0.09	2.48	-0.25	-2.0	15.8
Maintenance	44	0.59	1.18	0.00	0.0	5.5	44	-0.27	1.05	-0.35	-2.0	3.5
Treatment	49	0.98	2.78	0.43	0.0	19.1	49	0.04	2.40	-0.25	-2.0	15.8
Age At Onset Of The Diagnosis: <2 years												
Baseline	2	1.25	1.41	1.25	0.3	2.3						
Titration	2	1.33	1.89	1.33	0.0	2.7	2	0.08	0.47	0.08	-0.3	0.4
Maintenance	2	0.34	0.48	0.34	0.0	0.7	2	-0.91	0.93	-0.91	-1.6	-0.3
Treatment	2	0.68	0.96	0.68	0.0	1.4	2	-0.57	0.46	-0.57	-0.9	-0.3
Age At Onset Of The Diagnosis: 2 - <5 years												
Baseline	4	1.00	0.35	1.13	0.5	1.3						
Titration	4	1.39	1.62	1.22	0.0	3.1	4	0.39	1.54	0.34	-1.3	2.1
Maintenance	4	0.83	1.00	0.67	0.0	2.0	4	-0.17	1.34	-0.46	-1.3	1.5
Treatment	4	1.09	0.90	1.10	0.0	2.2	4	0.09	1.11	0.23	-1.3	1.2

Note: Change from Baseline is defined as the change from the Combined Baseline Phase, which is the 16 weeks prior to start of treatment.
Note: Other AEDs includes all anti-epileptic drugs except Valproate and Lamotrigine.

Reference: Subject Data Listing 8.4.1

表 2.2-12　治療期間における 28 日あたりの強直間代発作回数及び Combined ベースライン期間に対する変化量：SS（続き）

Table 7.7.1

Change in the Number of PGTC Seizures per 28 Days by Subgroup and Phase During the Treatment Phase

Population: Safety Set

Subgroup / Phase	Actual Value n	Actual Value Mean	Actual Value SD	Actual Value Med	Actual Value Min	Actual Value Max	Change From Baseline n	Change From Baseline Mean	Change From Baseline SD	Change From Baseline Med	Change From Baseline Min	Change From Baseline Max
Age At Onset Of The Diagnosis: 5 - <10 years												
Baseline	9	1.20	0.37	1.25	0.5	1.8						
Titration	9	0.44	1.33	0.00	0.0	4.0	9	-0.75	1.37	-1.25	-1.8	2.8
Maintenance	8	0.33	0.70	0.00	0.0	2.0	8	-0.86	0.77	-1.00	-1.8	0.7
Treatment	9	0.39	0.68	0.00	0.0	1.8	9	-0.80	0.75	-0.81	-1.8	0.5
Age At Onset Of The Diagnosis: 10 - <15 years												
Baseline	22	1.03	0.93	0.75	0.3	3.5						
Titration	22	1.51	4.03	0.00	0.0	19.1	22	0.48	3.51	-0.25	-2.0	15.8
Maintenance	18	0.68	1.49	0.00	0.0	5.5	18	-0.20	0.95	-0.28	-2.0	2.0
Treatment	22	1.55	4.07	0.00	0.0	19.1	22	0.53	3.46	-0.25	-2.0	15.8
Age At Onset Of The Diagnosis: 15 - <20 years												
Baseline	8	0.41	0.19	0.38	0.3	0.8						
Titration	8	0.48	0.66	0.00	0.0	1.3	8	0.07	0.61	-0.25	-0.5	1.1
Maintenance	8	0.81	1.36	0.33	0.0	4.0	8	0.41	1.36	-0.04	-0.8	3.5
Treatment	8	0.48	0.27	0.44	0.0	1.0	8	0.07	0.29	0.07	-0.3	0.5

Note: Change from Baseline is defined as the change from the Combined Baseline Phase, which is the 16 weeks prior to start of treatment.

Note: Other AEDs includes all anti-epileptic drugs except Valproate and Lamotrigine.

Reference: Subject Data Listing 8.4.1

表 2.2-12　治療期間における 28 日あたりの強直間代発作回数及び Combined ベースライン期間に対する変化量：SS（続き）

Table 7.7.1

Change in the Number of PGTC Seizures per 28 Days by Subgroup and Phase During the Treatment Phase

Population: Safety Set

Subgroup / Phase	Actual Value n	Actual Value Mean	Actual Value SD	Actual Value Med	Actual Value Min	Actual Value Max	Change From Baseline n	Change From Baseline Mean	Change From Baseline SD	Change From Baseline Med	Change From Baseline Min	Change From Baseline Max
Age At Onset Of The Diagnosis: >=20 years												
Baseline	4	0.75	0.61	0.63	0.3	1.5						
Titration	4	0.33	0.67	0.00	0.0	1.3	4	-0.42	0.77	-0.25	-1.5	0.3
Maintenance	4	0.16	0.31	0.00	0.0	0.6	4	-0.59	0.61	-0.31	-1.5	-0.3
Treatment	4	0.21	0.42	0.00	0.0	0.8	4	-0.54	0.64	-0.25	-1.5	-0.2
Childhood Absence Epilepsy: Yes												
Baseline	4	0.69	0.43	0.63	0.3	1.3						
Titration	4	1.33	1.89	0.67	0.0	4.0	4	0.65	1.48	0.17	-0.5	2.8
Maintenance	4	0.17	0.33	0.00	0.0	0.7	4	-0.52	0.61	-0.50	-1.3	0.2
Treatment	4	0.67	0.77	0.45	0.0	1.8	4	-0.02	0.38	-0.15	-0.3	0.5
Childhood Absence Epilepsy: No												
Baseline	33	1.04	0.82	0.75	0.3	3.5						
Titration	33	1.23	3.34	0.00	0.0	19.1	33	0.19	2.93	-0.25	-1.8	15.8
Maintenance	30	0.71	1.36	0.00	0.0	5.5	30	-0.21	1.15	-0.35	-1.8	3.5
Treatment	33	1.25	3.34	0.44	0.0	19.1	33	0.21	2.87	-0.25	-1.8	15.8

Note: Change from Baseline is defined as the change from the Combined Baseline Phase, which is the 16 weeks prior to start of treatment.
Note: Other AEDs includes all anti-epileptic drugs except Valproate and Lamotrigine.

Reference: Subject Data Listing 8.4.1

表 2.2-12　治療期間における 28 日あたりの強直間代発作回数及び Combined ベースライン期間に対する変化量：SS（続き）

Table 7.7.1

Change in the Number of PGTC Seizures per 28 Days by Subgroup and Phase During the Treatment Phase

Population: Safety Set

Subgroup / Phase	Actual Value n	Actual Value Mean	Actual Value SD	Actual Value Med	Actual Value Min	Actual Value Max	Change From Baseline n	Change From Baseline Mean	Change From Baseline SD	Change From Baseline Med	Change From Baseline Min	Change From Baseline Max
Epilepsy With Grand Mal Seizures On Awakening: Yes												
Baseline	0											
Titration	0						0					
Maintenance	0						0					
Treatment	0						0					
Epilepsy With Grand Mal Seizures On Awakening: No												
Baseline	35	1.01	0.81	0.75	0.3	3.5						
Titration	35	1.20	3.25	0.00	0.0	19.1	35	0.19	2.84	-0.25	-1.8	15.8
Maintenance	32	0.67	1.33	0.00	0.0	5.5	32	-0.23	1.12	-0.35	-1.8	3.5
Treatment	35	1.19	3.25	0.44	0.0	19.1	35	0.18	2.79	-0.25	-1.8	15.8
Epilepsies With Seizures Precipitated By Specific Modes Of Activation: Yes												
Baseline	0											
Titration	0						0					
Maintenance	0						0					
Treatment	0						0					

Note: Change from Baseline is defined as the change from the Combined Baseline Phase, which is the 16 weeks prior to start of treatment.

Note: Other AEDs includes all anti-epileptic drugs except Valproate and Lamotrigine.

Reference: Subject Data Listing 8.4.1

表 2.2-12　治療期間における 28 日あたりの強直間代発作回数及び Combined ベースライン期間に対する変化量：SS（続き）

Table 7.7.1

Change in the Number of PGTC Seizures per 28 Days by Subgroup and Phase During the Treatment Phase

Population: Safety Set

Subgroup / Phase	Actual Value n	Actual Value Mean	Actual Value SD	Actual Value Med	Actual Value Min	Actual Value Max	Change From Baseline n	Change From Baseline Mean	Change From Baseline SD	Change From Baseline Med	Change From Baseline Min	Change From Baseline Max
Epilepsies With Seizures Precipitated By Specific Modes Of Activation: No												
Baseline	34	1.03	0.81	0.75	0.3	3.5						
Titration	34	1.24	3.29	0.00	0.0	19.1	34	0.21	2.88	-0.25	-1.8	15.8
Maintenance	31	0.69	1.34	0.00	0.0	5.5	31	-0.23	1.14	-0.38	-1.8	3.5
Treatment	34	1.22	3.29	0.44	0.0	19.1	34	0.19	2.83	-0.25	-1.8	15.8
Juvenile Absence Epilepsy: Yes												
Baseline	3	1.60	1.56	1.25	0.3	3.3						
Titration	3	6.36	11.02	0.00	0.0	19.1	3	4.76	9.56	-0.25	-1.3	15.8
Maintenance	2	0.00	0.00	0.00	0.0	0.0	2	-0.75	0.71	-0.75	-1.3	-0.3
Treatment	3	6.36	11.02	0.00	0.0	19.1	3	4.76	9.56	-0.25	-1.3	15.8
Juvenile Absence Epilepsy: No												
Baseline	35	0.91	0.71	0.75	0.3	3.5						
Titration	35	0.66	0.94	0.00	0.0	2.7	35	-0.25	0.82	-0.25	-1.8	1.9
Maintenance	33	0.73	1.32	0.00	0.0	5.5	33	-0.14	1.13	-0.32	-1.8	3.5
Treatment	35	0.69	0.92	0.44	0.0	4.4	35	-0.21	0.64	-0.25	-1.8	0.9

Note: Change from Baseline is defined as the change from the Combined Baseline Phase, which is the 16 weeks prior to start of treatment.
Note: Other AEDs includes all anti-epileptic drugs except Valproate and Lamotrigine.

Reference: Subject Data Listing 8.4.1

表 2.2-12　治療期間における 28 日あたりの強直間代発作回数及び Combined ベースライン期間に対する変化量：SS（続き）

Table 7.7.1

Change in the Number of PGTC Seizures per 28 Days by Subgroup and Phase During the Treatment Phase

Population: Safety Set

Subgroup / Phase	Actual Value n	Actual Value Mean	Actual Value SD	Actual Value Med	Actual Value Min	Actual Value Max	Change From Baseline n	Change From Baseline Mean	Change From Baseline SD	Change From Baseline Med	Change From Baseline Min	Change From Baseline Max
Juvenile Myoclonic Epilepsy: Yes												
Baseline	16	0.58	0.45	0.50	0.3	2.0						
Titration	16	0.37	0.68	0.00	0.0	2.0	16	-0.21	0.50	-0.25	-0.8	1.1
Maintenance	15	0.22	0.55	0.00	0.0	2.0	15	-0.26	0.58	-0.25	-0.8	1.5
Treatment	16	0.35	0.59	0.00	0.0	2.0	16	-0.23	0.41	-0.25	-0.8	0.8
Juvenile Myoclonic Epilepsy: No												
Baseline	22	1.25	0.87	1.25	0.3	3.5						
Titration	22	1.64	4.03	0.00	0.0	19.1	22	0.39	3.58	-0.25	-1.8	15.8
Maintenance	20	1.00	1.59	0.00	0.0	5.5	20	-0.15	1.40	-0.55	-1.8	3.5
Treatment	22	1.70	4.02	0.74	0.0	19.1	22	0.45	3.51	-0.20	-1.8	15.8
Other Generalized Idiopathic Epilepsies Not Defined Above: Yes												
Baseline	20	1.13	0.79	1.13	0.3	3.5						
Titration	20	0.78	1.07	0.00	0.0	2.7	20	-0.34	0.99	-0.25	-1.8	1.9
Maintenance	19	1.05	1.61	0.00	0.0	5.5	19	-0.07	1.41	-0.38	-1.8	3.5
Treatment	20	0.89	1.08	0.74	0.0	4.4	20	-0.23	0.78	-0.20	-1.8	0.9

Note: Change from Baseline is defined as the change from the Combined Baseline Phase, which is the 16 weeks prior to start of treatment.
Note: Other AEDs includes all anti-epileptic drugs except Valproate and Lamotrigine.

Reference: Subject Data Listing 8.4.1

表 2.2-12　治療期間における 28 日あたりの強直間代発作回数及び Combined ベースライン期間に対する変化量：SS（続き）

Table 7.7.1

Change in the Number of PGTC Seizures per 28 Days by Subgroup and Phase During the Treatment Phase

Population: Safety Set

Subgroup / Phase	Actual Value n	Actual Value Mean	Actual Value SD	Actual Value Med	Actual Value Min	Actual Value Max	Change From Baseline n	Change From Baseline Mean	Change From Baseline SD	Change From Baseline Med	Change From Baseline Min	Change From Baseline Max
Other Generalized Idiopathic Epilepsies Not Defined Above: No												
Baseline	15	0.85	0.84	0.75	0.3	3.3						
Titration	15	1.76	4.85	0.00	0.0	19.1	15	0.90	4.16	-0.25	-1.3	15.8
Maintenance	13	0.10	0.25	0.00	0.0	0.7	13	-0.47	0.41	-0.32	-1.3	0.4
Treatment	15	1.58	4.87	0.00	0.0	19.1	15	0.73	4.18	-0.25	-1.3	15.8
Use Of Valproate: Yes												
Baseline	12	0.94	0.59	0.75	0.3	2.0						
Titration	12	0.60	0.77	0.00	0.0	2.0	12	-0.33	0.85	-0.25	-2.0	0.7
Maintenance	11	0.20	0.67	0.00	0.0	2.2	11	-0.64	0.80	-0.75	-2.0	1.2
Treatment	12	0.44	0.74	0.00	0.0	2.0	12	-0.50	0.75	-0.30	-2.0	0.9
Use Of Valproate: No												
Baseline	37	0.94	0.79	0.75	0.3	3.5						
Titration	37	1.17	3.23	0.00	0.0	19.1	37	0.23	2.81	-0.25	-1.8	15.8
Maintenance	33	0.72	1.29	0.00	0.0	5.5	33	-0.15	1.11	-0.25	-1.8	3.5
Treatment	37	1.16	3.17	0.44	0.0	19.1	37	0.22	2.71	-0.25	-1.8	15.8

Note: Change from Baseline is defined as the change from the Combined Baseline Phase, which is the 16 weeks prior to start of treatment.
Note: Other AEDs includes all anti-epileptic drugs except Valproate and Lamotrigine.

Reference: Subject Data Listing 8.4.1

表 2.2-12　治療期間における 28 日あたりの強直間代発作回数及び Combined ベースライン期間に対する変化量：SS（続き）

Table 7.7.1

Change in the Number of PGTC Seizures per 28 Days by Subgroup and Phase During the Treatment Phase

Population: Safety Set

Subgroup / Phase	Actual Value n	Actual Value Mean	Actual Value SD	Actual Value Med	Actual Value Min	Actual Value Max	Change From Baseline n	Change From Baseline Mean	Change From Baseline SD	Change From Baseline Med	Change From Baseline Min	Change From Baseline Max
Use Of Lamotrigine: Yes												
Baseline	24	0.79	0.69	0.63	0.3	3.5						
Titration	24	0.74	1.21	0.00	0.0	4.0	24	-0.05	1.02	-0.25	-1.5	2.8
Maintenance	22	0.79	1.44	0.00	0.0	5.5	22	-0.01	1.10	-0.25	-1.5	3.5
Treatment	24	0.72	1.04	0.22	0.0	4.4	24	-0.07	0.58	-0.20	-1.5	1.2
Use Of Lamotrigine: No												
Baseline	25	1.08	0.77	1.00	0.3	3.3						
Titration	25	1.31	3.80	0.00	0.0	19.1	25	0.23	3.36	-0.25	-2.0	15.8
Maintenance	22	0.39	0.84	0.00	0.0	3.3	22	-0.54	0.95	-0.67	-2.0	1.8
Treatment	25	1.23	3.78	0.43	0.0	19.1	25	0.15	3.34	-0.31	-2.0	15.8
Use Of Other AEDs: Yes												
Baseline	43	0.94	0.76	0.75	0.3	3.5						
Titration	43	1.07	3.01	0.00	0.0	19.1	43	0.13	2.64	-0.25	-2.0	15.8
Maintenance	39	0.66	1.24	0.00	0.0	5.5	39	-0.22	1.10	-0.25	-2.0	3.5
Treatment	43	1.05	2.95	0.44	0.0	19.1	43	0.11	2.55	-0.25	-2.0	15.8

Note: Change from Baseline is defined as the change from the Combined Baseline Phase, which is the 16 weeks prior to start of treatment.
Note: Other AEDs includes all anti-epileptic drugs except Valproate and Lamotrigine.

Reference: Subject Data Listing 8.4.1

表 2.2-12　治療期間における 28 日あたりの強直間代発作回数及び Combined ベースライン期間に対する変化量：SS（続き）

Table 7.7.1

Change in the Number of PGTC Seizures per 28 Days by Subgroup and Phase During the Treatment Phase

Population: Safety Set

Subgroup / Phase	Actual Value n	Actual Value Mean	Actual Value SD	Actual Value Med	Actual Value Min	Actual Value Max	Change From Baseline n	Change From Baseline Mean	Change From Baseline SD	Change From Baseline Med	Change From Baseline Min	Change From Baseline Max
Use Of Other AEDs: No												
Baseline	6	0.92	0.63	0.75	0.3	2.0						
Titration	6	0.75	0.87	0.58	0.0	2.0	6	-0.17	0.75	-0.13	-1.3	0.7
Maintenance	5	0.00	0.00	0.00	0.0	0.0	5	-0.70	0.37	-0.75	-1.3	-0.3
Treatment	6	0.48	0.78	0.22	0.0	2.0	6	-0.44	0.48	-0.28	-1.3	0.0

Note: Change from Baseline is defined as the change from the Combined Baseline Phase, which is the 16 weeks prior to start of treatment.

Note: Other AEDs includes all anti-epileptic drugs except Valproate and Lamotrigine.

Reference: Subject Data Listing 8.4.1

表 2.2-13　Combined ベースライン期間に対する治療期間の 28 日あたりの強直間代発作回数の変化率：SS

Table 7.8.1

Percent Change in PGTC Seizure Frequency per 28 Days from the Combined Baseline by Subgroup and Phase During the Treatment Phase

Population: Safety Set

Subgroup Phase	n	Mean	SD	Med	Min	Max
All Subjects						
Titration	49	-21.06	138.56	-100.00	-100.0	476.9
Maintenance	44	-26.37	156.16	-100.00	-100.0	700.0
Treatment	49	-25.37	106.67	-65.00	-100.0	476.9
Age At Onset Of The Diagnosis: <2 years						
Titration	2	-40.74	83.81	-40.74	-100.0	18.5
Maintenance	2	-84.82	21.46	-84.82	-100.0	-69.6
Treatment	2	-69.89	42.58	-69.89	-100.0	-39.8
Age At Onset Of The Diagnosis: 2 - <5 years						
Titration	4	26.47	153.57	-2.61	-100.0	211.1
Maintenance	4	33.33	188.56	-33.33	-100.0	300.0
Treatment	4	38.01	124.11	42.69	-100.0	166.7
Age At Onset Of The Diagnosis: 5 - <10 years						
Titration	9	-64.44	106.67	-100.00	-100.0	220.0
Maintenance	8	-73.95	55.69	-100.00	-100.0	56.3
Treatment	9	-68.46	54.63	-100.00	-100.0	42.2

Note: Other AEDs includes all anti-epileptic drugs except Valproate and Lamotrigine.

Reference: Subject Data Listing 8.4.1

表 2.2-13　Combined ベースライン期間に対する治療期間の 28 日あたりの強直間代発作回数の変化率：SS（続き）

Table 7.8.1

Percent Change in PGTC Seizure Frequency per 28 Days from the Combined Baseline by Subgroup and Phase During the Treatment Phase

Population: Safety Set

Subgroup Phase	n	Mean	SD	Med	Min	Max
Age At Onset Of The Diagnosis: 10 - <15 years						
Titration	22	-16.09	143.52	-100.00	-100.0	476.9
Maintenance	18	-58.96	76.89	-100.00	-100.0	121.1
Treatment	22	-25.62	128.59	-100.00	-100.0	476.9
Age At Onset Of The Diagnosis: 15 - <20 years						
Titration	8	18.06	192.35	-100.00	-100.0	433.3
Maintenance	8	108.33	292.63	-33.33	-100.0	700.0
Treatment	8	29.96	83.65	33.33	-100.0	148.9
Age At Onset Of The Diagnosis: >=20 years						
Titration	4	-66.67	66.67	-100.00	-100.0	33.3
Maintenance	4	-84.44	31.11	-100.00	-100.0	-37.8
Treatment	4	-78.79	42.42	-100.00	-100.0	-15.2
Childhood Absence Epilepsy: Yes						
Titration	4	24.44	154.98	-11.11	-100.0	220.0
Maintenance	4	-66.67	66.67	-100.00	-100.0	33.3
Treatment	4	-27.17	59.26	-25.45	-100.0	42.2

Note: Other AEDs includes all anti-epileptic drugs except Valproate and Lamotrigine.

Reference: Subject Data Listing 8.4.1

表 2.2-13　Combined ベースライン期間に対する治療期間の 28 日あたりの強直間代発作回数の変化率：SS（続き）

Table 7.8.1

Percent Change in PGTC Seizure Frequency per 28 Days from the Combined Baseline by Subgroup and Phase During the Treatment Phase

Population: Safety Set

Subgroup Phase	n	Mean	SD	Med	Min	Max
Childhood Absence Epilepsy: No						
Titration	33	-12.68	149.26	-100.00	-100.0	476.9
Maintenance	30	-16.77	174.00	-100.00	-100.0	700.0
Treatment	33	-15.85	115.21	-39.78	-100.0	476.9
Epilepsy With Grand Mal Seizures On Awakening: Yes						
Titration	0					
Maintenance	0					
Treatment	0					
Epilepsy With Grand Mal Seizures On Awakening: No						
Titration	35	-12.59	146.40	-100.00	-100.0	476.9
Maintenance	32	-21.98	169.54	-100.00	-100.0	700.0
Treatment	35	-18.94	112.73	-39.78	-100.0	476.9
Epilepsies With Seizures Precipitated By Specific Modes Of Activation: Yes						
Titration	0					
Maintenance	0					
Treatment	0					

Note: Other AEDs includes all anti-epileptic drugs except Valproate and Lamotrigine.

Reference: Subject Data Listing 8.4.1

表 2.2-13　Combined ベースライン期間に対する治療期間の 28 日あたりの強直間代発作回数の変化率：SS（続き）

Table 7.8.1

Percent Change in PGTC Seizure Frequency per 28 Days from the Combined Baseline by Subgroup and Phase During the Treatment Phase

Population: Safety Set

Subgroup Phase	n	Mean	SD	Med	Min	Max
Epilepsies With Seizures Precipitated By Specific Modes Of Activation: No						
Titration	34	-10.02	147.80	-100.00	-100.0	476.9
Maintenance	31	-19.46	171.73	-100.00	-100.0	700.0
Treatment	34	-16.55	113.53	-39.78	-100.0	476.9
Juvenile Absence Epilepsy: Yes						
Titration	3	92.31	333.09	-100.00	-100.0	476.9
Maintenance	2	-100.00	0.00	-100.00	-100.0	-100.0
Treatment	3	92.31	333.09	-100.00	-100.0	476.9
Juvenile Absence Epilepsy: No						
Titration	35	-29.08	119.71	-100.00	-100.0	433.3
Maintenance	33	-8.18	175.48	-100.00	-100.0	700.0
Treatment	35	-25.26	79.10	-39.78	-100.0	166.7
Juvenile Myoclonic Epilepsy: Yes						
Titration	16	-41.35	138.37	-100.00	-100.0	433.3
Maintenance	15	-51.00	119.45	-100.00	-100.0	300.0
Treatment	16	-45.60	85.00	-100.00	-100.0	166.7

Note: Other AEDs includes all anti-epileptic drugs except Valproate and Lamotrigine.

Reference: Subject Data Listing 8.4.1

表 2.2-13　Combined ベースライン期間に対する治療期間の 28 日あたりの強直間代発作回数の変化率：SS（続き）

Table 7.8.1

Percent Change in PGTC Seizure Frequency per 28 Days from the Combined Baseline by Subgroup and Phase During the Treatment Phase

Population: Safety Set

Subgroup Phase	n	Mean	SD	Med	Min	Max
Juvenile Myoclonic Epilepsy: No						
Titration	22	-3.60	146.29	-100.00	-100.0	476.9
Maintenance	20	8.09	202.14	-100.00	-100.0	700.0
Treatment	22	1.53	129.23	-22.58	-100.0	476.9
Other Generalized Idiopathic Epilepsies Not Defined Above: Yes						
Titration	20	-31.69	101.59	-100.00	-100.0	255.6
Maintenance	19	13.78	206.03	-100.00	-100.0	700.0
Treatment	20	-20.18	77.32	-22.58	-100.0	148.9
Other Generalized Idiopathic Epilepsies Not Defined Above: No						
Titration	15	12.87	191.91	-100.00	-100.0	476.9
Maintenance	13	-74.23	74.80	-100.00	-100.0	166.7
Treatment	15	-17.28	150.82	-100.00	-100.0	476.9
Use Of Valproate: Yes						
Titration	12	-30.93	90.45	-100.00	-100.0	133.3
Maintenance	11	-79.90	66.65	-100.00	-100.0	121.1
Treatment	12	-58.44	61.14	-100.00	-100.0	93.1

Note: Other AEDs includes all anti-epileptic drugs except Valproate and Lamotrigine.

Reference: Subject Data Listing 8.4.1

表 2.2-13　Combined ベースライン期間に対する治療期間の 28 日あたりの強直間代発作回数の変化率：SS（続き）

Table 7.8.1

Percent Change in PGTC Seizure Frequency per 28 Days from the Combined Baseline by Subgroup and Phase During the Treatment Phase

Population: Safety Set

Subgroup Phase	n	Mean	SD	Med	Min	Max
Use Of Valproate: No						
Titration	37	-17.86	151.84	-100.00	-100.0	476.9
Maintenance	33	-8.53	173.40	-100.00	-100.0	700.0
Treatment	37	-14.64	116.39	-39.78	-100.0	476.9
Use Of Lamotrigine: Yes						
Titration	24	-32.68	114.51	-100.00	-100.0	255.6
Maintenance	22	-9.74	185.09	-100.00	-100.0	700.0
Treatment	24	-30.68	81.36	-57.58	-100.0	166.7
Use Of Lamotrigine: No						
Titration	25	-9.90	159.89	-100.00	-100.0	476.9
Maintenance	22	-43.01	122.87	-100.00	-100.0	366.7
Treatment	25	-20.26	127.90	-65.00	-100.0	476.9
Use Of Other AEDs: Yes						
Titration	43	-21.93	143.82	-100.00	-100.0	476.9
Maintenance	39	-16.93	163.68	-100.00	-100.0	700.0
Treatment	43	-20.66	112.07	-65.00	-100.0	476.9

Note: Other AEDs includes all anti-epileptic drugs except Valproate and Lamotrigine.

Reference: Subject Data Listing 8.4.1

表 2.2-13　Combined ベースライン期間に対する治療期間の 28 日あたりの強直間代発作回数の変化率：SS（続き）

Table 7.8.1

Percent Change in PGTC Seizure Frequency per 28 Days from the Combined Baseline by Subgroup and Phase During the Treatment Phase

Population: Safety Set

Subgroup Phase	n	Mean	SD	Med	Min	Max
Use Of Other AEDs: No						
Titration	6	-14.81	102.48	-50.00	-100.0	133.3
Maintenance	5	-100.00	0.00	-100.00	-100.0	-100.0
Treatment	6	-59.10	46.68	-70.37	-100.0	0.0

Note: Other AEDs includes all anti-epileptic drugs except Valproate and Lamotrigine.

Reference: Subject Data Listing 8.4.1

表 2.2-14　Prospective ベースライン期間に対する治療期間の 28 日あたりの強直間代発作回数の変化率：SS

Table 7.8.2

Percent Change in PGTC Seizure Frequency per 28 Days from the Prospective Baseline by Subgroup and Phase During the Treatment Phase

Population: Safety Set

Subgroup Phase	n	Mean	SD	Med	Min	Max
All Subjects						
Titration	30	-38.71	81.05	-100.00	-100.0	166.7
Maintenance	26	-56.53	90.70	-100.00	-100.0	300.0
Treatment	30	-49.29	65.26	-68.23	-100.0	153.2
Age At Onset Of The Diagnosis: <2 years						
Titration	1	42.86		42.86	42.9	42.9
Maintenance	1	-63.41		-63.41	-63.4	-63.4
Treatment	1	-27.42		-27.42	-27.4	-27.4
Age At Onset Of The Diagnosis: 2 - <5 years						
Titration	3	-33.71	59.43	-15.94	-100.0	14.8
Maintenance	3	-83.60	28.41	-100.00	-100.0	-50.8
Treatment	3	-63.43	40.12	-69.79	-100.0	-20.5
Age At Onset Of The Diagnosis: 5 - <10 years						
Titration	8	-84.38	44.19	-100.00	-100.0	25.0
Maintenance	7	-90.61	18.50	-100.00	-100.0	-51.2
Treatment	8	-87.47	20.94	-100.00	-100.0	-44.4

Note: Other AEDs includes all anti-epileptic drugs except Valproate and Lamotrigine.

Reference: Subject Data Listing 8.3.1

表 2.2-14　Prospective ベースライン期間に対する治療期間の 28 日あたりの強直間代発作回数の変化率：SS（続き）

Table 7.8.2

Percent Change in PGTC Seizure Frequency per 28 Days from the Prospective Baseline by Subgroup and Phase During the Treatment Phase

Population: Safety Set

Subgroup Phase	n	Mean	SD	Med	Min	Max
Age At Onset Of The Diagnosis: 10 - <15 years						
Titration	14	-21.72	97.27	-60.34	-100.0	166.7
Maintenance	11	-53.24	77.57	-100.00	-100.0	152.6
Treatment	14	-28.27	84.08	-52.78	-100.0	153.2
Age At Onset Of The Diagnosis: 15 - <20 years						
Titration	2	-30.95	97.65	-30.95	-100.0	38.1
Maintenance	2	100.00	282.84	100.00	-100.0	300.0
Treatment	2	-26.61	37.64	-26.61	-53.2	0.0
Age At Onset Of The Diagnosis: >=20 years						
Titration	2	-30.95	97.65	-30.95	-100.0	38.1
Maintenance	2	-67.78	45.57	-67.78	-100.0	-35.6
Treatment	2	-56.06	62.14	-56.06	-100.0	-12.1
Childhood Absence Epilepsy: Yes						
Titration	2	31.55	9.26	31.55	25.0	38.1
Maintenance	2	-100.00	0.00	-100.00	-100.0	-100.0
Treatment	2	-48.84	6.21	-48.84	-53.2	-44.4

Note: Other AEDs includes all anti-epileptic drugs except Valproate and Lamotrigine.

Reference: Subject Data Listing 8.3.1

表 2.2-14　Prospective ベースライン期間に対する治療期間の 28 日あたりの強直間代発作回数の変化率：SS（続き）

Table 7.8.2

Percent Change in PGTC Seizure Frequency per 28 Days from the Prospective Baseline by Subgroup and Phase During the Treatment Phase

Population: Safety Set

Subgroup Phase	n	Mean	SD	Med	Min	Max
Childhood Absence Epilepsy: No						
Titration	21	-36.78	87.64	-100.00	-100.0	166.7
Maintenance	18	-43.11	105.96	-91.57	-100.0	300.0
Treatment	21	-40.02	73.19	-66.67	-100.0	153.2
Epilepsy With Grand Mal Seizures On Awakening: Yes						
Titration	0					
Maintenance	0					
Treatment	0					
Epilepsy With Grand Mal Seizures On Awakening: No						
Titration	22	-33.38	87.01	-81.55	-100.0	166.7
Maintenance	19	-46.11	103.80	-100.00	-100.0	300.0
Treatment	22	-40.62	71.48	-64.88	-100.0	153.2
Epilepsies With Seizures Precipitated By Specific Modes Of Activation: Yes						
Titration	0					
Maintenance	0					
Treatment	0					

Note: Other AEDs includes all anti-epileptic drugs except Valproate and Lamotrigine.

Reference: Subject Data Listing 8.3.1

表 2.2-14　Prospective ベースライン期間に対する治療期間の 28 日あたりの強直間代発作回数の変化率：SS（続き）

Table 7.8.2

Percent Change in PGTC Seizure Frequency per 28 Days from the Prospective Baseline by Subgroup and Phase During the Treatment Phase

Population: Safety Set

Subgroup Phase	n	Mean	SD	Med	Min	Max
Epilepsies With Seizures Precipitated By Specific Modes Of Activation: No						
Titration	22	-33.38	87.01	-81.55	-100.0	166.7
Maintenance	19	-46.11	103.80	-100.00	-100.0	300.0
Treatment	22	-40.62	71.48	-64.88	-100.0	153.2
Juvenile Absence Epilepsy: Yes						
Titration	2	26.62	179.07	26.62	-100.0	153.2
Maintenance	1	-100.00		-100.00	-100.0	-100.0
Treatment	2	26.62	179.07	26.62	-100.0	153.2
Juvenile Absence Epilepsy: No						
Titration	20	-39.38	79.13	-81.55	-100.0	166.7
Maintenance	18	-43.11	105.96	-91.57	-100.0	300.0
Treatment	20	-47.35	58.61	-64.88	-100.0	120.7
Juvenile Myoclonic Epilepsy: Yes						
Titration	7	-88.67	19.42	-100.00	-100.0	-57.6
Maintenance	6	-96.21	9.29	-100.00	-100.0	-77.2
Treatment	7	-90.50	16.37	-100.00	-100.0	-63.1

Note: Other AEDs includes all anti-epileptic drugs except Valproate and Lamotrigine.

Reference: Subject Data Listing 8.3.1

表 2.2-14　Prospective ベースライン期間に対する治療期間の 28 日あたりの強直間代発作回数の変化率：SS（続き）

Table 7.8.2

Percent Change in PGTC Seizure Frequency per 28 Days from the Prospective Baseline by Subgroup and Phase During the Treatment Phase

Population: Safety Set

Subgroup Phase	n	Mean	SD	Med	Min	Max
Juvenile Myoclonic Epilepsy: No						
Titration	17	-18.45	93.67	-54.55	-100.0	166.7
Maintenance	15	-33.25	113.95	-83.14	-100.0	300.0
Treatment	17	-27.07	75.91	-42.46	-100.0	153.2
Other Generalized Idiopathic Epilepsies Not Defined Above: Yes						
Titration	14	-28.93	87.50	-77.27	-100.0	166.7
Maintenance	13	-22.98	119.55	-63.41	-100.0	300.0
Treatment	14	-32.88	63.98	-34.94	-100.0	120.7
Other Generalized Idiopathic Epilepsies Not Defined Above: No						
Titration	8	-41.17	91.55	-81.55	-100.0	153.2
Maintenance	6	-96.21	9.29	-100.00	-100.0	-77.2
Treatment	8	-54.18	86.00	-85.19	-100.0	153.2
Use Of Valproate: Yes						
Titration	7	-52.14	70.71	-100.00	-100.0	60.0
Maintenance	6	-57.89	103.14	-100.00	-100.0	152.6
Treatment	7	-56.52	80.64	-100.00	-100.0	120.7

Note: Other AEDs includes all anti-epileptic drugs except Valproate and Lamotrigine.

Reference: Subject Data Listing 8.3.1

表 2.2-14　Prospective ベースライン期間に対する治療期間の 28 日あたりの強直間代発作回数の変化率：SS（続き）

Table 7.8.2

Percent Change in PGTC Seizure Frequency per 28 Days from the Prospective Baseline by Subgroup and Phase During the Treatment Phase

Population: Safety Set

Subgroup Phase	n	Mean	SD	Med	Min	Max
Use Of Valproate: No						
Titration	23	-34.62	84.97	-100.00	-100.0	166.7
Maintenance	20	-56.11	89.58	-91.57	-100.0	300.0
Treatment	23	-47.09	61.80	-66.67	-100.0	153.2
Use Of Lamotrigine: Yes						
Titration	14	-26.88	83.53	-56.06	-100.0	166.7
Maintenance	13	-43.08	108.07	-77.24	-100.0	300.0
Treatment	14	-43.43	47.91	-32.54	-100.0	57.9
Use Of Lamotrigine: No						
Titration	16	-49.05	80.05	-100.00	-100.0	153.2
Maintenance	13	-69.97	71.20	-100.00	-100.0	152.6
Treatment	16	-54.42	78.64	-94.34	-100.0	153.2
Use Of Other AEDs: Yes						
Titration	27	-33.26	83.57	-100.00	-100.0	166.7
Maintenance	24	-52.90	93.62	-100.00	-100.0	300.0
Treatment	27	-45.02	67.28	-66.67	-100.0	153.2

Note: Other AEDs includes all anti-epileptic drugs except Valproate and Lamotrigine.

Reference: Subject Data Listing 8.3.1

表 2.2-14　Prospective ベースライン期間に対する治療期間の 28 日あたりの強直間代発作回数の変化率：SS（続き）

Table 7.8.2

Percent Change in PGTC Seizure Frequency per 28 Days from the Prospective Baseline by Subgroup and Phase During the Treatment Phase

Population: Safety Set

Subgroup Phase	n	Mean	SD	Med	Min	Max
Use Of Other AEDs: No						
Titration	3	-87.70	21.31	-100.00	-100.0	-63.1
Maintenance	2	-100.00	0.00	-100.00	-100.0	-100.0
Treatment	3	-87.70	21.31	-100.00	-100.0	-63.1

Note: Other AEDs includes all anti-epileptic drugs except Valproate and Lamotrigine.

Reference: Subject Data Listing 8.3.1

2.2.3.4.2 臨床全般評価の変化／被験者による全般評価の変化

本治験の SS での維持期間完了時又は早期中止来院時における臨床全般評価の変化を表 2.2-15 に、被験者による全般評価の変化を表 2.2-16 に示した。

臨床全般評価及び被験者による全般評価は、いずれも維持期間完了時に 33 例（82.5%）で改善が認められた。

表 2.2-15　臨床全般評価の変化：SS

Table 10.1.1
Clinical Global Impression of Change
Population: Safety Set

Visit Type	Value	N = 49 n (%)
End of Maintenance Phase	Total	40 (100)
	Very Much Improved	13 (32.5)
	Much Improved	16 (40.0)
	Minimally Improved	4 (10.0)
	No Change	4 (10.0)
	Minimally Worse	3 (7.5)
	Much Worse	0
	Very Much Worse	0
	Improved	33 (82.5)
	No Change	4 (10.0)
	Worsened	3 (7.5)

Note: Percentages are based on the number of subjects evaluated during the phase.
Note: The category of Worsened represents the sum of Minimally Worse, Much Worse, and Very Much Worse. The category of Improved represents the sum of Very Much Improved, Much Improved, and Minimally Improved.

Reference: Subject Data Listing 8.5.1

表 2.2-15　臨床全般評価の変化：SS（続き）

Table 10.1.1
Clinical Global Impression of Change
Population: Safety Set

Visit Type	Value	N = 49 n (%)
Early Termination	Total	7 (100)
	Very Much Improved	0
	Much Improved	0
	Minimally Improved	0
	No Change	2 (28.6)
	Minimally Worse	3 (42.9)
	Much Worse	2 (28.6)
	Very Much Worse	0
	Improved	0
	No Change	2 (28.6)
	Worsened	5 (71.4)

Note: Percentages are based on the number of subjects evaluated during the phase.
Note: The category of Worsened represents the sum of Minimally Worse, Much Worse, and Very Much Worse. The category of Improved represents the sum of Very Much Improved, Much Improved, and Minimally Improved.

Reference: Subject Data Listing 8.5.1

表 2.2-15　臨床全般評価の変化：SS（続き）

Table 10.1.1
Clinical Global Impression of Change
Population: Safety Set

Visit Type	Value	N = 49 n (%)
Overall	Total	47 (100)
	Very Much Improved	13 (27.7)
	Much Improved	16 (34.0)
	Minimally Improved	4 (8.5)
	No Change	6 (12.8)
	Minimally Worse	6 (12.8)
	Much Worse	2 (4.3)
	Very Much Worse	0
	Improved	33 (70.2)
	No Change	6 (12.8)
	Worsened	8 (17.0)

Note: Percentages are based on the number of subjects evaluated during the phase.
Note: The category of Worsened represents the sum of Minimally Worse, Much Worse, and Very Much Worse. The category of Improved represents the sum of Very Much Improved, Much Improved, and Minimally Improved.

Reference: Subject Data Listing 8.5.1

表 2.2-16　被験者による全般評価の変化：SS

Table 10.2.1
Patient Global Impression of Change
Population: Safety Set

Visit Type	Value	N = 49 n (%)
End of Maintenance Phase	Total	40 (100)
	Very Much Improved	9 (22.5)
	Much Improved	20 (50.0)
	Minimally Improved	4 (10.0)
	No Change	4 (10.0)
	Minimally Worse	2 (5.0)
	Much Worse	1 (2.5)
	Very Much Worse	0
	Improved	33 (82.5)
	No Change	4 (10.0)
	Worsened	3 (7.5)

Note: Percentages are based on the number of subjects evaluated during the phase.
Note: The category of Worsened represents the sum of Minimally Worse, Much Worse, and Very Much Worse. The category of Improved represents the sum of Very Much Improved, Much Improved, and Minimally Improved.

Reference: Subject Data Listing 8.5.1

表 2.2-16　被験者による全般評価の変化：SS（続き）

Table 10.2.1
Patient Global Impression of Change
Population: Safety Set

Visit Type	Value	N = 49 n (%)
Early Termination	Total	7 (100)
	Very Much Improved	0
	Much Improved	0
	Minimally Improved	0
	No Change	1 (14.3)
	Minimally Worse	5 (71.4)
	Much Worse	1 (14.3)
	Very Much Worse	0
	Improved	0
	No Change	1 (14.3)
	Worsened	6 (85.7)

Note: Percentages are based on the number of subjects evaluated during the phase.
Note: The category of Worsened represents the sum of Minimally Worse, Much Worse, and Very Much Worse. The category of Improved represents the sum of Very Much Improved, Much Improved, and Minimally Improved.

Reference: Subject Data Listing 8.5.1

表 2.2-16　被験者による全般評価の変化：SS（続き）

Table 10.2.1
Patient Global Impression of Change
Population: Safety Set

Visit Type	Value	N = 49 n (%)
Overall	Total	47 (100)
	Very Much Improved	9 (19.1)
	Much Improved	20 (42.6)
	Minimally Improved	4 (8.5)
	No Change	5 (10.6)
	Minimally Worse	7 (14.9)
	Much Worse	2 (4.3)
	Very Much Worse	0
	Improved	33 (70.2)
	No Change	5 (10.6)
	Worsened	9 (19.1)

Note: Percentages are based on the number of subjects evaluated during the phase.
Note: The category of Worsened represents the sum of Minimally Worse, Much Worse, and Very Much Worse. The category of Improved represents the sum of Very Much Improved, Much Improved, and Minimally Improved.

Reference: Subject Data Listing 8.5.1

2.2.3.5 有害事象

本治験では MedDRA version 9.1 を用いて有害事象を集計した。

治験薬との因果関係は、治験責任医師が「関連なし（Not related）」、「おそらく関連なし（Unlikely related）」、「どちらともいえない（Possibly related）」、「関連あり（Related）」の 4 段階で評価した。このうち、「どちらともいえない」、「関連あり」の有害事象を「治験薬との因果関係が否定できない有害事象」として取り扱った。

2.2.3.5.1 有害事象発現例数の概要

本治験の治験薬投与開始後に認められた有害事象発現例数の概要を表 2.2-17 に示した。

本治験では、治験薬投与開始後に有害事象が 43 例（87.8%）に認められた。

表 2.2-17　有害事象発現例数の概要：SS

Table 9.1.1

Incidence of Treatment-Emergent Adverse Events (TEAEs) - Overview

Population: Safety Set

Category	N = 49 n (%) [#]
Any TEAEs	43 (87.8) [224]
Serious TEAEs	1 (2.0) [1]
TEAEs leading to discontinuation	5 (10.2) [11]
Drug-related TEAEs	34 (69.4) [132]
Severe TEAEs	2 (4.1) [2]
TEAEs with fatal outcome	0
TEAEs requiring dose change	11 (22.4) [33]

Note: n=number of subjects reporting at least one TEAE in that category during study conduct; (%)=percentage of subjects among total N; [#]=the number of individual occurrences of the TEAE.

Reference: Subject Data Listing 6.1.1

2.2.3.5.2 有害事象の発現状況

本治験の治験薬投与開始後に認められた重症度別の有害事象を表 2.2-18 に示した。

強直間代発作に関連する有害事象（医師記載用語：小発作てんかん）を除き、本治験で認められた有害事象は、部分発作を有するてんかん患者を対象とした臨床試験で認められた有害事象と類似していた。比較的よくみられる有害事象（発現率が 15%超の PT）は、浮動性めまい（19 例、38.8%）、悪心（13 例、26.5%）、頭痛（8 例、16.3%）及び傾眠（8 例、16.3%）であった。

表 2.2-18　重症度別の有害事象：SS

Table 9.6.1

Incidence of Treatment-Emergent Adverse Events (TEAEs) by Maximum Intensity

Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Intensity	N = 49 n (%) [#]
Any System Organ Class	Any	43 (87.8) [224]
	Mild	18 (36.7) [152]
	Moderate	23 (46.9) [70]
	Severe	2 (4.1) [2]
血液およびリンパ系障害	Any	1 (2.0) [2]
	Mild	1 (2.0) [2]
	Moderate	0
	Severe	0
白血球増加症	Any	1 (2.0) [1]
	Mild	1 (2.0) [1]
	Moderate	0
	Severe	0
好中球増加症	Any	1 (2.0) [1]
	Mild	1 (2.0) [1]
	Moderate	0
	Severe	0

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term; (%)=percentage of subjects among total N; [#]=the number of individual occurrences of the TEAE.

Note: Each subject is counted once within each System Organ Class and Preferred Term according to the maximum intensity for all TEAEs within that System Organ Class or Preferred Term.

Reference: Subject Data Listing 6.1.1

表 2.2-18　重症度別の有害事象：SS（続き）

Table 9.6.1
Incidence of Treatment-Emergent Adverse Events (TEAEs) by Maximum Intensity
Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Intensity	N = 49 n (%) [#]
耳および迷路障害	Any	1 (2.0) [1]
	Mild	1 (2.0) [1]
	Moderate	0
	Severe	0
回転性めまい	Any	1 (2.0) [1]
	Mild	1 (2.0) [1]
	Moderate	0
	Severe	0
眼障害	Any	6 (12.2) [7]
	Mild	4 (8.2) [4]
	Moderate	2 (4.1) [3]
	Severe	0
複視	Any	4 (8.2) [4]
	Mild	2 (4.1) [2]
	Moderate	2 (4.1) [2]
	Severe	0

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term; (%)=percentage of subjects among total N; [#]=the number of individual occurrences of the TEAE.
Note: Each subject is counted once within each System Organ Class and Preferred Term according to the maximum intensity for all TEAEs within that System Organ Class or Preferred Term.

Reference: Subject Data Listing 6.1.1

表 2.2-18　重症度別の有害事象：SS（続き）

Table 9.6.1
Incidence of Treatment-Emergent Adverse Events (TEAEs) by Maximum Intensity
Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Intensity	N = 49 n (%) [#]
霧視	Any	2 (4.1) [2]
	Mild	1 (2.0) [1]
	Moderate	1 (2.0) [1]
	Severe	0
眼乾燥	Any	1 (2.0) [1]
	Mild	1 (2.0) [1]
	Moderate	0
	Severe	0
胃腸障害	Any	19 (38.8) [37]
	Mild	11 (22.4) [23]
	Moderate	7 (14.3) [13]
	Severe	1 (2.0) [1]
悪心	Any	13 (26.5) [15]
	Mild	8 (16.3) [10]
	Moderate	5 (10.2) [5]
	Severe	0

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term; (%)=percentage of subjects among total N; [#]=the number of individual occurrences of the TEAE.
Note: Each subject is counted once within each System Organ Class and Preferred Term according to the maximum intensity for all TEAEs within that System Organ Class or Preferred Term.

Reference: Subject Data Listing 6.1.1

表 2.2-18　重症度別の有害事象：SS（続き）

Table 9.6.1
Incidence of Treatment-Emergent Adverse Events (TEAEs) by Maximum Intensity
Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Intensity	N = 49 n (%) [#]
嘔吐	Any	7 (14.3) [9]
	Mild	5 (10.2) [6]
	Moderate	2 (4.1) [3]
	Severe	0
便秘	Any	2 (4.1) [2]
	Mild	1 (2.0) [1]
	Moderate	1 (2.0) [1]
	Severe	0
下痢	Any	2 (4.1) [2]
	Mild	1 (2.0) [1]
	Moderate	1 (2.0) [1]
	Severe	0
上腹部痛	Any	1 (2.0) [1]
	Mild	1 (2.0) [1]
	Moderate	0
	Severe	0

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term; (%)=percentage of subjects among total N; [#]=the number of individual occurrences of the TEAE.
Note: Each subject is counted once within each System Organ Class and Preferred Term according to the maximum intensity for all TEAEs within that System Organ Class or Preferred Term.

Reference: Subject Data Listing 6.1.1

表 2.2-18　重症度別の有害事象：SS（続き）

Table 9.6.1
Incidence of Treatment-Emergent Adverse Events (TEAEs) by Maximum Intensity
Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Intensity	N = 49 n (%) [#]
口内乾燥	Any	1 (2.0) [1]
	Mild	1 (2.0) [1]
	Moderate	0
	Severe	0
硬便	Any	1 (2.0) [1]
	Mild	1 (2.0) [1]
	Moderate	0
	Severe	0
鼓腸	Any	1 (2.0) [1]
	Mild	1 (2.0) [1]
	Moderate	0
	Severe	0
胃食道逆流性疾患	Any	1 (2.0) [1]
	Mild	0
	Moderate	1 (2.0) [1]
	Severe	0

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term; (%)=percentage of subjects among total N; [#]=the number of individual occurrences of the TEAE.
Note: Each subject is counted once within each System Organ Class and Preferred Term according to the maximum intensity for all TEAEs within that System Organ Class or Preferred Term.

Reference: Subject Data Listing 6.1.1

表 2.2-18　重症度別の有害事象：SS（続き）

Table 9.6.1
Incidence of Treatment-Emergent Adverse Events (TEAEs) by Maximum Intensity
Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Intensity	N = 49 n (%) [#]
血便排泄	Any	1 (2.0) [1]
	Mild	0
	Moderate	1 (2.0) [1]
	Severe	0
口の感覚鈍麻	Any	1 (2.0) [1]
	Mild	0
	Moderate	1 (2.0) [1]
	Severe	0
直腸出血	Any	1 (2.0) [1]
	Mild	1 (2.0) [1]
	Moderate	0
	Severe	0
歯痛	Any	1 (2.0) [1]
	Mild	0
	Moderate	0
	Severe	1 (2.0) [1]

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term; (%)=percentage of subjects among total N; [#]=the number of individual occurrences of the TEAE.
Note: Each subject is counted once within each System Organ Class and Preferred Term according to the maximum intensity for all TEAEs within that System Organ Class or Preferred Term.

Reference: Subject Data Listing 6.1.1

表 2.2-18　重症度別の有害事象：SS（続き）

Table 9.6.1
Incidence of Treatment-Emergent Adverse Events (TEAEs) by Maximum Intensity
Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Intensity	N = 49 n (%) [#]
全身障害および投与局所様態	Any	16 (32.7) [22]
	Mild	10 (20.4) [15]
	Moderate	6 (12.2) [7]
	Severe	0
疲労	Any	6 (12.2) [6]
	Mild	4 (8.2) [4]
	Moderate	2 (4.1) [2]
	Severe	0
歩行障害	Any	5 (10.2) [5]
	Mild	3 (6.1) [3]
	Moderate	2 (4.1) [2]
	Severe	0
悪寒	Any	4 (8.2) [5]
	Mild	2 (4.1) [3]
	Moderate	2 (4.1) [2]
	Severe	0

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term; (%)=percentage of subjects among total N; [#]=the number of individual occurrences of the TEAE.
Note: Each subject is counted once within each System Organ Class and Preferred Term according to the maximum intensity for all TEAEs within that System Organ Class or Preferred Term.

Reference: Subject Data Listing 6.1.1

表 2.2-18　重症度別の有害事象：SS（続き）

Table 9.6.1
Incidence of Treatment-Emergent Adverse Events (TEAEs) by Maximum Intensity
Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Intensity	N = 49 n (%) [#]
胸痛	Any	1 (2.0) [1]
	Mild	1 (2.0) [1]
	Moderate	0
	Severe	0
酩酊感	Any	1 (2.0) [2]
	Mild	1 (2.0) [2]
	Moderate	0
	Severe	0
腫瘤	Any	1 (2.0) [1]
	Mild	1 (2.0) [1]
	Moderate	0
	Severe	0
末梢性浮腫	Any	1 (2.0) [1]
	Mild	1 (2.0) [1]
	Moderate	0
	Severe	0

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term; (%)=percentage of subjects among total N; [#]=the number of individual occurrences of the TEAE.
Note: Each subject is counted once within each System Organ Class and Preferred Term according to the maximum intensity for all TEAEs within that System Organ Class or Preferred Term.

Reference: Subject Data Listing 6.1.1

表 2.2-18　重症度別の有害事象：SS（続き）

Table 9.6.1
Incidence of Treatment-Emergent Adverse Events (TEAEs) by Maximum Intensity
Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Intensity	N = 49 n (%) [#]
評価不能の事象	Any	1 (2.0) [1]
	Mild	0
	Moderate	1 (2.0) [1]
	Severe	0
感染症および寄生虫症	Any	9 (18.4) [9]
	Mild	5 (10.2) [5]
	Moderate	4 (8.2) [4]
	Severe	0
鼻咽頭炎	Any	2 (4.1) [2]
	Mild	1 (2.0) [1]
	Moderate	1 (2.0) [1]
	Severe	0
上気道感染	Any	2 (4.1) [2]
	Mild	2 (4.1) [2]
	Moderate	0
	Severe	0

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term; (%)=percentage of subjects among total N; [#]=the number of individual occurrences of the TEAE.
Note: Each subject is counted once within each System Organ Class and Preferred Term according to the maximum intensity for all TEAEs within that System Organ Class or Preferred Term.

Reference: Subject Data Listing 6.1.1

表 2.2-18　重症度別の有害事象：SS（続き）

Table 9.6.1
Incidence of Treatment-Emergent Adverse Events (TEAEs) by Maximum Intensity
Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Intensity	N = 49 n (%) [#]
単純ヘルペス	Any	1 (2.0) [1]
	Mild	1 (2.0) [1]
	Moderate	0
	Severe	0
副鼻腔炎	Any	1 (2.0) [1]
	Mild	0
	Moderate	1 (2.0) [1]
	Severe	0
腟感染	Any	1 (2.0) [1]
	Mild	0
	Moderate	1 (2.0) [1]
	Severe	0
ウイルス感染	Any	1 (2.0) [1]
	Mild	1 (2.0) [1]
	Moderate	0
	Severe	0

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term; (%)=percentage of subjects among total N; [#]=the number of individual occurrences of the TEAE.
Note: Each subject is counted once within each System Organ Class and Preferred Term according to the maximum intensity for all TEAEs within that System Organ Class or Preferred Term.

Reference: Subject Data Listing 6.1.1

表 2.2-18　重症度別の有害事象：SS（続き）

Table 9.6.1
Incidence of Treatment-Emergent Adverse Events (TEAEs) by Maximum Intensity
Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Intensity	N = 49 n (%) [#]
外陰膣真菌感染	Any	1 (2.0) [1]
	Mild	0
	Moderate	1 (2.0) [1]
	Severe	0
傷害、中毒および処置合併症	Any	8 (16.3) [15]
	Mild	6 (12.2) [12]
	Moderate	2 (4.1) [3]
	Severe	0
挫傷	Any	3 (6.1) [4]
	Mild	1 (2.0) [1]
	Moderate	2 (4.1) [3]
	Severe	0
転倒	Any	2 (4.1) [2]
	Mild	2 (4.1) [2]
	Moderate	0
	Severe	0

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term; (%)=percentage of subjects among total N; [#]=the number of individual occurrences of the TEAE.
Note: Each subject is counted once within each System Organ Class and Preferred Term according to the maximum intensity for all TEAEs within that System Organ Class or Preferred Term.

Reference: Subject Data Listing 6.1.1

表 2.2-18　重症度別の有害事象：SS（続き）

Table 9.6.1
Incidence of Treatment-Emergent Adverse Events (TEAEs) by Maximum Intensity
Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Intensity	N = 49 n (%) [#]
引っかき傷	Any	2 (4.1) [2]
	Mild	2 (4.1) [2]
	Moderate	0
	Severe	0
熱傷	Any	2 (4.1) [2]
	Mild	2 (4.1) [2]
	Moderate	0
	Severe	0
擦過傷	Any	1 (2.0) [1]
	Mild	1 (2.0) [1]
	Moderate	0
	Severe	0
関節捻挫	Any	1 (2.0) [1]
	Mild	1 (2.0) [1]
	Moderate	0
	Severe	0

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term; (%)=percentage of subjects among total N; [#]=the number of individual occurrences of the TEAE.
Note: Each subject is counted once within each System Organ Class and Preferred Term according to the maximum intensity for all TEAEs within that System Organ Class or Preferred Term.

Reference: Subject Data Listing 6.1.1

表 2.2-18　重症度別の有害事象：SS（続き）

Table 9.6.1
Incidence of Treatment-Emergent Adverse Events (TEAEs) by Maximum Intensity
Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Intensity	N = 49 n (%) [#]
口腔内損傷	Any	1 (2.0) [1]
	Mild	1 (2.0) [1]
	Moderate	0
	Severe	0
眼窩周囲血腫	Any	1 (2.0) [1]
	Mild	1 (2.0) [1]
	Moderate	0
	Severe	0
サンバーン	Any	1 (2.0) [1]
	Mild	1 (2.0) [1]
	Moderate	0
	Severe	0
臨床検査	Any	3 (6.1) [3]
	Mild	3 (6.1) [3]
	Moderate	0
	Severe	0

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term; (%)=percentage of subjects among total N; [#]=the number of individual occurrences of the TEAE.
Note: Each subject is counted once within each System Organ Class and Preferred Term according to the maximum intensity for all TEAEs within that System Organ Class or Preferred Term.

Reference: Subject Data Listing 6.1.1

表 2.2-18　重症度別の有害事象：SS（続き）

Table 9.6.1
Incidence of Treatment-Emergent Adverse Events (TEAEs) by Maximum Intensity
Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Intensity	N = 49 n (%) [#]
アラニン・アミノトランスフェラーゼ増加	Any	1 (2.0) [1]
	Mild	1 (2.0) [1]
	Moderate	0
	Severe	0
血圧上昇	Any	1 (2.0) [1]
	Mild	1 (2.0) [1]
	Moderate	0
	Severe	0
つぎ足歩行検査異常	Any	1 (2.0) [1]
	Mild	1 (2.0) [1]
	Moderate	0
	Severe	0
代謝および栄養障害	Any	2 (4.1) [2]
	Mild	2 (4.1) [2]
	Moderate	0
	Severe	0

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term; (%)=percentage of subjects among total N; [#]=the number of individual occurrences of the TEAE.
Note: Each subject is counted once within each System Organ Class and Preferred Term according to the maximum intensity for all TEAEs within that System Organ Class or Preferred Term.

Reference: Subject Data Listing 6.1.1

表 2.2-18　重症度別の有害事象：SS（続き）

Table 9.6.1
Incidence of Treatment-Emergent Adverse Events (TEAEs) by Maximum Intensity
Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Intensity	N = 49 n (%) [#]
食欲減退	Any	1 (2.0) [1]
	Mild	1 (2.0) [1]
	Moderate	0
	Severe	0
低カリウム血症	Any	1 (2.0) [1]
	Mild	1 (2.0) [1]
	Moderate	0
	Severe	0
筋骨格系および結合組織障害	Any	6 (12.2) [6]
	Mild	5 (10.2) [5]
	Moderate	1 (2.0) [1]
	Severe	0
関節痛	Any	1 (2.0) [1]
	Mild	1 (2.0) [1]
	Moderate	0
	Severe	0

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term; (%)=percentage of subjects among total N; [#]=the number of individual occurrences of the TEAE.
Note: Each subject is counted once within each System Organ Class and Preferred Term according to the maximum intensity for all TEAEs within that System Organ Class or Preferred Term.

Reference: Subject Data Listing 6.1.1

表 2.2-18　重症度別の有害事象：SS（続き）

Table 9.6.1
Incidence of Treatment-Emergent Adverse Events (TEAEs) by Maximum Intensity
Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Intensity	N = 49 n (%) [#]
背部痛	Any	1 (2.0) [1]
	Mild	0
	Moderate	1 (2.0) [1]
	Severe	0
筋骨格硬直	Any	1 (2.0) [1]
	Mild	1 (2.0) [1]
	Moderate	0
	Severe	0
筋痛	Any	1 (2.0) [1]
	Mild	1 (2.0) [1]
	Moderate	0
	Severe	0
頚部痛	Any	1 (2.0) [1]
	Mild	1 (2.0) [1]
	Moderate	0
	Severe	0

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term; (%)=percentage of subjects among total N; [#]=the number of individual occurrences of the TEAE.
Note: Each subject is counted once within each System Organ Class and Preferred Term according to the maximum intensity for all TEAEs within that System Organ Class or Preferred Term.

Reference: Subject Data Listing 6.1.1

表 2.2-18　重症度別の有害事象：SS（続き）

Table 9.6.1
Incidence of Treatment-Emergent Adverse Events (TEAEs) by Maximum Intensity
Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Intensity	N = 49 n (%) [#]
肩回旋筋腱板症候群	Any	1 (2.0) [1]
	Mild	1 (2.0) [1]
	Moderate	0
	Severe	0
神経系障害	Any	34 (69.4) [78]
	Mild	17 (34.7) [47]
	Moderate	16 (32.7) [30]
	Severe	1 (2.0) [1]
浮動性めまい	Any	19 (38.8) [27]
	Mild	12 (24.5) [17]
	Moderate	7 (14.3) [10]
	Severe	0
頭痛	Any	8 (16.3) [8]
	Mild	5 (10.2) [5]
	Moderate	3 (6.1) [3]
	Severe	0

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term; (%)=percentage of subjects among total N; [#]=the number of individual occurrences of the TEAE.
Note: Each subject is counted once within each System Organ Class and Preferred Term according to the maximum intensity for all TEAEs within that System Organ Class or Preferred Term.

Reference: Subject Data Listing 6.1.1

表 2.2-18　重症度別の有害事象：SS（続き）

Table 9.6.1
Incidence of Treatment-Emergent Adverse Events (TEAEs) by Maximum Intensity
Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Intensity	N = 49 n (%) [#]
傾眠	Any	8 (16.3) [8]
	Mild	8 (16.3) [8]
	Moderate	0
	Severe	0
振戦	Any	6 (12.2) [8]
	Mild	3 (6.1) [5]
	Moderate	3 (6.1) [3]
	Severe	0
小発作てんかん	Any	5 (10.2) [5]
	Mild	2 (4.1) [2]
	Moderate	2 (4.1) [2]
	Severe	1 (2.0) [1]
片頭痛	Any	4 (8.2) [4]
	Mild	1 (2.0) [1]
	Moderate	3 (6.1) [3]
	Severe	0

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term; (%)=percentage of subjects among total N; [#]=the number of individual occurrences of the TEAE.
Note: Each subject is counted once within each System Organ Class and Preferred Term according to the maximum intensity for all TEAEs within that System Organ Class or Preferred Term.

Reference: Subject Data Listing 6.1.1

表 2.2-18　重症度別の有害事象：SS（続き）

Table 9.6.1
Incidence of Treatment-Emergent Adverse Events (TEAEs) by Maximum Intensity
Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Intensity	N = 49 n (%) [#]
健忘	Any	2 (4.1) [2]
	Mild	2 (4.1) [2]
	Moderate	0
	Severe	0
協調運動異常	Any	2 (4.1) [2]
	Mild	0
	Moderate	2 (4.1) [2]
	Severe	0
構語障害	Any	2 (4.1) [3]
	Mild	1 (2.0) [1]
	Moderate	1 (2.0) [2]
	Severe	0
眼振	Any	2 (4.1) [2]
	Mild	2 (4.1) [2]
	Moderate	0
	Severe	0

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term; (%)=percentage of subjects among total N; [#]=the number of individual occurrences of the TEAE.
Note: Each subject is counted once within each System Organ Class and Preferred Term according to the maximum intensity for all TEAEs within that System Organ Class or Preferred Term.

Reference: Subject Data Listing 6.1.1

表 2.2-18　重症度別の有害事象：SS（続き）

Table 9.6.1
Incidence of Treatment-Emergent Adverse Events (TEAEs) by Maximum Intensity
Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Intensity	N = 49 n (%) [#]
平衡障害	Any	1 (2.0) [3]
	Mild	0
	Moderate	1 (2.0) [1]
	Severe	0
小脳性運動失調	Any	1 (2.0) [1]
	Mild	0
	Moderate	1 (2.0) [1]
	Severe	0
認知障害	Any	1 (2.0) [1]
	Mild	0
	Moderate	1 (2.0) [1]
	Severe	0
よだれ	Any	1 (2.0) [1]
	Mild	1 (2.0) [1]
	Moderate	0
	Severe	0

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term; (%)=percentage of subjects among total N; [#]=the number of individual occurrences of the TEAE.
Note: Each subject is counted once within each System Organ Class and Preferred Term according to the maximum intensity for all TEAEs within that System Organ Class or Preferred Term.

Reference: Subject Data Listing 6.1.1

表 2.2-18　重症度別の有害事象：SS（続き）

Table 9.6.1
Incidence of Treatment-Emergent Adverse Events (TEAEs) by Maximum Intensity
Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Intensity	N = 49 n (%) [#]
大発作痙攣	Any	1 (2.0) [1]
	Mild	0
	Moderate	1 (2.0) [1]
	Severe	0
記憶障害	Any	1 (2.0) [1]
	Mild	1 (2.0) [1]
	Moderate	0
	Severe	0
鎮静	Any	1 (2.0) [1]
	Mild	0
	Moderate	1 (2.0) [1]
	Severe	0
精神障害	Any	8 (16.3) [13]
	Mild	5 (10.2) [10]
	Moderate	3 (6.1) [3]
	Severe	0

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term; (%)=percentage of subjects among total N; [#]=the number of individual occurrences of the TEAE.
Note: Each subject is counted once within each System Organ Class and Preferred Term according to the maximum intensity for all TEAEs within that System Organ Class or Preferred Term.

Reference: Subject Data Listing 6.1.1

表 2.2-18　重症度別の有害事象：SS（続き）

Table 9.6.1
Incidence of Treatment-Emergent Adverse Events (TEAEs) by Maximum Intensity
Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Intensity	N = 49 n (%) [#]
不眠症	Any	6 (12.2) [6]
	Mild	3 (6.1) [3]
	Moderate	3 (6.1) [3]
	Severe	0
うつ病	Any	2 (4.1) [2]
	Mild	2 (4.1) [2]
	Moderate	0
	Severe	0
異常な夢	Any	1 (2.0) [1]
	Mild	1 (2.0) [1]
	Moderate	0
	Severe	0
泣き	Any	1 (2.0) [1]
	Mild	1 (2.0) [1]
	Moderate	0
	Severe	0

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term; (%)=percentage of subjects among total N; [#]=the number of individual occurrences of the TEAE.
Note: Each subject is counted once within each System Organ Class and Preferred Term according to the maximum intensity for all TEAEs within that System Organ Class or Preferred Term.

Reference: Subject Data Listing 6.1.1

表 2.2-18　重症度別の有害事象：SS（続き）

Table 9.6.1
Incidence of Treatment-Emergent Adverse Events (TEAEs) by Maximum Intensity
Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Intensity	N = 49 n (%) [#]
失見当識	Any	1 (2.0) [1]
	Mild	1 (2.0) [1]
	Moderate	0
	Severe	0
ディスフェミア	Any	1 (2.0) [1]
	Mild	1 (2.0) [1]
	Moderate	0
	Severe	0
幻覚	Any	1 (2.0) [1]
	Mild	1 (2.0) [1]
	Moderate	0
	Severe	0
腎および尿路障害	Any	3 (6.1) [4]
	Mild	2 (4.1) [2]
	Moderate	1 (2.0) [2]
	Severe	0

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term; (%)=percentage of subjects among total N; [#]=the number of individual occurrences of the TEAE.
Note: Each subject is counted once within each System Organ Class and Preferred Term according to the maximum intensity for all TEAEs within that System Organ Class or Preferred Term.

Reference: Subject Data Listing 6.1.1

表 2.2-18　重症度別の有害事象：SS（続き）

Table 9.6.1
Incidence of Treatment-Emergent Adverse Events (TEAEs) by Maximum Intensity
Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Intensity	N = 49 n (%) [#]
血尿	Any	2 (4.1) [2]
	Mild	1 (2.0) [1]
	Moderate	1 (2.0) [1]
	Severe	0
緊張性膀胱	Any	1 (2.0) [1]
	Mild	1 (2.0) [1]
	Moderate	0
	Severe	0
蛋白尿	Any	1 (2.0) [1]
	Mild	0
	Moderate	1 (2.0) [1]
	Severe	0
生殖系および乳房障害	Any	2 (4.1) [2]
	Mild	1 (2.0) [1]
	Moderate	1 (2.0) [1]
	Severe	0

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term; (%)=percentage of subjects among total N; [#]=the number of individual occurrences of the TEAE.
Note: Each subject is counted once within each System Organ Class and Preferred Term according to the maximum intensity for all TEAEs within that System Organ Class or Preferred Term.

Reference: Subject Data Listing 6.1.1

表 2.2-18　重症度別の有害事象：SS（続き）

Table 9.6.1
Incidence of Treatment-Emergent Adverse Events (TEAEs) by Maximum Intensity
Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Intensity	N = 49 n (%) [#]
乳房腫瘤	Any	1 (2.0) [1]
	Mild	1 (2.0) [1]
	Moderate	0
	Severe	0
膣嚢胞	Any	1 (2.0) [1]
	Mild	0
	Moderate	1 (2.0) [1]
	Severe	0
呼吸器、胸郭および縦隔障害	Any	9 (18.4) [12]
	Mild	7 (14.3) [10]
	Moderate	2 (4.1) [2]
	Severe	0
呼吸困難	Any	4 (8.2) [4]
	Mild	3 (6.1) [3]
	Moderate	1 (2.0) [1]
	Severe	0

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term; (%)=percentage of subjects among total N; [#]=the number of individual occurrences of the TEAE.
Note: Each subject is counted once within each System Organ Class and Preferred Term according to the maximum intensity for all TEAEs within that System Organ Class or Preferred Term.

Reference: Subject Data Listing 6.1.1

表 2.2-18　重症度別の有害事象：SS（続き）

Table 9.6.1
Incidence of Treatment-Emergent Adverse Events (TEAEs) by Maximum Intensity
Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Intensity	N = 49 n (%) [#]
鼻閉	Any	2 (4.1) [2]
	Mild	2 (4.1) [2]
	Moderate	0
	Severe	0
鼻出血	Any	1 (2.0) [1]
	Mild	1 (2.0) [1]
	Moderate	0
	Severe	0
上気道分泌増加	Any	1 (2.0) [1]
	Mild	1 (2.0) [1]
	Moderate	0
	Severe	0
咽喉頭疼痛	Any	1 (2.0) [1]
	Mild	1 (2.0) [1]
	Moderate	0
	Severe	0

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term; (%)=percentage of subjects among total N; [#]=the number of individual occurrences of the TEAE.
Note: Each subject is counted once within each System Organ Class and Preferred Term according to the maximum intensity for all TEAEs within that System Organ Class or Preferred Term.

Reference: Subject Data Listing 6.1.1

表 2.2-18　重症度別の有害事象：SS（続き）

Table 9.6.1
Incidence of Treatment-Emergent Adverse Events (TEAEs) by Maximum Intensity
Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Intensity	N = 49 n (%) [#]
鼻漏	Any	1 (2.0) [1]
	Mild	1 (2.0) [1]
	Moderate	0
	Severe	0
副鼻腔うっ血	Any	1 (2.0) [1]
	Mild	0
	Moderate	1 (2.0) [1]
	Severe	0
上気道の炎症	Any	1 (2.0) [1]
	Mild	1 (2.0) [1]
	Moderate	0
	Severe	0
皮膚および皮下組織障害	Any	8 (16.3) [8]
	Mild	7 (14.3) [7]
	Moderate	1 (2.0) [1]
	Severe	0

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term; (%)=percentage of subjects among total N; [#]=the number of individual occurrences of the TEAE.
Note: Each subject is counted once within each System Organ Class and Preferred Term according to the maximum intensity for all TEAEs within that System Organ Class or Preferred Term.

Reference: Subject Data Listing 6.1.1

表 2.2-18　重症度別の有害事象：SS（続き）

Table 9.6.1
Incidence of Treatment-Emergent Adverse Events (TEAEs) by Maximum Intensity
Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Intensity	N = 49 n (%) [#]
そう痒症	Any	3 (6.1) [3]
	Mild	2 (4.1) [2]
	Moderate	1 (2.0) [1]
	Severe	0
発疹	Any	2 (4.1) [2]
	Mild	2 (4.1) [2]
	Moderate	0
	Severe	0
脱毛症	Any	1 (2.0) [1]
	Mild	1 (2.0) [1]
	Moderate	0
	Severe	0
斑状出血	Any	1 (2.0) [1]
	Mild	1 (2.0) [1]
	Moderate	0
	Severe	0

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term; (%)=percentage of subjects among total N; [#]=the number of individual occurrences of the TEAE.
Note: Each subject is counted once within each System Organ Class and Preferred Term according to the maximum intensity for all TEAEs within that System Organ Class or Preferred Term.

Reference: Subject Data Listing 6.1.1

表 2.2-18　重症度別の有害事象：SS（続き）

Table 9.6.1
Incidence of Treatment-Emergent Adverse Events (TEAEs) by Maximum Intensity
Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Intensity	N = 49 n (%) [#]
斑状丘疹状皮疹	Any	1 (2.0) [1]
	Mild	1 (2.0) [1]
	Moderate	0
	Severe	0
血管障害	Any	3 (6.1) [3]
	Mild	3 (6.1) [3]
	Moderate	0
	Severe	0
ほてり	Any	2 (4.1) [2]
	Mild	2 (4.1) [2]
	Moderate	0
	Severe	0
潮紅	Any	1 (2.0) [1]
	Mild	1 (2.0) [1]
	Moderate	0
	Severe	0

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term; (%)=percentage of subjects among total N; [#]=the number of individual occurrences of the TEAE.
Note: Each subject is counted once within each System Organ Class and Preferred Term according to the maximum intensity for all TEAEs within that System Organ Class or Preferred Term.

Reference: Subject Data Listing 6.1.1

2.2.3.5.3 治験薬との因果関係が否定できない有害事象

本治験の治験薬投与開始後に認められた治験薬との因果関係別の有害事象を表 2.2-19 に示した。

表 2.2-19　治験薬との因果関係別の有害事象：SS

Table 9.7.1

Incidence of Treatment-Emergent Adverse Events (TEAEs) by Relationship per Investigator

Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Drug Relationship	N = 49 n (%) [#]
Any System Organ Class	Any	43 (87.8) [224]
	Related	34 (69.4) [132]
	Not Related	32 (65.3) [92]
血液およびリンパ系障害	Any	1 (2.0) [2]
	Related	0
	Not Related	1 (2.0) [2]
白血球増加症	Any	1 (2.0) [1]
	Related	0
	Not Related	1 (2.0) [1]
好中球増加症	Any	1 (2.0) [1]
	Related	0
	Not Related	1 (2.0) [1]
耳および迷路障害	Any	1 (2.0) [1]
	Related	1 (2.0) [1]
	Not Related	0

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term; (%)=percentage of subjects among total N; [#]=the number of individual occurrences of the TEAE.
Note: A subject may be counted more than once according to the relationship of the TEAEs.
Note: Drug-related TEAEs are those with a relationship of "related ", "possibly related", or those with missing responses.

Reference: Subject Data Listing 6.1.1

表 2.2-19　治験薬との因果関係別の有害事象：SS（続き）

Table 9.7.1

Incidence of Treatment-Emergent Adverse Events (TEAEs) by Relationship per Investigator

Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Drug Relationship	N = 49 n (%) [#]
回転性めまい	Any	1 (2.0) [1]
	Related	1 (2.0) [1]
	Not Related	0
眼障害	Any	6 (12.2) [7]
	Related	6 (12.2) [7]
	Not Related	0
複視	Any	4 (8.2) [4]
	Related	4 (8.2) [4]
	Not Related	0
霧視	Any	2 (4.1) [2]
	Related	2 (4.1) [2]
	Not Related	0
眼乾燥	Any	1 (2.0) [1]
	Related	1 (2.0) [1]
	Not Related	0

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term; (%)=percentage of subjects among total N; [#]=the number of individual occurrences of the TEAE.
Note: A subject may be counted more than once according to the relationship of the TEAEs.
Note: Drug-related TEAEs are those with a relationship of "related ", "possibly related", or those with missing responses.

Reference: Subject Data Listing 6.1.1

表 2.2-19　治験薬との因果関係別の有害事象：SS（続き）

Table 9.7.1

Incidence of Treatment-Emergent Adverse Events (TEAEs) by Relationship per Investigator

Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Drug Relationship	N = 49 n (%) [#]
胃腸障害	Any	19 (38.8) [37]
	Related	14 (28.6) [29]
	Not Related	6 (12.2) [8]
悪心	Any	13 (26.5) [15]
	Related	11 (22.4) [13]
	Not Related	2 (4.1) [2]
嘔吐	Any	7 (14.3) [9]
	Related	6 (12.2) [8]
	Not Related	1 (2.0) [1]
便秘	Any	2 (4.1) [2]
	Related	2 (4.1) [2]
	Not Related	0
下痢	Any	2 (4.1) [2]
	Related	2 (4.1) [2]
	Not Related	0

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term; (%)=percentage of subjects among total N; [#]=the number of individual occurrences of the TEAE.
Note: A subject may be counted more than once according to the relationship of the TEAEs.
Note: Drug-related TEAEs are those with a relationship of "related ", "possibly related", or those with missing responses.

Reference: Subject Data Listing 6.1.1

表 2.2-19　治験薬との因果関係別の有害事象：SS（続き）

Table 9.7.1

Incidence of Treatment-Emergent Adverse Events (TEAEs) by Relationship per Investigator

Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Drug Relationship	N = 49 n (%) [#]
上腹部痛	Any	1 (2.0) [1]
	Related	1 (2.0) [1]
	Not Related	0
口内乾燥	Any	1 (2.0) [1]
	Related	1 (2.0) [1]
	Not Related	0
硬便	Any	1 (2.0) [1]
	Related	0
	Not Related	1 (2.0) [1]
鼓腸	Any	1 (2.0) [1]
	Related	0
	Not Related	1 (2.0) [1]
胃食道逆流性疾患	Any	1 (2.0) [1]
	Related	0
	Not Related	1 (2.0) [1]

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term; (%)=percentage of subjects among total N; [#]=the number of individual occurrences of the TEAE.
Note: A subject may be counted more than once according to the relationship of the TEAEs.
Note: Drug-related TEAEs are those with a relationship of "related ", "possibly related", or those with missing responses.

Reference: Subject Data Listing 6.1.1

表 2.2-19　治験薬との因果関係別の有害事象：SS（続き）

Table 9.7.1

Incidence of Treatment-Emergent Adverse Events (TEAEs) by Relationship per Investigator

Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Drug Relationship	N = 49 n (%) [#]
血便排泄	Any	1 (2.0) [1]
	Related	1 (2.0) [1]
	Not Related	0
口の感覚鈍麻	Any	1 (2.0) [1]
	Related	1 (2.0) [1]
	Not Related	0
直腸出血	Any	1 (2.0) [1]
	Related	0
	Not Related	1 (2.0) [1]
歯痛	Any	1 (2.0) [1]
	Related	0
	Not Related	1 (2.0) [1]
全身障害および投与局所様態	Any	16 (32.7) [22]
	Related	10 (20.4) [12]
	Not Related	9 (18.4) [10]

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term; (%)=percentage of subjects among total N; [#]=the number of individual occurrences of the TEAE.
Note: A subject may be counted more than once according to the relationship of the TEAEs.
Note: Drug-related TEAEs are those with a relationship of "related ", "possibly related", or those with missing responses.

Reference: Subject Data Listing 6.1.1

表 2.2-19　治験薬との因果関係別の有害事象：SS（続き）

Table 9.7.1

Incidence of Treatment-Emergent Adverse Events (TEAEs) by Relationship per Investigator

Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Drug Relationship	N = 49 n (%) [#]
疲労	Any	6 (12.2) [6]
	Related	5 (10.2) [5]
	Not Related	1 (2.0) [1]
歩行障害	Any	5 (10.2) [5]
	Related	4 (8.2) [4]
	Not Related	1 (2.0) [1]
悪寒	Any	4 (8.2) [5]
	Related	1 (2.0) [1]
	Not Related	4 (8.2) [4]
胸痛	Any	1 (2.0) [1]
	Related	0
	Not Related	1 (2.0) [1]
酩酊感	Any	1 (2.0) [2]
	Related	1 (2.0) [2]
	Not Related	0

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term; (%)=percentage of subjects among total N; [#]=the number of individual occurrences of the TEAE.

Note: A subject may be counted more than once according to the relationship of the TEAEs.

Note: Drug-related TEAEs are those with a relationship of "related ", "possibly related", or those with missing responses.

Reference: Subject Data Listing 6.1.1

表 2.2-19　治験薬との因果関係別の有害事象：SS（続き）

Table 9.7.1

Incidence of Treatment-Emergent Adverse Events (TEAEs) by Relationship per Investigator

Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Drug Relationship	N = 49 n (%) [#]
腫瘤	Any	1 (2.0) [1]
	Related	0
	Not Related	1 (2.0) [1]
末梢性浮腫	Any	1 (2.0) [1]
	Related	0
	Not Related	1 (2.0) [1]
評価不能の事象	Any	1 (2.0) [1]
	Related	0
	Not Related	1 (2.0) [1]
感染症および寄生虫症	Any	9 (18.4) [9]
	Related	0
	Not Related	9 (18.4) [9]
鼻咽頭炎	Any	2 (4.1) [2]
	Related	0
	Not Related	2 (4.1) [2]

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term; (%)=percentage of subjects among total N; [#]=the number of individual occurrences of the TEAE.

Note: A subject may be counted more than once according to the relationship of the TEAEs.

Note: Drug-related TEAEs are those with a relationship of "related ", "possibly related", or those with missing responses.

Reference: Subject Data Listing 6.1.1

表 2.2-19　治験薬との因果関係別の有害事象：SS（続き）

Table 9.7.1

Incidence of Treatment-Emergent Adverse Events (TEAEs) by Relationship per Investigator

Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Drug Relationship	N = 49 n (%) [#]
上気道感染	Any	2 (4.1) [2]
	Related	0
	Not Related	2 (4.1) [2]
単純ヘルペス	Any	1 (2.0) [1]
	Related	0
	Not Related	1 (2.0) [1]
副鼻腔炎	Any	1 (2.0) [1]
	Related	0
	Not Related	1 (2.0) [1]
腟感染	Any	1 (2.0) [1]
	Related	0
	Not Related	1 (2.0) [1]
ウイルス感染	Any	1 (2.0) [1]
	Related	0
	Not Related	1 (2.0) [1]

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term; (%)=percentage of subjects among total N; [#]=the number of individual occurrences of the TEAE.
Note: A subject may be counted more than once according to the relationship of the TEAEs.
Note: Drug-related TEAEs are those with a relationship of "related ", "possibly related", or those with missing responses.

Reference: Subject Data Listing 6.1.1

表 2.2-19　治験薬との因果関係別の有害事象：SS（続き）

Table 9.7.1

Incidence of Treatment-Emergent Adverse Events (TEAEs) by Relationship per Investigator

Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Drug Relationship	N = 49 n (%) [#]
外陰腟真菌感染	Any	1 (2.0) [1]
	Related	0
	Not Related	1 (2.0) [1]
傷害、中毒および処置合併症	Any	8 (16.3) [15]
	Related	0
	Not Related	8 (16.3) [15]
挫傷	Any	3 (6.1) [4]
	Related	0
	Not Related	3 (6.1) [4]
転倒	Any	2 (4.1) [2]
	Related	0
	Not Related	2 (4.1) [2]
引っかき傷	Any	2 (4.1) [2]
	Related	0
	Not Related	2 (4.1) [2]

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term; (%)=percentage of subjects among total N; [#]=the number of individual occurrences of the TEAE.
Note: A subject may be counted more than once according to the relationship of the TEAEs.
Note: Drug-related TEAEs are those with a relationship of "related ", "possibly related", or those with missing responses.

Reference: Subject Data Listing 6.1.1

表 2.2-19　治験薬との因果関係別の有害事象：SS（続き）

Table 9.7.1

Incidence of Treatment-Emergent Adverse Events (TEAEs) by Relationship per Investigator

Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Drug Relationship	N = 49 n (%) [#]
熱傷	Any	2 (4.1) [2]
	Related	0
	Not Related	2 (4.1) [2]
擦過傷	Any	1 (2.0) [1]
	Related	0
	Not Related	1 (2.0) [1]
関節捻挫	Any	1 (2.0) [1]
	Related	0
	Not Related	1 (2.0) [1]
口腔内損傷	Any	1 (2.0) [1]
	Related	0
	Not Related	1 (2.0) [1]
眼窩周囲血腫	Any	1 (2.0) [1]
	Related	0
	Not Related	1 (2.0) [1]

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term; (%)=percentage of subjects among total N; [#]=the number of individual occurrences of the TEAE.
Note: A subject may be counted more than once according to the relationship of the TEAEs.
Note: Drug-related TEAEs are those with a relationship of "related ", "possibly related", or those with missing responses.

Reference: Subject Data Listing 6.1.1

表 2.2-19　治験薬との因果関係別の有害事象：SS（続き）

Table 9.7.1

Incidence of Treatment-Emergent Adverse Events (TEAEs) by Relationship per Investigator

Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Drug Relationship	N = 49 n (%) [#]
サンバーン	Any	1 (2.0) [1]
	Related	0
	Not Related	1 (2.0) [1]
臨床検査	Any	3 (6.1) [3]
	Related	2 (4.1) [2]
	Not Related	1 (2.0) [1]
アラニン・アミノトランスフェラーゼ増加	Any	1 (2.0) [1]
	Related	1 (2.0) [1]
	Not Related	0
血圧上昇	Any	1 (2.0) [1]
	Related	0
	Not Related	1 (2.0) [1]
つぎ足歩行検査異常	Any	1 (2.0) [1]
	Related	1 (2.0) [1]
	Not Related	0

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term; (%)=percentage of subjects among total N; [#]=the number of individual occurrences of the TEAE.
Note: A subject may be counted more than once according to the relationship of the TEAEs.
Note: Drug-related TEAEs are those with a relationship of "related ", "possibly related", or those with missing responses.

Reference: Subject Data Listing 6.1.1

表 2.2-19　治験薬との因果関係別の有害事象：SS（続き）

Table 9.7.1

Incidence of Treatment-Emergent Adverse Events (TEAEs) by Relationship per Investigator

Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Drug Relationship	N = 49 n (%) [#]
代謝および栄養障害	Any	2 (4.1) [2]
	Related	1 (2.0) [1]
	Not Related	1 (2.0) [1]
食欲減退	Any	1 (2.0) [1]
	Related	1 (2.0) [1]
	Not Related	0
低カリウム血症	Any	1 (2.0) [1]
	Related	0
	Not Related	1 (2.0) [1]
筋骨格系および結合組織障害	Any	6 (12.2) [6]
	Related	0
	Not Related	6 (12.2) [6]
関節痛	Any	1 (2.0) [1]
	Related	0
	Not Related	1 (2.0) [1]

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term; (%)=percentage of subjects among total N; [#]=the number of individual occurrences of the TEAE.
Note: A subject may be counted more than once according to the relationship of the TEAEs.
Note: Drug-related TEAEs are those with a relationship of "related ", "possibly related", or those with missing responses.

Reference: Subject Data Listing 6.1.1

表 2.2-19　治験薬との因果関係別の有害事象：SS（続き）

Table 9.7.1

Incidence of Treatment-Emergent Adverse Events (TEAEs) by Relationship per Investigator

Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Drug Relationship	N = 49 n (%) [#]
背部痛	Any	1 (2.0) [1]
	Related	0
	Not Related	1 (2.0) [1]
筋骨格硬直	Any	1 (2.0) [1]
	Related	0
	Not Related	1 (2.0) [1]
筋痛	Any	1 (2.0) [1]
	Related	0
	Not Related	1 (2.0) [1]
頚部痛	Any	1 (2.0) [1]
	Related	0
	Not Related	1 (2.0) [1]
肩回旋筋腱板症候群	Any	1 (2.0) [1]
	Related	0
	Not Related	1 (2.0) [1]

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term; (%)=percentage of subjects among total N; [#]=the number of individual occurrences of the TEAE.
Note: A subject may be counted more than once according to the relationship of the TEAEs.
Note: Drug-related TEAEs are those with a relationship of "related ", "possibly related", or those with missing responses.

Reference: Subject Data Listing 6.1.1

表 2.2-19　治験薬との因果関係別の有害事象：SS（続き）

Table 9.7.1

Incidence of Treatment-Emergent Adverse Events (TEAEs) by Relationship per Investigator

Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Drug Relationship	N = 49 n (%) [#]
神経系障害	Any	34 (69.4) [78]
	Related	31 (63.3) [67]
	Not Related	7 (14.3) [11]
浮動性めまい	Any	19 (38.8) [27]
	Related	19 (38.8) [27]
	Not Related	0
頭痛	Any	8 (16.3) [8]
	Related	4 (8.2) [4]
	Not Related	4 (8.2) [4]
傾眠	Any	8 (16.3) [8]
	Related	8 (16.3) [8]
	Not Related	0
振戦	Any	6 (12.2) [8]
	Related	5 (10.2) [7]
	Not Related	1 (2.0) [1]

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term; (%)=percentage of subjects among total N; [#]=the number of individual occurrences of the TEAE.
Note: A subject may be counted more than once according to the relationship of the TEAEs.
Note: Drug-related TEAEs are those with a relationship of "related ", "possibly related", or those with missing responses.

Reference: Subject Data Listing 6.1.1

表 2.2-19　治験薬との因果関係別の有害事象：SS（続き）

Table 9.7.1

Incidence of Treatment-Emergent Adverse Events (TEAEs) by Relationship per Investigator

Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Drug Relationship	N = 49 n (%) [#]
小発作てんかん	Any	5 (10.2) [5]
	Related	5 (10.2) [5]
	Not Related	0
片頭痛	Any	4 (8.2) [4]
	Related	1 (2.0) [1]
	Not Related	3 (6.1) [3]
健忘	Any	2 (4.1) [2]
	Related	1 (2.0) [1]
	Not Related	1 (2.0) [1]
協調運動異常	Any	2 (4.1) [2]
	Related	2 (4.1) [2]
	Not Related	0
構語障害	Any	2 (4.1) [3]
	Related	2 (4.1) [3]
	Not Related	0

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term; (%)=percentage of subjects among total N; [#]=the number of individual occurrences of the TEAE.
Note: A subject may be counted more than once according to the relationship of the TEAEs.
Note: Drug-related TEAEs are those with a relationship of "related ", "possibly related", or those with missing responses.

Reference: Subject Data Listing 6.1.1

表 2.2-19　治験薬との因果関係別の有害事象：SS（続き）

Table 9.7.1

Incidence of Treatment-Emergent Adverse Events (TEAEs) by Relationship per Investigator

Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Drug Relationship	N = 49 n (%) [#]
眼振	Any	2 (4.1) [2]
	Related	2 (4.1) [2]
	Not Related	0
平衡障害	Any	1 (2.0) [3]
	Related	1 (2.0) [3]
	Not Related	0
小脳性運動失調	Any	1 (2.0) [1]
	Related	1 (2.0) [1]
	Not Related	0
認知障害	Any	1 (2.0) [1]
	Related	1 (2.0) [1]
	Not Related	0
よだれ	Any	1 (2.0) [1]
	Related	0
	Not Related	1 (2.0) [1]

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term; (%)=percentage of subjects among total N; [#]=the number of individual occurrences of the TEAE.
Note: A subject may be counted more than once according to the relationship of the TEAEs.
Note: Drug-related TEAEs are those with a relationship of "related ", "possibly related", or those with missing responses.

Reference: Subject Data Listing 6.1.1

表 2.2-19　治験薬との因果関係別の有害事象：SS（続き）

Table 9.7.1

Incidence of Treatment-Emergent Adverse Events (TEAEs) by Relationship per Investigator

Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Drug Relationship	N = 49 n (%) [#]
大発作痙攣	Any	1 (2.0) [1]
	Related	1 (2.0) [1]
	Not Related	0
記憶障害	Any	1 (2.0) [1]
	Related	0
	Not Related	1 (2.0) [1]
鎮静	Any	1 (2.0) [1]
	Related	1 (2.0) [1]
	Not Related	0
精神障害	Any	8 (16.3) [13]
	Related	7 (14.3) [9]
	Not Related	4 (8.2) [4]
不眠症	Any	6 (12.2) [6]
	Related	3 (6.1) [3]
	Not Related	3 (6.1) [3]

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term; (%)=percentage of subjects among total N; [#]=the number of individual occurrences of the TEAE.
Note: A subject may be counted more than once according to the relationship of the TEAEs.
Note: Drug-related TEAEs are those with a relationship of "related ", "possibly related", or those with missing responses.

Reference: Subject Data Listing 6.1.1

表 2.2-19　治験薬との因果関係別の有害事象：SS（続き）

Table 9.7.1

Incidence of Treatment-Emergent Adverse Events (TEAEs) by Relationship per Investigator

Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Drug Relationship	N = 49 n (%) [#]
うつ病	Any	2 (4.1) [2]
	Related	2 (4.1) [2]
	Not Related	0
異常な夢	Any	1 (2.0) [1]
	Related	1 (2.0) [1]
	Not Related	0
泣き	Any	1 (2.0) [1]
	Related	1 (2.0) [1]
	Not Related	0
失見当識	Any	1 (2.0) [1]
	Related	1 (2.0) [1]
	Not Related	0
ディスフェミア	Any	1 (2.0) [1]
	Related	0
	Not Related	1 (2.0) [1]

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term; (%)=percentage of subjects among total N; [#]=the number of individual occurrences of the TEAE.
Note: A subject may be counted more than once according to the relationship of the TEAEs.
Note: Drug-related TEAEs are those with a relationship of "related ", "possibly related", or those with missing responses.

Reference: Subject Data Listing 6.1.1

表 2.2-19　治験薬との因果関係別の有害事象：SS（続き）

Table 9.7.1

Incidence of Treatment-Emergent Adverse Events (TEAEs) by Relationship per Investigator

Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Drug Relationship	N = 49 n (%) [#]
幻覚	Any	1 (2.0) [1]
	Related	1 (2.0) [1]
	Not Related	0
腎および尿路障害	Any	3 (6.1) [4]
	Related	0
	Not Related	3 (6.1) [4]
血尿	Any	2 (4.1) [2]
	Related	0
	Not Related	2 (4.1) [2]
緊張性膀胱	Any	1 (2.0) [1]
	Related	0
	Not Related	1 (2.0) [1]
蛋白尿	Any	1 (2.0) [1]
	Related	0
	Not Related	1 (2.0) [1]

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term; (%)=percentage of subjects among total N; [#]=the number of individual occurrences of the TEAE.
Note: A subject may be counted more than once according to the relationship of the TEAEs.
Note: Drug-related TEAEs are those with a relationship of "related ", "possibly related", or those with missing responses.

Reference: Subject Data Listing 6.1.1

表 2.2-19　治験薬との因果関係別の有害事象：SS（続き）

Table 9.7.1

Incidence of Treatment-Emergent Adverse Events (TEAEs) by Relationship per Investigator

Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Drug Relationship	N = 49 n (%) [#]
生殖系および乳房障害	Any	2 (4.1) [2]
	Related	0
	Not Related	2 (4.1) [2]
乳房腫瘤	Any	1 (2.0) [1]
	Related	0
	Not Related	1 (2.0) [1]
膣嚢胞	Any	1 (2.0) [1]
	Related	0
	Not Related	1 (2.0) [1]
呼吸器、胸郭および縦隔障害	Any	9 (18.4) [12]
	Related	1 (2.0) [1]
	Not Related	9 (18.4) [11]
呼吸困難	Any	4 (8.2) [4]
	Related	0
	Not Related	4 (8.2) [4]

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term; (%)=percentage of subjects among total N; [#]=the number of individual occurrences of the TEAE.
Note: A subject may be counted more than once according to the relationship of the TEAEs.
Note: Drug-related TEAEs are those with a relationship of "related ", "possibly related", or those with missing responses.

Reference: Subject Data Listing 6.1.1

表 2.2-19　治験薬との因果関係別の有害事象：SS（続き）

Table 9.7.1

Incidence of Treatment-Emergent Adverse Events (TEAEs) by Relationship per Investigator

Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Drug Relationship	N = 49 n (%) [#]
鼻閉	Any	2 (4.1) [2]
	Related	0
	Not Related	2 (4.1) [2]
鼻出血	Any	1 (2.0) [1]
	Related	1 (2.0) [1]
	Not Related	0
上気道分泌増加	Any	1 (2.0) [1]
	Related	0
	Not Related	1 (2.0) [1]
咽喉頭疼痛	Any	1 (2.0) [1]
	Related	0
	Not Related	1 (2.0) [1]
鼻漏	Any	1 (2.0) [1]
	Related	0
	Not Related	1 (2.0) [1]

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term; (%)=percentage of subjects among total N; [#]=the number of individual occurrences of the TEAE.
Note: A subject may be counted more than once according to the relationship of the TEAEs.
Note: Drug-related TEAEs are those with a relationship of "related ", "possibly related", or those with missing responses.

Reference: Subject Data Listing 6.1.1

表 2.2-19　治験薬との因果関係別の有害事象：SS（続き）

Table 9.7.1

Incidence of Treatment-Emergent Adverse Events (TEAEs) by Relationship per Investigator

Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Drug Relationship	N = 49 n (%) [#]
副鼻腔うっ血	Any	1 (2.0) [1]
	Related	0
	Not Related	1 (2.0) [1]
上気道の炎症	Any	1 (2.0) [1]
	Related	0
	Not Related	1 (2.0) [1]
皮膚および皮下組織障害	Any	8 (16.3) [8]
	Related	2 (4.1) [2]
	Not Related	6 (12.2) [6]
そう痒症	Any	3 (6.1) [3]
	Related	1 (2.0) [1]
	Not Related	2 (4.1) [2]
発疹	Any	2 (4.1) [2]
	Related	0
	Not Related	2 (4.1) [2]

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term; (%)=percentage of subjects among total N; [#]=the number of individual occurrences of the TEAE.
Note: A subject may be counted more than once according to the relationship of the TEAEs.
Note: Drug-related TEAEs are those with a relationship of "related ", "possibly related", or those with missing responses.

Reference: Subject Data Listing 6.1.1

表 2.2-19　治験薬との因果関係別の有害事象：SS（続き）

Table 9.7.1

Incidence of Treatment-Emergent Adverse Events (TEAEs) by Relationship per Investigator

Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Drug Relationship	N = 49 n (%) [#]
脱毛症	Any	1 (2.0) [1]
	Related	1 (2.0) [1]
	Not Related	0
斑状出血	Any	1 (2.0) [1]
	Related	0
	Not Related	1 (2.0) [1]
斑状丘疹状皮疹	Any	1 (2.0) [1]
	Related	0
	Not Related	1 (2.0) [1]
血管障害	Any	3 (6.1) [3]
	Related	1 (2.0) [1]
	Not Related	2 (4.1) [2]
ほてり	Any	2 (4.1) [2]
	Related	1 (2.0) [1]
	Not Related	1 (2.0) [1]

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term; (%)=percentage of subjects among total N; [#]=the number of individual occurrences of the TEAE.
Note: A subject may be counted more than once according to the relationship of the TEAEs.
Note: Drug-related TEAEs are those with a relationship of "related ", "possibly related", or those with missing responses.

Reference: Subject Data Listing 6.1.1

表 2.2-19　治験薬との因果関係別の有害事象：SS（続き）

Table 9.7.1

Incidence of Treatment-Emergent Adverse Events (TEAEs) by Relationship per Investigator

Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Drug Relationship	N = 49 n (%) [#]
潮紅	Any	1 (2.0) [1]
	Related	0
	Not Related	1 (2.0) [1]

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term; (%)=percentage of subjects among total N; [#]=the number of individual occurrences of the TEAE.

Note: A subject may be counted more than once according to the relationship of the TEAEs.

Note: Drug-related TEAEs are those with a relationship of "related ", "possibly related", or those with missing responses.

Reference: Subject Data Listing 6.1.1

2.2.3.5.4 死亡

本治験では、死亡は認められなかった。

2.2.3.5.5 重篤な有害事象

本治験の治験薬投与開始後に認められた重篤な有害事象を表 2.2-20 に示した。

本治験では、治験薬投与開始後に重篤な有害事象が 1 例（小発作てんかん、医師記載用語：小発作重積）に認められた。

表 2.2-20　重篤な有害事象：SS

Table 9.5.1

Incidence of Serious Treatment-Emergent Adverse Events (TEAEs)

Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	N = 49 n (%) [#]
Any System Organ Class	1 (2.0) [1]
神経系障害	1 (2.0) [1]
小発作てんかん	1 (2.0) [1]

Note: n=number of subjects reporting at least one TEAE in that category during study conduct; (%)=percentage of subjects among total N; [#]=the number of individual occurrences of the TEAE.

Reference: Subject Data Listing 6.2.1

2.2.3.5.6 治験薬の投与中止に至った有害事象

本治験で認められた治験薬の投与中止に至った有害事象を表 2.2-21 に示した。

本治験では、9 例が治験を中止した。中止理由は、有害事象（5 例）及び同意撤回（4 例）であった。治験薬の投与中止に至った有害事象の内訳は、浮動性めまい（1 例）、大発作痙攣（医師記載用語：全般性強直間代発作増加、1 例）、小発作てんかん（医師記載用語：欠神発作増加、1 例）、回転性めまい、複視、歩行障害、幻覚、悪心、鎮静及び霧視（1 例）並びに小発作てんかん（医師記載用語：小発作重積、1 例）であった。

表 2.2-21　治験薬の投与中止に至った有害事象：SS

Table 9.4.1
Incidence of Treatment-Emergent Adverse Events (TEAEs) Leading to Discontinuation
Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	N = 49 n (%) [#]
Any System Organ Class	5 (10.2) [11]
耳および迷路障害	1 (2.0) [1]
回転性めまい	1 (2.0) [1]
眼障害	1 (2.0) [2]
複視	1 (2.0) [1]
霧視	1 (2.0) [1]
胃腸障害	1 (2.0) [1]
悪心	1 (2.0) [1]
全身障害および投与局所様態	1 (2.0) [1]
歩行障害	1 (2.0) [1]
神経系障害	5 (10.2) [5]
小発作てんかん	2 (4.1) [2]
浮動性めまい	1 (2.0) [1]
大発作痙攣	1 (2.0) [1]
鎮静	1 (2.0) [1]

Note: n=number of subjects reporting at least one TEAE in that category during study conduct; (%)=percentage of subjects among total N; [#]=the number of individual occurrences of the TEAE.

Reference: Subject Data Listing 6.4.1

表 2.2-21　治験薬の投与中止に至った有害事象：SS（続き）

Table 9.4.1
Incidence of Treatment-Emergent Adverse Events (TEAEs) Leading to Discontinuation
Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	N = 49 n (%) [#]
精神障害	1 (2.0) [1]
幻覚	1 (2.0) [1]

Note: n=number of subjects reporting at least one TEAE in that category during study conduct; (%)=percentage of subjects among total N; [#]=the number of individual occurrences of the TEAE.

Reference: Subject Data Listing 6.4.1

2.2.3.5.7 その他の注目すべき有害事象

本治験の治験薬投与開始後に認められたその他の注目すべき有害事象を表 2.2-22 に示した。

本治験では、治験薬投与開始後に認められた有害事象のうち、その他の注目すべき有害事象として、肝毒性関連、自殺関連、心臓障害関連、並びに失神及び意識消失の有害事象の有無を確認した。

本治験では、アラニン・アミノトランスフェラーゼ増加が 1 例に認められた。

表 2.2-22　その他の注目すべき有害事象：SS

Table 9.8.1

Incidence of Other Significant Treatment-Emergent Adverse Events (TEAEs)

Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	N = 49 n (%) [#]
Any System Organ Class	1 (2.0) [1]
臨床検査	1 (2.0) [1]
アラニン・アミノトランスフェラーゼ増加	1 (2.0) [1]

Note: n=number of subjects reporting at least one TEAE in that category during study conduct; (%)=percentage of subjects among total N; [#]=the number of individual occurrences of the TEAE.

Reference: Subject Data Listing 6.5.1

2.2.3.6 臨床検査、バイタルサイン（体重を含む）、12 誘導心電図及び身体所見（神経学的検査を含む）

本治験でのスクリーニング時、ベースライン及び各来院時の測定値、並びにベースラインからの変化量について、血液学的検査を表 2.2-23 に、血液生化学検査を表 2.2-24 に示した。また、バイタルサイン（体重を含む）のスクリーニング時、ベースライン及び各来院時の測定値、並びにベースラインからの変化量を表 2.2-25 に示した。

血液学的検査、血液生化学検査及び尿検査の中央値は、いずれも基準範囲内であり、ベースラインからの変化量は臨床的に重要ではなかった。

12 誘導心電図、バイタルサイン（脈拍数、収縮期血圧、拡張期血圧）及び体重、並びに身体所見及び神経学的検査の結果から、臨床的に重要な所見は認められなかった。

表 2.2-23　血液学的検査の測定値及びベースラインからの変化量：SS

Table 11.1.1
Laboratory Parameters by Visit - Hematology
Population: Safety Set

		Actual Value						Change From Baseline				
Visit	n	Mean	SD	Median	Min	Max	n	Mean	SD	Median	Min	Max
Lab Parameter: Erythrocytes (T/L)												
VISIT 1 (Scr)	49	4.50	0.42	4.54	3.6	5.4						
VISIT 2 (BL)	48	4.53	0.34	4.53	3.7	5.5						
VISIT 6	43	4.50	0.41	4.51	3.5	5.4	43	-0.04	0.21	-0.01	-0.5	0.5
VISIT 7	47	4.43	0.37	4.39	3.6	5.3	47	-0.08	0.16	-0.07	-0.4	0.3
Min Post-BL	48	4.39	0.37	4.36	3.5	5.3	48	-0.12	0.17	-0.15	-0.5	0.3
Max Post-BL	48	4.52	0.39	4.51	3.6	5.4	48	0.01	0.19	0.01	-0.5	0.5

Note: Scr=Screening; BL=Baseline.
Note: Baseline=last non-missing value prior to LCM treatment at Visit 2.
Note: Min (Max) Post-Baseline=Minimum (Maximum) of all reported values during the Treatment Phase.

Reference: Subject Data Listing 7.1.1

表 2.2-23　血液学的検査の測定値及びベースラインからの変化量：SS（続き）

Table 11.1.1
Laboratory Parameters by Visit - Hematology
Population: Safety Set

		Actual Value						Change From Baseline				
Visit	n	Mean	SD	Median	Min	Max	n	Mean	SD	Median	Min	Max
Lab Parameter: Hematocrit (%)												
VISIT 1 (Scr)	49	41.45	4.43	40.40	32.4	54.0						
VISIT 2 (BL)	48	42.03	3.69	41.00	36.0	51.1						
VISIT 6	43	41.74	4.29	41.40	33.8	51.6	43	-0.23	2.14	-0.20	-4.1	4.2
VISIT 7	47	41.13	3.71	40.90	33.4	52.6	47	-0.60	1.68	-0.60	-5.6	4.3
Min Post-BL	48	40.68	3.76	40.60	33.4	51.6	48	-1.00	1.71	-0.90	-5.6	3.3
Max Post-BL	48	41.88	4.11	41.50	34.9	52.6	48	0.20	1.97	0.15	-4.1	4.3

Note: Scr=Screening; BL=Baseline.
Note: Baseline=last non-missing value prior to LCM treatment at Visit 2.
Note: Min (Max) Post-Baseline=Minimum (Maximum) of all reported values during the Treatment Phase.

Reference: Subject Data Listing 7.1.1

表 2.2-23　血液学的検査の測定値及びベースラインからの変化量：SS（続き）

Table 11.1.1
Laboratory Parameters by Visit - Hematology
Population: Safety Set

		Actual Value						Change From Baseline				
Visit	n	Mean	SD	Median	Min	Max	n	Mean	SD	Median	Min	Max
Lab Parameter: Hemoglobin (g/L)												
VISIT 1 (Scr)	49	139.29	15.04	136.00	107.0	179.0						
VISIT 2 (BL)	48	140.96	13.02	137.50	120.0	178.0						
VISIT 6	43	139.49	14.85	137.00	113.0	173.0	43	-1.14	6.94	0.00	-15.0	16.0
VISIT 7	47	137.21	13.01	137.00	111.0	168.0	47	-2.68	5.05	-2.00	-15.0	10.0
Min Post-BL	48	135.79	13.26	135.50	111.0	166.0	48	-3.81	5.38	-3.50	-15.0	10.0
Max Post-BL	48	139.56	14.47	137.50	113.0	173.0	48	-0.04	6.27	0.00	-15.0	16.0

Note: Scr=Screening; BL=Baseline.
Note: Baseline=last non-missing value prior to LCM treatment at Visit 2.
Note: Min (Max) Post-Baseline=Minimum (Maximum) of all reported values during the Treatment Phase.

Reference: Subject Data Listing 7.1.1

表 2.2-23　血液学的検査の測定値及びベースラインからの変化量：SS（続き）

Table 11.1.1
Laboratory Parameters by Visit - Hematology
Population: Safety Set

		Actual Value						Change From Baseline				
Visit	n	Mean	SD	Median	Min	Max	n	Mean	SD	Median	Min	Max
Lab Parameter: Leukocytes (G/L)												
VISIT 1 (Scr)	49	7.06	2.56	6.30	3.4	15.0						
VISIT 2 (BL)	48	6.71	2.10	6.40	3.1	12.0						
VISIT 6	43	6.68	2.44	6.40	2.9	15.2	43	-0.03	2.07	-0.20	-5.6	7.6
VISIT 7	47	6.37	2.11	5.80	2.9	14.4	47	-0.35	1.61	-0.60	-5.3	4.0
Min Post-BL	48	6.05	1.94	5.75	2.9	12.3	48	-0.66	1.48	-0.65	-5.6	3.2
Max Post-BL	48	6.94	2.44	6.55	3.4	15.2	48	0.23	2.00	0.05	-5.3	7.6

Note: Scr=Screening; BL=Baseline.
Note: Baseline=last non-missing value prior to LCM treatment at Visit 2.
Note: Min (Max) Post-Baseline=Minimum (Maximum) of all reported values during the Treatment Phase.

Reference: Subject Data Listing 7.1.1

表 2.2-23　血液学的検査の測定値及びベースラインからの変化量：SS（続き）

Table 11.1.1
Laboratory Parameters by Visit - Hematology
Population: Safety Set

		Actual Value						Change From Baseline				
Visit	n	Mean	SD	Median	Min	Max	n	Mean	SD	Median	Min	Max
Lab Parameter: Lymphocytes/Leukocytes (%)												
VISIT 1 (Scr)	49	31.44	7.99	31.60	14.6	60.7						
VISIT 2 (BL)	48	31.98	10.33	30.20	12.2	67.1						
VISIT 6	43	32.52	8.99	33.80	10.3	57.8	43	0.24	9.17	0.40	-25.0	21.9
VISIT 7	47	32.69	8.43	31.80	17.5	57.0	47	0.53	7.48	-0.10	-17.7	24.0
Min Post-BL	48	30.18	8.10	30.65	10.3	47.8	48	-1.95	8.55	-2.45	-25.0	21.9
Max Post-BL	48	35.33	8.13	35.25	17.5	57.8	48	3.21	7.02	2.85	-10.1	24.0

Note: Scr=Screening; BL=Baseline.
Note: Baseline=last non-missing value prior to LCM treatment at Visit 2.
Note: Min (Max) Post-Baseline=Minimum (Maximum) of all reported values during the Treatment Phase.

Reference: Subject Data Listing 7.1.1

表 2.2-23　血液学的検査の測定値及びベースラインからの変化量：SS（続き）

Table 11.1.1
Laboratory Parameters by Visit - Hematology
Population: Safety Set

		Actual Value						Change From Baseline				
Visit	n	Mean	SD	Median	Min	Max	n	Mean	SD	Median	Min	Max
Lab Parameter: Basophils/Leukocytes (%)												
VISIT 1 (Scr)	49	0.38	0.22	0.30	0.0	1.2						
VISIT 2 (BL)	48	0.36	0.16	0.40	0.1	0.8						
VISIT 6	43	0.36	0.21	0.30	0.1	1.2	43	0.00	0.22	0.00	-0.3	0.6
VISIT 7	47	0.40	0.20	0.40	0.0	0.9	47	0.05	0.21	0.00	-0.4	0.5
Min Post-BL	48	0.29	0.16	0.30	0.0	0.8	48	-0.07	0.18	-0.10	-0.4	0.4
Max Post-BL	48	0.47	0.21	0.40	0.2	1.2	48	0.11	0.20	0.10	-0.3	0.6

Note: Scr=Screening; BL=Baseline.
Note: Baseline=last non-missing value prior to LCM treatment at Visit 2.
Note: Min (Max) Post-Baseline=Minimum (Maximum) of all reported values during the Treatment Phase.

Reference: Subject Data Listing 7.1.1

表 2.2-23　血液学的検査の測定値及びベースラインからの変化量：SS（続き）

Table 11.1.1
Laboratory Parameters by Visit - Hematology
Population: Safety Set

	Actual Value					Change From Baseline				
Visit	n	Mean	SD	Median	Min	Max	n	Mean	SD	Median	Min	Max
Lab Parameter: Eosinophils (G/L)												
VISIT 1 (Scr)	49	0.16	0.21	0.10	0.0	1.1						
VISIT 2 (BL)	48	0.15	0.18	0.10	0.0	1.0						
VISIT 6	43	0.15	0.22	0.10	0.0	1.1	43	0.00	0.19	0.00	-0.6	1.0
VISIT 7	47	0.15	0.17	0.10	0.0	0.8	47	0.01	0.11	0.00	-0.3	0.3
Min Post-BL	48	0.11	0.14	0.10	0.0	0.8	48	-0.03	0.11	0.00	-0.6	0.1
Max Post-BL	48	0.18	0.23	0.10	0.0	1.1	48	0.03	0.17	0.00	-0.3	1.0

Note: Scr=Screening; BL=Baseline.
Note: Baseline=last non-missing value prior to LCM treatment at Visit 2.
Note: Min (Max) Post-Baseline=Minimum (Maximum) of all reported values during the Treatment Phase.

Reference: Subject Data Listing 7.1.1

表 2.2-23　血液学的検査の測定値及びベースラインからの変化量：SS（続き）

Table 11.1.1
Laboratory Parameters by Visit - Hematology
Population: Safety Set

	Actual Value					Change From Baseline				
Visit	n	Mean	SD	Median	Min	Max	n	Mean	SD	Median	Min	Max
Lab Parameter: Eosinophils/Leukocytes (%)												
VISIT 1 (Scr)	49	2.06	2.19	1.30	0.0	9.4						
VISIT 2 (BL)	48	2.14	2.31	1.30	0.0	12.5						
VISIT 6	43	2.22	2.72	1.30	0.0	13.8	43	-0.02	2.40	-0.10	-5.1	12.8
VISIT 7	47	2.23	2.26	1.40	0.1	10.6	47	0.13	1.44	0.00	-3.0	3.9
Min Post-BL	48	1.73	1.91	1.15	0.0	10.6	48	-0.40	1.29	-0.20	-5.1	2.3
Max Post-BL	48	2.64	2.79	1.60	0.1	13.8	48	0.52	2.25	0.20	-2.6	12.8

Note: Scr=Screening; BL=Baseline.
Note: Baseline=last non-missing value prior to LCM treatment at Visit 2.
Note: Min (Max) Post-Baseline=Minimum (Maximum) of all reported values during the Treatment Phase.

Reference: Subject Data Listing 7.1.1

表 2.2-23　血液学的検査の測定値及びベースラインからの変化量：SS（続き）

Table 11.1.1
Laboratory Parameters by Visit - Hematology
Population: Safety Set

		Actual Value						Change From Baseline				
Visit	n	Mean	SD	Median	Min	Max	n	Mean	SD	Median	Min	Max
Lab Parameter: Monocytes/Leukocytes (%)												
VISIT 1 (Scr)	49	5.82	2.57	5.00	0.6	13.1						
VISIT 2 (BL)	48	5.93	2.98	5.30	2.2	18.9						
VISIT 6	43	5.66	2.60	5.10	1.4	12.3	43	-0.43	2.33	-0.10	-9.0	4.0
VISIT 7	47	5.80	2.62	5.00	2.1	13.4	47	-0.22	2.53	0.30	-11.0	4.9
Min Post-BL	48	5.06	2.32	4.50	1.4	11.1	48	-0.94	2.26	-0.80	-11.0	2.8
Max Post-BL	48	6.44	2.58	5.90	2.5	13.4	48	0.43	2.28	0.60	-9.0	4.9

Note: Scr=Screening; BL=Baseline.
Note: Baseline=last non-missing value prior to LCM treatment at Visit 2.
Note: Min (Max) Post-Baseline=Minimum (Maximum) of all reported values during the Treatment Phase.

Reference: Subject Data Listing 7.1.1

表 2.2-23　血液学的検査の測定値及びベースラインからの変化量：SS（続き）

Table 11.1.1
Laboratory Parameters by Visit - Hematology
Population: Safety Set

		Actual Value						Change From Baseline				
Visit	n	Mean	SD	Median	Min	Max	n	Mean	SD	Median	Min	Max
Lab Parameter: Neutrophils (G/L)												
VISIT 1 (Scr)	49	4.36	2.03	3.80	1.2	11.8						
VISIT 2 (BL)	48	4.15	1.87	3.80	0.6	9.9						
VISIT 6	43	4.11	2.15	3.70	1.5	13.3	43	0.00	2.06	-0.20	-6.2	7.9
VISIT 7	47	3.86	1.73	3.20	1.5	9.3	47	-0.28	1.51	-0.40	-5.2	3.7
Min Post-BL	48	3.51	1.47	3.20	1.5	7.1	48	-0.63	1.42	-0.40	-6.2	2.8
Max Post-BL	48	4.38	2.14	4.10	1.9	13.3	48	0.25	1.94	0.00	-5.2	7.9

Note: Scr=Screening; BL=Baseline.
Note: Baseline=last non-missing value prior to LCM treatment at Visit 2.
Note: Min (Max) Post-Baseline=Minimum (Maximum) of all reported values during the Treatment Phase.

Reference: Subject Data Listing 7.1.1

表 2.2-23　血液学的検査の測定値及びベースラインからの変化量：SS（続き）

Table 11.1.1
Laboratory Parameters by Visit - Hematology
Population: Safety Set

		Actual Value						Change From Baseline				
Visit	n	Mean	SD	Median	Min	Max	n	Mean	SD	Median	Min	Max
Lab Parameter: Neutrophils/Leukocytes (%)												
VISIT 1 (Scr)	49	60.29	8.59	60.20	34.5	79.0						
VISIT 2 (BL)	48	59.59	12.22	61.80	17.1	84.2						
VISIT 6	43	59.23	10.06	57.30	36.5	87.3	43	0.21	11.04	-1.40	-24.9	30.3
VISIT 7	47	58.87	9.85	61.10	33.1	78.3	47	-0.48	9.04	-0.60	-23.6	19.9
Min Post-BL	48	56.15	9.13	56.30	33.1	78.3	48	-3.25	8.64	-3.25	-24.9	16.0
Max Post-BL	48	61.79	9.49	62.60	47.4	87.3	48	2.39	10.36	1.45	-23.6	30.3

Note: Scr=Screening; BL=Baseline.
Note: Baseline=last non-missing value prior to LCM treatment at Visit 2.
Note: Min (Max) Post-Baseline=Minimum (Maximum) of all reported values during the Treatment Phase.

Reference: Subject Data Listing 7.1.1

表 2.2-23　血液学的検査の測定値及びベースラインからの変化量：SS（続き）

Table 11.1.1
Laboratory Parameters by Visit - Hematology
Population: Safety Set

		Actual Value						Change From Baseline				
Visit	n	Mean	SD	Median	Min	Max	n	Mean	SD	Median	Min	Max
Lab Parameter: Platelet (G/L)												
VISIT 1 (Scr)	49	234.80	58.61	234.00	119.0	400.0						
VISIT 2 (BL)	47	231.77	55.64	235.00	113.0	345.0						
VISIT 6	41	225.88	60.06	223.00	120.0	363.0	41	-5.07	27.85	1.00	-91.0	44.0
VISIT 7	46	227.09	54.91	223.00	115.0	328.0	46	-10.54	28.49	-9.00	-103.0	50.0
Min Post-BL	48	217.52	56.57	218.00	115.0	328.0	48	-17.60	26.37	-15.50	-103.0	44.0
Max Post-BL	48	238.65	60.26	232.00	120.0	418.0	48	3.52	23.18	2.00	-48.0	68.0

Note: Scr=Screening; BL=Baseline.
Note: Baseline=last non-missing value prior to LCM treatment at Visit 2.
Note: Min (Max) Post-Baseline=Minimum (Maximum) of all reported values during the Treatment Phase.

Reference: Subject Data Listing 7.1.1

表 2.2-24　血液生化学検査の測定値及びベースラインからの変化量：SS

Table 11.2.1
Laboratory Parameters by Visit - Chemistry
Population: Safety Set

		Actual Value						Change From Baseline				
Visit	n	Mean	SD	Median	Min	Max	n	Mean	SD	Median	Min	Max
Lab Parameter: Alanine Aminotransferase (U/L)												
VISIT 1 (Scr)	48	25.33	17.27	21.50	9.0	98.0						
VISIT 2 (BL)	47	24.62	17.01	19.00	9.0	96.0						
VISIT 6	42	25.93	19.63	20.00	9.0	95.0	42	0.48	14.83	1.00	-36.0	76.0
VISIT 7	47	23.96	15.40	21.00	8.0	74.0	47	-0.53	9.02	0.00	-30.0	20.0
Min Post-BL	48	21.46	13.56	18.00	8.0	69.0	48	-2.90	9.31	-1.00	-36.0	19.0
Max Post-BL	48	27.27	19.56	22.50	10.0	95.0	48	2.92	13.08	2.50	-21.0	76.0

Note: Scr=Screening; BL=Baseline.
Note: Baseline last non-missing value prior to LCM treatment at Visit 2.
Note: Min (Max) Post-Baseline=Minimum (Maximum) of all reported values during the Treatment Phase.

Reference: Subject Data Listing 7.2.1

表 2.2-24　血液生化学検査の測定値及びベースラインからの変化量：SS（続き）

Table 11.2.1
Laboratory Parameters by Visit - Chemistry
Population: Safety Set

Visit	Actual Value n	Actual Value Mean	Actual Value SD	Actual Value Median	Actual Value Min	Actual Value Max	Change From Baseline n	Change From Baseline Mean	Change From Baseline SD	Change From Baseline Median	Change From Baseline Min	Change From Baseline Max
Lab Parameter: Aspartate Aminotransferase (U/L)												
VISIT 1 (Scr)	48	23.77	12.37	20.50	8.0	81.0						
VISIT 2 (BL)	47	23.55	12.51	21.00	7.0	86.0						
VISIT 6	42	22.83	10.67	20.50	10.0	64.0	42	-1.74	7.19	-1.00	-22.0	13.0
VISIT 7	47	23.45	10.61	20.00	10.0	54.0	47	-0.15	8.12	0.00	-35.0	23.0
Min Post-BL	48	20.92	8.98	19.00	10.0	51.0	48	-2.56	7.28	-1.50	-35.0	13.0
Max Post-BL	48	24.56	11.32	21.00	12.0	64.0	48	1.08	7.25	1.00	-22.0	23.0

Note: Scr=Screening; BL=Baseline.
Note: Baseline last non-missing value prior to LCM treatment at Visit 2.
Note: Min (Max) Post-Baseline=Minimum (Maximum) of all reported values during the Treatment Phase.

Reference: Subject Data Listing 7.2.1

表 2.2-24　血液生化学検査の測定値及びベースラインからの変化量：SS（続き）

Table 11.2.1
Laboratory Parameters by Visit - Chemistry
Population: Safety Set

		Actual Value						Change From Baseline				
Visit	n	Mean	SD	Median	Min	Max	n	Mean	SD	Median	Min	Max
Lab Parameter: Alkaline Phosphatase (U/L)												
VISIT 1 (Scr)	49	89.49	33.20	81.00	46.0	232.0						
VISIT 2 (BL)	47	88.70	32.28	81.00	38.0	230.0						
VISIT 6	42	89.10	32.75	85.00	37.0	230.0	42	0.71	9.46	0.00	-18.0	27.0
VISIT 7	47	87.64	30.40	82.00	39.0	212.0	47	0.00	11.17	-1.00	-29.0	24.0
Min Post-BL	48	84.33	29.90	79.50	37.0	212.0	48	-2.92	9.58	-2.00	-29.0	18.0
Max Post-BL	48	90.67	31.68	88.00	39.0	230.0	48	3.42	9.93	1.50	-17.0	27.0

Note: Scr=Screening; BL=Baseline.
Note: Baseline last non-missing value prior to LCM treatment at Visit 2.
Note: Min (Max) Post-Baseline=Minimum (Maximum) of all reported values during the Treatment Phase.

Reference: Subject Data Listing 7.2.1

表 2.2-24　血液生化学検査の測定値及びベースラインからの変化量：SS（続き）

Table 11.2.1
Laboratory Parameters by Visit - Chemistry
Population: Safety Set

Visit	Actual Value n	Actual Value Mean	Actual Value SD	Actual Value Median	Actual Value Min	Actual Value Max	Change From Baseline n	Change From Baseline Mean	Change From Baseline SD	Change From Baseline Median	Change From Baseline Min	Change From Baseline Max
Lab Parameter: Gamma Glutamyl Transferase (U/L)												
VISIT 1 (Scr)	49	46.14	54.90	27.00	4.0	325.0						
VISIT 2 (BL)	47	46.49	54.59	25.00	6.0	304.0						
VISIT 6	42	50.69	62.50	27.50	5.0	355.0	42	2.26	10.15	1.00	-14.0	51.0
VISIT 7	47	46.85	52.68	27.00	6.0	301.0	47	1.09	12.02	0.00	-29.0	45.0
Min Post-BL	48	43.48	51.52	26.50	5.0	301.0	48	-1.85	8.54	-1.50	-29.0	27.0
Max Post-BL	48	50.44	59.45	29.50	7.0	355.0	48	5.10	11.69	2.00	-14.0	51.0

Note: Scr=Screening; BL=Baseline.
Note: Baseline last non-missing value prior to LCM treatment at Visit 2.
Note: Min (Max) Post-Baseline=Minimum (Maximum) of all reported values during the Treatment Phase.

Reference: Subject Data Listing 7.2.1

表 2.2-24　血液生化学検査の測定値及びベースラインからの変化量：SS（続き）

Table 11.2.1
Laboratory Parameters by Visit - Chemistry
Population: Safety Set

		Actual Value						Change From Baseline				
Visit	n	Mean	SD	Median	Min	Max	n	Mean	SD	Median	Min	Max
Lab Parameter: Bilirubin (umol/L)												
VISIT 1 (Scr)	49	6.14	3.56	5.13	1.7	18.8						
VISIT 2 (BL)	47	6.33	3.81	5.13	1.7	22.2						
VISIT 6	42	5.99	3.36	5.13	1.7	18.8	42	-0.24	1.79	0.00	-3.4	3.4
VISIT 7	47	5.50	2.44	5.13	1.7	12.0	47	-0.73	2.52	0.00	-10.3	3.4
Min Post-BL	48	5.13	2.37	5.13	1.7	12.0	48	-1.07	2.36	0.00	-10.3	1.7
Max Post-BL	48	6.27	3.16	5.13	1.7	18.8	48	0.07	1.87	0.00	-3.4	3.4

Note: Scr=Screening; BL=Baseline.
Note: Baseline last non-missing value prior to LCM treatment at Visit 2.
Note: Min (Max) Post-Baseline=Minimum (Maximum) of all reported values during the Treatment Phase.

Reference: Subject Data Listing 7.2.1

表 2.2-24　血液生化学検査の測定値及びベースラインからの変化量：SS（続き）

Table 11.2.1
Laboratory Parameters by Visit - Chemistry
Population: Safety Set

	Actual Value					Change From Baseline				
Visit	n	Mean	SD	Median	Min	Max	n	Mean	SD	Median	Min	Max
Lab Parameter: Protein (g/L)												
VISIT 1 (Scr)	49	71.71	4.24	71.00	61.0	84.0						
VISIT 2 (BL)	47	70.89	4.36	71.00	61.0	82.0						
VISIT 6	42	71.19	4.00	70.50	64.0	80.0	42	0.19	4.44	0.00	-8.0	10.0
VISIT 7	47	70.36	4.38	71.00	61.0	83.0	47	-0.43	3.19	0.00	-6.0	5.0
Min Post-BL	48	69.38	3.73	69.00	61.0	80.0	48	-1.46	3.21	-2.00	-8.0	5.0
Max Post-BL	48	71.96	4.26	72.00	64.0	83.0	48	1.13	3.94	2.00	-7.0	10.0

Note: Scr=Screening; BL=Baseline.
Note: Baseline last non-missing value prior to LCM treatment at Visit 2.
Note: Min (Max) Post-Baseline=Minimum (Maximum) of all reported values during the Treatment Phase.

Reference: Subject Data Listing 7.2.1

表 2.2-24　血液生化学検査の測定値及びベースラインからの変化量：SS（続き）

Table 11.2.1
Laboratory Parameters by Visit - Chemistry
Population: Safety Set

	Actual Value					Change From Baseline				
Visit	n	Mean	SD	Median	Min	Max	n	Mean	SD	Median	Min	Max
Lab Parameter: Albumin (g/L)												
VISIT 1 (Scr)	49	45.86	2.55	45.00	42.0	53.0						
VISIT 2 (BL)	47	45.32	2.63	45.00	41.0	51.0						
VISIT 6	42	45.40	2.85	46.00	40.0	51.0	42	0.24	2.47	0.00	-5.0	6.0
VISIT 7	47	45.11	2.65	45.00	39.0	52.0	47	-0.21	2.00	0.00	-4.0	3.0
Min Post-BL	48	44.48	2.48	45.00	39.0	49.0	48	-0.83	1.95	-1.00	-5.0	3.0
Max Post-BL	48	46.04	2.73	46.00	40.0	52.0	48	0.73	2.22	1.00	-4.0	6.0

Note: Scr=Screening; BL=Baseline.
Note: Baseline last non-missing value prior to LCM treatment at Visit 2.
Note: Min (Max) Post-Baseline=Minimum (Maximum) of all reported values during the Treatment Phase.

Reference: Subject Data Listing 7.2.1

表 2.2-24　血液生化学検査の測定値及びベースラインからの変化量：SS（続き）

Table 11.2.1
Laboratory Parameters by Visit - Chemistry
Population: Safety Set

		Actual Value						Change From Baseline				
Visit	n	Mean	SD	Median	Min	Max	n	Mean	SD	Median	Min	Max
Lab Parameter: Blood Urea Nitrogen (mmol/L)												
VISIT 1 (Scr)	49	4.82	1.42	4.28	2.5	8.9						
VISIT 2 (BL)	47	4.61	1.45	4.28	2.1	10.4						
VISIT 6	42	4.71	1.37	4.64	2.1	8.2	42	0.09	1.19	0.36	-3.2	2.5
VISIT 7	47	4.55	1.21	5.00	2.1	7.9	47	-0.04	1.17	0.00	-2.9	2.5
Min Post-BL	48	4.17	1.17	3.93	2.1	7.9	48	-0.39	0.97	-0.36	-3.2	1.1
Max Post-BL	48	4.92	1.31	5.36	2.1	8.2	48	0.36	1.22	0.36	-2.9	2.5

Note: Scr=Screening; BL=Baseline.
Note: Baseline last non-missing value prior to LCM treatment at Visit 2.
Note: Min (Max) Post-Baseline=Minimum (Maximum) of all reported values during the Treatment Phase.

Reference: Subject Data Listing 7.2.1

表 2.2-24　血液生化学検査の測定値及びベースラインからの変化量：SS（続き）

Table 11.2.1
Laboratory Parameters by Visit - Chemistry
Population: Safety Set

		Actual Value						Change From Baseline				
Visit	n	Mean	SD	Median	Min	Max	n	Mean	SD	Median	Min	Max
Lab Parameter: Creatinine (umol/L)												
VISIT 1 (Scr)	49	76.94	13.48	79.56	53.0	114.9						
VISIT 2 (BL)	47	78.00	15.52	79.56	44.2	120.2						
VISIT 6	41	76.76	16.79	75.14	46.0	125.5	41	-0.58	11.66	0.00	-23.0	37.1
VISIT 7	47	75.93	14.51	70.72	42.4	106.1	47	-1.50	11.44	0.00	-35.4	17.7
Min Post-BL	48	72.58	15.35	70.72	42.4	106.1	48	-4.90	10.92	-2.21	-35.4	17.7
Max Post-BL	48	80.33	14.33	79.56	53.0	125.5	48	2.85	10.70	3.09	-17.7	37.1

Note: Scr=Screening; BL=Baseline.
Note: Baseline last non-missing value prior to LCM treatment at Visit 2.
Note: Min (Max) Post-Baseline=Minimum (Maximum) of all reported values during the Treatment Phase.

Reference: Subject Data Listing 7.2.1

表 2.2-24　血液生化学検査の測定値及びベースラインからの変化量：SS（続き）

Table 11.2.1
Laboratory Parameters by Visit - Chemistry
Population: Safety Set

Visit	Actual Value n	Actual Value Mean	Actual Value SD	Actual Value Median	Actual Value Min	Actual Value Max	Change From Baseline n	Change From Baseline Mean	Change From Baseline SD	Change From Baseline Median	Change From Baseline Min	Change From Baseline Max
Lab Parameter: Bicarbonate (mmol/L)												
VISIT 1 (Scr)	49	27.12	3.11	27.00	18.0	33.0						
VISIT 2 (BL)	47	27.13	3.94	27.00	17.0	35.0						
VISIT 6	42	26.67	3.07	26.00	20.0	32.0	42	-0.67	2.51	-1.00	-7.0	7.0
VISIT 7	47	27.36	3.19	28.00	20.0	33.0	47	0.04	2.77	0.00	-7.0	8.0
Min Post-BL	48	26.13	2.90	26.00	20.0	31.0	48	-1.04	2.77	-1.00	-7.0	7.0
Max Post-BL	48	27.85	3.14	28.00	20.0	33.0	48	0.69	2.36	0.00	-3.0	8.0

Note: Scr=Screening; BL=Baseline.
Note: Baseline last non-missing value prior to LCM treatment at Visit 2.
Note: Min (Max) Post-Baseline=Minimum (Maximum) of all reported values during the Treatment Phase.

Reference: Subject Data Listing 7.2.1

表 2.2-24　血液生化学検査の測定値及びベースラインからの変化量：SS（続き）

Table 11.2.1
Laboratory Parameters by Visit - Chemistry
Population: Safety Set

Visit	Actual Value n	Mean	SD	Median	Min	Max	Change From Baseline n	Mean	SD	Median	Min	Max
Lab Parameter: Calcium (mmol/L)												
VISIT 1 (Scr)	49	2.33	0.10	2.30	2.1	2.6						
VISIT 2 (BL)	47	2.33	0.10	2.33	2.1	2.6						
VISIT 6	42	2.33	0.11	2.33	2.1	2.6	42	0.01	0.11	0.00	-0.2	0.3
VISIT 7	47	2.31	0.10	2.33	2.1	2.5	47	-0.01	0.09	-0.03	-0.2	0.3
Min Post-BL	48	2.28	0.09	2.28	2.1	2.5	48	-0.04	0.09	-0.05	-0.2	0.2
Max Post-BL	48	2.36	0.10	2.34	2.2	2.6	48	0.03	0.10	0.05	-0.2	0.3

Note: Scr=Screening; BL=Baseline.
Note: Baseline last non-missing value prior to LCM treatment at Visit 2.
Note: Min (Max) Post-Baseline=Minimum (Maximum) of all reported values during the Treatment Phase.

Reference: Subject Data Listing 7.2.1

表 2.2-24　血液生化学検査の測定値及びベースラインからの変化量：SS（続き）

Table 11.2.1
Laboratory Parameters by Visit - Chemistry
Population: Safety Set

		Actual Value						Change From Baseline				
Visit	n	Mean	SD	Median	Min	Max	n	Mean	SD	Median	Min	Max
Lab Parameter: Chloride (mmol/L)												
VISIT 1 (Scr)	49	106.53	3.45	106.00	99.0	114.0						
VISIT 2 (BL)	47	106.40	3.21	106.00	100.0	113.0						
VISIT 6	42	106.19	3.37	106.50	99.0	113.0	42	-0.19	1.89	0.00	-4.0	3.0
VISIT 7	47	106.55	3.46	106.00	99.0	114.0	47	0.04	2.72	0.00	-7.0	6.0
Min Post-BL	48	105.60	3.60	106.00	99.0	114.0	48	-0.96	2.38	-1.00	-7.0	2.0
Max Post-BL	48	107.29	3.20	107.00	99.0	114.0	48	0.73	2.29	1.00	-7.0	6.0

Note: Scr=Screening; BL=Baseline.
Note: Baseline last non-missing value prior to LCM treatment at Visit 2.
Note: Min (Max) Post-Baseline=Minimum (Maximum) of all reported values during the Treatment Phase.

Reference: Subject Data Listing 7.2.1

表 2.2-24　血液生化学検査の測定値及びベースラインからの変化量：SS（続き）

Table 11.2.1
Laboratory Parameters by Visit - Chemistry
Population: Safety Set

		Actual Value						Change From Baseline				
Visit	n	Mean	SD	Median	Min	Max	n	Mean	SD	Median	Min	Max
Lab Parameter: Phosphate (mmol/L)												
VISIT 1 (Scr)	46	1.25	0.18	1.28	0.9	1.6						
VISIT 2 (BL)	47	1.20	0.17	1.20	0.9	1.7						
VISIT 6	40	1.22	0.16	1.23	0.8	1.6	40	0.01	0.23	0.00	-0.6	0.5
VISIT 7	46	1.20	0.16	1.18	0.9	1.5	46	-0.01	0.22	-0.03	-0.6	0.5
Min Post-BL	48	1.15	0.14	1.15	0.8	1.4	48	-0.06	0.20	-0.06	-0.6	0.3
Max Post-BL	48	1.27	0.15	1.29	0.9	1.6	48	0.05	0.21	0.00	-0.6	0.5

Note: Scr=Screening; BL=Baseline.
Note: Baseline last non-missing value prior to LCM treatment at Visit 2.
Note: Min (Max) Post-Baseline=Minimum (Maximum) of all reported values during the Treatment Phase.

Reference: Subject Data Listing 7.2.1

表 2.2-24　血液生化学検査の測定値及びベースラインからの変化量：SS（続き）

Table 11.2.1
Laboratory Parameters by Visit - Chemistry
Population: Safety Set

		Actual Value						Change From Baseline				
Visit	n	Mean	SD	Median	Min	Max	n	Mean	SD	Median	Min	Max
Lab Parameter: Potassium (mmol/L)												
VISIT 1 (Scr)	46	4.27	0.32	4.20	3.8	5.1						
VISIT 2 (BL)	47	4.24	0.33	4.20	3.0	5.0						
VISIT 6	40	4.24	0.38	4.20	3.5	5.2	40	-0.05	0.40	-0.10	-0.7	0.7
VISIT 7	46	4.24	0.38	4.20	3.5	5.4	46	-0.01	0.44	-0.05	-0.7	1.5
Min Post-BL	48	4.11	0.38	4.10	3.5	5.4	48	-0.13	0.44	-0.20	-0.7	1.5
Max Post-BL	48	4.36	0.39	4.30	3.5	5.4	48	0.11	0.43	0.10	-0.6	1.5

Note: Scr=Screening; BL=Baseline.
Note: Baseline last non-missing value prior to LCM treatment at Visit 2.
Note: Min (Max) Post-Baseline=Minimum (Maximum) of all reported values during the Treatment Phase.

Reference: Subject Data Listing 7.2.1

表 2.2-24　血液生化学検査の測定値及びベースラインからの変化量：SS（続き）

Table 11.2.1
Laboratory Parameters by Visit - Chemistry
Population: Safety Set

Visit	Actual Value n	Mean	SD	Median	Min	Max	Change From Baseline n	Mean	SD	Median	Min	Max
Lab Parameter: Sodium (mmol/L)												
VISIT 1 (Scr)	49	140.86	2.42	141.00	134.0	148.0						
VISIT 2 (BL)	47	141.28	2.13	141.00	134.0	146.0						
VISIT 6	42	141.29	2.37	141.00	137.0	147.0	42	0.10	2.14	0.00	-5.0	4.0
VISIT 7	47	141.70	2.33	142.00	136.0	147.0	47	0.38	2.42	1.00	-7.0	6.0
Min Post-BL	48	140.79	2.29	141.00	136.0	147.0	48	-0.54	2.14	-0.50	-7.0	4.0
Max Post-BL	48	142.27	2.44	142.00	136.0	147.0	48	0.94	2.46	1.00	-7.0	6.0

Note: Scr=Screening; BL=Baseline.
Note: Baseline last non-missing value prior to LCM treatment at Visit 2.
Note: Min (Max) Post-Baseline=Minimum (Maximum) of all reported values during the Treatment Phase.

Reference: Subject Data Listing 7.2.1

表 2.2-24　血液生化学検査の測定値及びベースラインからの変化量：SS（続き）

Table 11.2.1
Laboratory Parameters by Visit - Chemistry
Population: Safety Set

	Actual Value					Change From Baseline				
Visit	n	Mean	SD	Median	Min	Max	n	Mean	SD	Median	Min	Max
Lab Parameter: Glucose (mmol/L)												
VISIT 1 (Scr)	47	5.08	1.16	4.83	3.7	10.8						
VISIT 2 (BL)	47	5.36	2.71	4.77	3.6	18.0						
VISIT 6	40	5.06	1.59	4.72	3.4	13.2	40	-0.06	1.30	-0.14	-4.8	3.3
VISIT 7	46	4.94	1.28	4.88	2.6	11.4	46	-0.17	1.36	-0.03	-6.7	2.5
Min Post-BL	48	4.62	1.26	4.52	2.6	11.4	48	-0.47	1.28	-0.28	-6.7	1.9
Max Post-BL	48	5.32	1.43	5.05	2.9	13.2	48	0.24	1.28	0.19	-4.8	3.3

Note: Scr=Screening; BL=Baseline.
Note: Baseline last non-missing value prior to LCM treatment at Visit 2.
Note: Min (Max) Post-Baseline=Minimum (Maximum) of all reported values during the Treatment Phase.

Reference: Subject Data Listing 7.2.1

表 2.2-24　血液生化学検査の測定値及びベースラインからの変化量：SS（続き）

Table 11.2.1
Laboratory Parameters by Visit - Chemistry
Population: Safety Set

		Actual Value						Change From Baseline				
Visit	n	Mean	SD	Median	Min	Max	n	Mean	SD	Median	Min	Max
Lab Parameter: Uric Acid (umol/L)												
VISIT 1 (Scr)	49	283.08	69.84	279.56	154.6	541.3						
VISIT 2 (BL)	47	272.85	72.20	273.61	142.8	434.2						
VISIT 6	42	272.48	75.18	252.79	119.0	517.5	42	-6.23	39.23	-11.90	-77.3	89.2
VISIT 7	47	266.01	69.61	255.76	154.6	493.7	47	-4.94	42.28	-5.95	-136.8	83.3
Min Post-BL	48	254.65	67.98	243.87	119.0	493.7	48	-17.97	39.81	-20.82	-136.8	65.4
Max Post-BL	48	279.93	71.94	264.69	178.4	517.5	48	7.31	35.50	2.97	-71.4	89.2

Note: Scr=Screening; BL=Baseline.
Note: Baseline last non-missing value prior to LCM treatment at Visit 2.
Note: Min (Max) Post-Baseline=Minimum (Maximum) of all reported values during the Treatment Phase.

Reference: Subject Data Listing 7.2.1

表 2.2-25　バイタルサインの測定値及びベースラインからの変化量：SS

Table 12.1.1
Vital Signs by Visit
Population: Safety Set

		Actual Value						Change From Baseline				
Visit	n	Mean	SD	Median	Min	Max	n	Mean	SD	Median	Min	Max
Vital Sign: Systolic Blood Pressure (mmHg)												
VISIT 1 (Scr)	49	116.0	12.8	114.0	96	148						
VISIT 2 (BL)	49	116.9	12.7	116.0	89	143						
VISIT 3	48	117.3	14.1	119.0	93	144	48	0.5	10.5	-0.5	-23	26
VISIT 4	47	116.3	13.6	116.0	93	148	47	0.0	13.1	1.0	-36	32
VISIT 5	44	117.9	11.6	118.0	96	146	44	1.5	8.8	2.5	-17	16
VISIT 6	43	116.8	13.4	116.0	92	144	43	0.2	11.2	0.0	-25	28
VISIT 7	48	115.9	13.6	115.0	87	157	48	-0.5	9.8	1.0	-30	22
END OF TAPER	5	117.6	18.6	122.0	93	135	5	0.2	13.3	4.0	-19	16
FINAL VISIT	8	115.4	18.6	111.0	88	142	8	-2.8	16.4	-3.0	-24	20
Min Post-BL	49	109.8	12.0	108.0	87	139	49	-7.1	9.8	-7.0	-36	16
Max Post-BL	49	125.5	13.4	126.0	98	157	49	8.6	10.3	8.0	-15	32

Note: Scr=Screening; BL=Baseline.
Note: Baseline=last non-missing value prior to LCM treatment at Visit 2.
Note: Min (Max) Post-Baseline=Minimum (Maximum) of all reported values during the Treatment Phase.

Reference: Subject Data Listing 8.6.1

表 2.2-25　バイタルサインの測定値及びベースラインからの変化量：SS（続き）

Table 12.1.1
Vital Signs by Visit
Population: Safety Set

		Actual Value					Change From Baseline					
Visit	n	Mean	SD	Median	Min	Max	n	Mean	SD	Median	Min	Max
Vital Sign: Diastolic Blood Pressure (mmHg)												
VISIT 1 (Scr)	49	75.1	9.1	75.0	53	99						
VISIT 2 (BL)	49	75.1	8.8	74.0	58	96						
VISIT 3	48	75.6	9.4	75.5	53	98	48	0.6	7.9	0.5	-14	20
VISIT 4	47	75.3	11.5	78.0	52	100	47	0.7	12.4	1.0	-34	22
VISIT 5	44	73.6	8.8	72.0	52	92	44	-1.1	8.4	-2.0	-28	18
VISIT 6	43	74.8	9.1	76.0	49	100	43	0.0	10.0	0.0	-24	27
VISIT 7	48	74.3	7.6	74.5	55	90	48	-0.5	8.0	0.0	-17	20
END OF TAPER	5	73.8	13.4	72.0	61	96	5	-0.8	7.9	-4.0	-8	12
FINAL VISIT	8	75.4	10.8	75.0	63	92	8	0.4	8.5	-1.0	-12	15
Min Post-BL	49	68.1	9.1	68.0	49	95	49	-7.0	8.7	-6.0	-34	10
Max Post-BL	49	81.5	7.8	81.0	65	100	49	6.4	8.1	6.0	-10	27

Note: Scr=Screening; BL=Baseline.
Note: Baseline=last non-missing value prior to LCM treatment at Visit 2.
Note: Min (Max) Post-Baseline=Minimum (Maximum) of all reported values during the Treatment Phase.

Reference: Subject Data Listing 8.6.1

表 2.2-25　バイタルサインの測定値及びベースラインからの変化量：SS（続き）

Table 12.1.1
Vital Signs by Visit
Population: Safety Set

		Actual Value						Change From Baseline				
Visit	n	Mean	SD	Median	Min	Max	n	Mean	SD	Median	Min	Max
Vital Sign: Pulse Rate (bpm)												
VISIT 1 (Scr)	49	74.2	13.0	72.0	51	125						
VISIT 2 (BL)	49	73.1	11.0	72.0	50	100						
VISIT 3	48	79.3	12.8	78.0	60	122	48	6.1	10.3	5.5	-21	36
VISIT 4	47	76.4	11.2	76.0	56	110	47	3.3	9.3	2.0	-16	22
VISIT 5	44	76.8	11.6	76.0	60	107	44	4.3	10.1	4.0	-19	25
VISIT 6	43	76.5	11.4	74.0	60	103	43	4.2	8.2	4.0	-14	24
VISIT 7	48	75.3	10.8	76.5	53	95	48	2.4	8.6	2.0	-18	24
END OF TAPER	5	81.2	12.5	80.0	64	96	5	2.2	13.4	7.0	-17	15
FINAL VISIT	8	80.3	9.3	83.5	63	92	8	3.1	8.8	3.0	-13	14
Min Post-BL	49	69.2	9.7	67.0	53	95	49	-3.9	8.1	-4.0	-21	20
Max Post-BL	49	84.6	11.6	84.0	64	122	49	11.5	8.8	12.0	-9	36

Note: Scr=Screening; BL=Baseline.
Note: Baseline=last non-missing value prior to LCM treatment at Visit 2.
Note: Min (Max) Post-Baseline=Minimum (Maximum) of all reported values during the Treatment Phase.

Reference: Subject Data Listing 8.6.1

表 2.2-25　バイタルサインの測定値及びベースラインからの変化量：SS（続き）

Table 12.1.1
Vital Signs by Visit
Population: Safety Set

		Actual Value						Change From Baseline				
Visit	n	Mean	SD	Median	Min	Max	n	Mean	SD	Median	Min	Max
Vital Sign: Temperature (C)												
VISIT 1 (Scr)	48	36.61	0.36	36.65	35.8	37.2						
VISIT 2 (BL)	48	36.56	0.41	36.60	35.5	37.3						
VISIT 7	47	36.70	0.36	36.80	35.9	37.3	46	0.12	0.43	0.10	-0.7	1.2
Min Post-BL	47	36.70	0.36	36.80	35.9	37.3	46	0.12	0.43	0.10	-0.7	1.2
Max Post-BL	47	36.70	0.36	36.80	35.9	37.3	46	0.12	0.43	0.10	-0.7	1.2

Note: Scr=Screening; BL=Baseline.
Note: Baseline=last non-missing value prior to LCM treatment at Visit 2.
Note: Min (Max) Post-Baseline=Minimum (Maximum) of all reported values during the Treatment Phase.

Reference: Subject Data Listing 8.6.1

表 2.2-25　バイタルサインの測定値及びベースラインからの変化量：SS（続き）

Table 12.1.1
Vital Signs by Visit
Population: Safety Set

		Actual Value						Change From Baseline				
Visit	n	Mean	SD	Median	Min	Max	n	Mean	SD	Median	Min	Max
Vital Sign: Weight (kg)												
VISIT 1 (Scr)	49	77.90	19.80	74.40	40.6	124.3						
VISIT 7	48	77.75	19.54	73.50	40.9	119.7	48	0.81	3.02	0.40	-7.0	8.5
Min Post-BL	48	77.75	19.54	73.50	40.9	119.7	48	0.81	3.02	0.40	-7.0	8.5
Max Post-BL	48	77.75	19.54	73.50	40.9	119.7	48	0.81	3.02	0.40	-7.0	8.5

Note: Scr=Screening; BL=Baseline.
Note: Baseline=last non-missing value prior to LCM treatment at Visit 2.
Note: Min (Max) Post-Baseline=Minimum (Maximum) of all reported values during the Treatment Phase.

Reference: Subject Data Listing 8.6.1

2.2.4 薬物動態

本治験の PK-PPS での第 6 回及び第 7 回来院時の血漿中ラコサミド濃度を表 2.2-26 に示した。

各測定時の血漿中ラコサミド濃度は、実際に投与された用量を反映しており、濃度及びその変動は予測範囲内であった。

表 2.2-26　血漿中ラコサミド濃度：PK-PPS

Table 15.1.1
LCM Plasma Concentration (ng/mL) by Time Point
Population: Pharmacokinetic Per-Protocol Set

Time Point	n	n>LOQ [a]	geoMean	arithMean	arithSD	CV (%)	Median	Min	Max
Visit 6 (6-12h post-dose)	40	40	7903.30	8437.48	3012.8	35.7	7880.5	3633	15786
Visit 7 (6-12h post-dose)	45	45	7909.40	8549.58	3395.8	39.7	8233.0	3307	17898

[a] n >LOQ=Number of subjects with plasma levels > LOQ (lower limit of quantification: 5.00 ng/mL).
Note: Summary statistics are only calculated if at least 2/3 of data are above the lower LOQ.
Note: Values below LOQ are set to LOQ/2 for calculation of all summary statistics.

Reference: Subject Data Listing 4.5.1

2.2.5 結論

安全性評価では、発作コントロールが得られていない強直間代発作を有するてんかん患者に、最高 400 mg/日までのラコサミドを最大 3 剤の抗てんかん薬と併用投与した時、良好な忍容性が認められた。

てんかん患者の強直間代発作の併用療法としてラコサミドを投与した結果、強直間代発作回数及びミオクロニー発作発現日数の減少、並びに欠神発作発現日数のわずかな減少が認められた。一部の被験者（10.2%）では、小発作てんかん（医師記載用語：欠神発作増加等）の有害事象が認められたが、本治験は非対照の臨床試験であることから、ラコサミドに関連するものか、原疾患の自然経過によるものかを判別することはできなかった。強直間代発作に関連する有害事象（医師記載用語：小発作てんかん）を除き、本治験の有害事象のプロファイルは、部分発作を有するてんかん患者を対象としたラコサミド併用療法の臨床試験の有害事象のプロファイルと類似していた。

2.3　SP0962 試験［発作コントロールが得られていない強直間代発作を有するてんかん患者を対象とするラコサミド投与における安全性及び発作回数を検討する非盲検、長期継続投与試験］（5.3.5.2.3：参考資料）

治験方法の概略（表 2.3-1）及び結果の要約を示した。

表 2.3-1　試験方法の概略

項目	内容
標題	発作コントロールが得られていない強直間代発作を有するてんかん患者を対象に、ラコサミドを経口投与した時の安全性及び発作回数を評価する非盲検、長期継続投与試験
開発の相	第 II 相
目的	・　発作コントロールが得られていない強直間代発作を有するてんかん患者を対象に、ラコサミドを長期経口投与した時の安全性及び発作回数のデータを収集する ・　SP0961 試験を完了した被験者に、ラコサミド継続投与の機会を提供する
治験デザイン	多施設共同、非盲検、長期継続投与
治験方法	本治験の対象は、SP0961 試験を完了した被験者とした。 本治験は、治療期間（56 週間）と治験終了期間（最長 5 週間）から構成された。 SP0961 試験の第 7 回来院（最終の規定来院）時に本治験の治療期間（第 1 回来院）を開始し、その後、4 週間ごとに第 2 及び 3 回来院を実施した。第 3 回来院から早期中止来院又は最終の規定来院までは 8 週間ごとに来院を実施した。また、第 4 回来院以降は各来院の間（4 週間目）に電話調査を実施した。 本治験の治験薬の開始用量は、SP0961 試験の維持期間終了時の用量とした。治療期間を通じて、被験者の忍容性及び発作コントロールが最適となるように、治験責任医師の判断により治験薬の用量調整（増減）を可能とした。最高用量は 800 mg/日とした。1 週間あたりに最大で 100 mg/日の増量を可能とし、500、600、700 及び 800 mg/日への増量は来院時（規定来院又は規定外来院）に実施した。また、700 及び 800 mg/日への増量では、増量した 1 週間後に規定外の電話調査を実施し、忍容性を確認した。 臨床的に重要な増悪、又はミオクロニー発作若しくは欠神発作が新たに発現した場合は、48 時間以内に来院し、減量又は治験中止を判断した。また、来院 1 週間後に電話調査を実施した。 治療期間を完了（最終の規定来院）又は早期中止（早期中止来院）した被験者は、治験終了期間に移行した。治験終了期間では、最終の規定来院時又は早期中止来院時に 200 mg/日超を投与された被験者は、毎週 200 mg/日ずつ減量することを推奨した。また、最終の規定来院時又は早期中止来院時に 200 mg/日以下を投与された被験者は、減量せずに治験薬の投与を終了した。いずれの被験者も、最終投与 2 週間後に治験終了来院を実施した。

表 2.3-1　試験方法の概略（続き）

項目	内容
併用薬及び併用療法	併用抗てんかん薬： 1～3 剤の抗てんかん薬の併用を可能とした。てんかんの治療を目的としたベンゾジアゼピン系薬剤は、併用抗てんかん薬 1 剤としてカウントした。 臨床的に適切と判断された場合は、治験責任医師がメディカルモニターと相談した上で併用抗てんかん薬を慎重に減量及び中止し、ラコサミドの単剤投与を可能とした。 抗てんかん薬の新規投与は、ラコサミドの最大耐用量で十分な効果が得られない場合のみ可能とした。 併用制限薬及び併用制限療法： ベンゾジアゼピン系薬剤：てんかん以外の治療を目的とし、用法・用量を変更せずに使用する場合は、併用を可能とした。なお、てんかん以外の治療を目的としても併用抗てんかん薬 1 剤としてカウントした。 緊急処置薬： ベンゾジアゼピン系薬剤の頓用使用は、てんかんに対する緊急処置を目的とし、1 週間に 1 回の頻度で使用する場合のみ可能とした。治験期間中のてんかん以外の治療を目的とした頓用使用は、不可とした。
被験者数	計画例数：45 例 登録例数：39 例、完了例数：29 例 安全性解析対象集団（SS）：39 例、最大の解析対象集団（FAS）：39 例 【被験者数設定の根拠】 本治験では統計的仮説に基づいた被験者数の算出は行わなかった。
対象	発作コントロールが得られていない強直間代発作を有するてんかん患者
主な選択/除外基準	選択基準： 1)　SP0961 試験を完了した被験者 2)　本治験に参加することが有益であると治験責任医師が判断した被検者 除外基準： 1)　SP0961 試験の中止基準に該当する、又は重篤な有害事象が継続中の被験者
治験薬、投与量及び投与方法	治験薬： ラコサミド 50 mg 錠：バッチ番号 BX1003849、BX1004480 ラコサミド 100 mg 錠：バッチ番号 BX1003901、BX1004482 投与量及び投与方法： 治験薬は、朝・夕 1 日 2 回経口投与した。 1)　治療期間 被験者の忍容性及び発作コントロールが最適となるように、治験責任医師の判断により治験薬の用量調整（増減）を可能とした。 治験薬の開始用量は、SP0961 試験の維持期間終了時の用量とし、1 日 2 回、約 12 時間ごとに同用量を経口投与した。本治験開始時に、治験責任医師の判断により用量

表 2.3-1　試験方法の概略（続き）

<table>
<tr><th colspan="2">項目</th><th>内容</th></tr>
<tr><td colspan="2">治験薬、投与量及び投与方法（続き）</td><td>の維持又は 100 mg/日の増減を決定した。最高用量は 800 mg/日とした。1 週間あたりに最大で 100 mg/日の増量を可能とし、500、600、700 及び 800 mg/日への増量は来院時（規定来院又は規定外来院）に実施した。800 mg/日への増量は、700 mg/日の投与を 1 週間以上継続した後に決定した。臨床的に重要な増悪、又はミオクロニー発作若しくは欠神発作が新たに発現した場合は、48 時間以内に来院し、減量又は治験中止を判断した。

2)　治験終了期間又は治験中止時
治験薬の推奨減量スケジュールを下表に示した。減量は、最終の規定来院時又は早期中止来院時に 200 mg/日超を投与された被験者のみ実施し､200 mg/日以下を投与された被験者は、減量せずに治験薬の投与を終了した。毎週 200 mg/日ずつ減量することを推奨したが、安全性上の懸念が認められた場合は、メディカルモニターに相談した上で、より速やかな減量を可能とした。また、医療上必要な場合は、より緩やかな減量を可能とした。

治験薬の推奨減量スケジュール
<table>
<tr><th>治療期間完了時
又は早期中止来院時
の用量</th><th>第 1 週</th><th>第 2 週</th><th>第 3 週</th></tr>
<tr><td>800 mg/日</td><td>600 mg/日</td><td>400 mg/日</td><td>200 mg/日</td></tr>
<tr><td>700 mg/日</td><td>500 mg/日</td><td>300 mg/日</td><td>100 mg/日</td></tr>
<tr><td>600 mg/日</td><td>400 mg/日</td><td>200 mg/日</td><td>—</td></tr>
<tr><td>500 mg/日</td><td>300 mg/日</td><td>100 mg/日</td><td>—</td></tr>
<tr><td>400 mg/日</td><td>200 mg/日</td><td>—</td><td>—</td></tr>
<tr><td>300 mg/日</td><td>100 mg/日</td><td>—</td><td>—</td></tr>
<tr><td>200 mg/日</td><td>—</td><td>—</td><td>—</td></tr>
<tr><td>100 mg/日</td><td>—</td><td>—</td><td>—</td></tr>
</table>
</td></tr>
<tr><td colspan="2">投与期間</td><td>最長投与期間 59 週間
· 治療期間 56 週間
· 治験終了期間 最長 3 週間</td></tr>
<tr><td>評価項目</td><td>安全性</td><td>主要評価項目
· 被験者及び／又は介護者の自発的報告又は治験責任医師の観察により報告された有害事象
· 有害事象による中止例
その他の評価項目
· 臨床検査値（血液学的検査、血液生化学検査、尿検査）の変化
· 12 誘導心電図の変化
· バイタルサイン（血圧及び脈拍数）、体重及び身体所見（神経学的検査を含む）の変化</td></tr>
</table>

表 2.3-1　試験方法の概略（続き）

項目		内容
評価項目（続き）	有効性関連	発作回数 特に記載のない限り、SP0961 試験のベースラインを本治験のベースラインとした。 · Prospective ベースライン期間に対する治療期間の 28 日あたりの欠神発作発現日数の変化量及び変化率 · Prospective ベースライン期間に対する治療期間の 28 日あたりのミオクロニー発作発現日数の変化量及び変化率 · Prospective ベースライン期間及び Combined ベースライン期間に対する治療期間の 28 日あたりの強直間代発作回数の変化率 · 治療期間における 6 及び 12 ヵ月間の強直間代発作の消失状態 探索的評価項目 · 第 5 回来院時及び最終の規定来院時の臨床全般評価の変化 · 第 5 回来院時及び最終の規定来院時の被験者による全般評価の変化
統計解析方法		解析対象集団の定義： SS：本治験に登録され、本治験の治験薬を 1 回以上投与された被験者 FAS：SS のうち、治療期間の発作日誌の評価が 1 回以上得られた被験者 安全性の解析は SS、有効性関連の解析は FAS を対象とした。 安全性： 治験薬投与開始後に認められた有害事象について発現例数及び発現率を求めた。 治験薬投与開始後に認められた有害事象は、本治験の治験薬初回投与日から最終投与 30 日後までに認められた事象、又は SP0961 試験実施時に発現し本治験の治験薬初回投与日から最終投与 30 日後までに悪化した事象と定義した。 臨床検査値、バイタルサイン及び体重について、測定値及び Prospective ベースライン期間からの変化量の記述統計量を来院時別に求めた。 12 誘導心電図の所見及び身体所見（神経学的検査を含む）について、各来院時の被験者数及び割合をカテゴリー別に集計した。 有効性関連： Prospective ベースライン期間及び治療期間の 28 日あたりの欠神発作及びミオクロニー発作発現日数、並びに Prospective ベースライン期間に対する変化量及び変化率の記述統計量を求めた。 Combined ベースライン期間及び Prospective ベースライン期間に対する治療期間の 28 日あたりの強直間代発作回数の変化率の記述統計量を求めた。 治療期間において強直間代発作の消失状態を 6 及び 12 ヵ月間達成した被験者数及び割合を求めた。 第 5 回来院時及び最終の規定来院時又は早期中止来院時の臨床全般評価の変化及び被験者による全般評価の変化をカテゴリー別に集計した。
治験責任医師		19 名
治験実施医療機関		19 医療機関（米国）
公表文献		なし
治験実施期間		2010 年 8 月 ■ 日～2012 年 10 月 ■ 日

2.3.1 被験者の内訳

本治験の SS での被験者の内訳及び中止理由を表 2.3-2 に示した。

本治験では 39 例が登録された。このうち、29 例（74.4%）が本治験を完了し、10 例（25.6%）が本治験を中止した。中止理由は、同意撤回（4 例、10.3%）、有害事象（2 例、5.1%）、その他（2 例、5.1%：妊娠及び服薬不遵守が各 1 例）、効果不十分及び治験実施計画書からの逸脱（各 1 例、2.6%）であった。

表 2.3-2　被験者の内訳及び中止理由：SS

Table 1.4.1
Disposition and Discontinuation Reasons
Population: Safety Set

Disposition	N = 39 n (%)
Completed Study	29 (74.4)
Discontinued	10 (25.6)
Reason for Discontinuation	
ADVERSE EVENT	2 (5.1)
LACK OF EFFICACY	1 (2.6)
PROTOCOL VIOLATION	1 (2.6)
LOST TO FOLLOW-UP	0
WITHDRAWAL BY SUBJECT	4 (10.3)
OTHER	2 (5.1)

Reference: Subject Data Listing 1.4.1

2.3.2 被験者背景

2.3.2.1 人口統計学的特性及び疾患特性

本治験の SS での人口統計学的特性及びベースラインの疾患特性を表 2.3-3 に示した。

表 2.3-3　人口統計学的特性及びベースラインの疾患特性：SS

Table 3.1.1
Demographics and Baseline Characteristics Summary
Population: Safety Set

Parameter	Statistic	N = 39
Age (years)	n	39
	Mean	30.3
	SD	10.7
	Median	28.0
	Min	17
	Max	55
Age category (years)		
<18	n (%)	3 (7.7)
18-<65	n (%)	36 (92.3)
>=65	n (%)	0
16-20	n (%)	6 (15.4)
>20-25	n (%)	12 (30.8)
>25-40	n (%)	15 (38.5)
>40	n (%)	6 (15.4)
Gender		
Male	n (%)	11 (28.2)
Female	n (%)	28 (71.8)
Race		
American Indian/Alaskan Native	n (%)	0
Asian	n (%)	0
Black	n (%)	6 (15.4)
Native Hawaiian/Other Pacific Islander	n (%)	0
White	n (%)	33 (84.6)
Other/Mixed	n (%)	0

[1] Subjects may be counted under more than one classification.
[2] The 2 subjects who responded No to Generalized Idiopathic also responded Unknown to Juvenile absence epilepsy.
Note: Demographics and Baseline Characteristics in this table are as reported at Visit 1 of study SP0961.
Reference: Subject Data Listings 2.1.1, 2.2.1, and 2.3.1

表 2.3-3　人口統計学的特性及びベースラインの疾患特性：SS（続き）

Table 3.1.1
Demographics and Baseline Characteristics Summary
Population: Safety Set

Parameter	Statistic	N = 39
Ethnicity		
Hispanic or Latino	n (%)	1 (2.6)
Not Hispanic or Latino	n (%)	38 (97.4)
Weight (kg)	n	39
	Mean	77.66
	SD	17.58
	Median	74.40
	Min	42.2
	Max	113.4
Height (cm)	n	39
	Mean	167.88
	SD	8.25
	Median	167.60
	Min	152.4
	Max	185.4
BMI (kg/m2)	n	39
	Mean	27.54
	SD	5.90
	Median	26.40
	Min	17.0
	Max	39.1

[1] Subjects may be counted under more than one classification.
[2] The 2 subjects who responded No to Generalized Idiopathic also responded Unknown to Juvenile absence epilepsy.
Note: Demographics and Baseline Characteristics in this table are as reported at Visit 1 of study SP0961.
Reference: Subject Data Listings 2.1.1, 2.2.1, and 2.3.1

表 2.3-3　人口統計学的特性及びベースラインの疾患特性：SS（続き）

Table 3.1.1
Demographics and Baseline Characteristics Summary
Population: Safety Set

Parameter	Statistic	N = 39
BMI Category		
<18.5	n (%)	1 (2.6)
18.5-<25	n (%)	16 (41.0)
25-<30	n (%)	7 (17.9)
>=30	n (%)	15 (38.5)
Missing	n (%)	0
Time Since Diagnosis (years)	n	39
	Mean	18.31
	SD	12.43
	Median	13.85
	Min	3.1
	Max	51.4
Age at Diagnosis of the Disease (years)	n	39
	Mean	12.0
	SD	7.5
	Median	12.0
	Min	0
	Max	43
Number of Concomitant AEDs at Baseline		
1	n (%)	13 (33.3)
2	n (%)	18 (46.2)
3	n (%)	8 (20.5)
Missing	n (%)	0

[1] Subjects may be counted under more than one classification.
[2] The 2 subjects who responded No to Generalized Idiopathic also responded Unknown to Juvenile absence epilepsy.
Note: Demographics and Baseline Characteristics in this table are as reported at Visit 1 of study SP0961.
Reference: Subject Data Listings 2.1.1, 2.2.1, and 2.3.1

表 2.3-3　人口統計学的特性及びベースラインの疾患特性：SS（続き）

Table 3.1.1

Demographics and Baseline Characteristics Summary

Population: Safety Set

Parameter	Statistic	N = 39
ILAE Seizure Classification History [1]		
Partial Onset Seizures	n (%)	0
Simple partial	n (%)	0
Complex partial	n (%)	0
Partial evolving to secondary generalized	n (%)	0
Generalized Seizures	n (%)	39 (100)
Absence	n (%)	26 (66.7)
Myoclonic	n (%)	21 (53.8)
Clonic	n (%)	0
Tonic	n (%)	1 (2.6)
Tonic-clonic	n (%)	39 (100)
Atonic	n (%)	0
Unclassified epileptic seizures	n (%)	0

[1] Subjects may be counted under more than one classification.

[2] The 2 subjects who responded No to Generalized Idiopathic also responded Unknown to Juvenile absence epilepsy.

Note: Demographics and Baseline Characteristics in this table are as reported at Visit 1 of study SP0961.

Reference: Subject Data Listings 2.1.1, 2.2.1, and 2.3.1

表 2.3-3　人口統計学的特性及びベースラインの疾患特性：SS（続き）

Table 3.1.1 Demographics and Baseline Characteristics Summary
Population: Safety Set

Parameter	Statistic	N = 39
ILAE Epilepsy Syndrome Classification		
Generalized Idiopathic [2]		
No	n (%)	2 (5.1)
Yes	n (%)	37 (94.9)
Childhood absence epilepsy		
Yes	n (%)	3 (7.7)
No	n (%)	28 (71.8)
Unknown	n (%)	6 (15.4)
Epilepsy with grand mal seizures on awakening		
Yes	n (%)	0
No	n (%)	30 (76.9)
Unknown	n (%)	7 (17.9)
Epilepsies with seizures precipitated by specific modes of activation		
Yes	n (%)	0
No	n (%)	29 (74.4)
Unknown	n (%)	8 (20.5)
Juvenile absence epilepsy		
Yes	n (%)	2 (5.1)
No	n (%)	30 (76.9)
Unknown	n (%)	7 (17.9)
Juvenile myoclonic epilepsy		
Yes	n (%)	14 (35.9)
No	n (%)	18 (46.2)
Unknown	n (%)	5 (12.8)
Other generalized idiopathic epilepsies not defined above		
Yes	n (%)	17 (43.6)
No	n (%)	13 (33.3)
Unknown	n (%)	7 (17.9)

[1] Subjects may be counted under more than one classification.
[2] The 2 subjects who responded No to Generalized Idiopathic also responded Unknown to Juvenile absence epilepsy.
Note: Demographics and Baseline Characteristics in this table are as reported at Visit 1 of study SP0961.
Reference: Subject Data Listings 2.1.1, 2.2.1, and 2.3.1

2.3.2.2 抗てんかん薬

本治験の SS での治療期間中に併用していた抗てんかん薬を表 2.3-4 に示した。

表 2.3-4　治療期間中の併用抗てんかん薬：SS

Table 5.2.1
Concomitant AED Use Summary
Population: Safety Set

WHO-DRL (Version: Q2/2004) ATC class level 4 Generic Name	N = 39 n (%)
Number of subjects with at least one medication	39 (100)
ANTIEPILEPTICS	11 (28.2)
VIMPAT [1]	11 (28.2)
BENZODIAZEPINE DERIVATIVES	10 (25.6)
CLONAZEPAM	5 (12.8)
LORAZEPAM	4 (10.3)
DIAZEPAM	3 (7.7)
MIDAZOLAM	1 (2.6)
CARBOXAMIDE DERIVATIVES	1 (2.6)
RUFINAMIDE	1 (2.6)
FATTY ACID DERIVATIVES	12 (30.8)
VALPROATE	12 (30.8)
HYDANTOIN DERIVATIVES	4 (10.3)
PHENYTOIN	4 (10.3)

Note: Subjects reporting the same class more than once are counted once per class but may be counted under more than one generic name.
Note: Phenobarbital use includes: phenobarbital, phenobarbital sodium, methylphenobarbital, and primidone. Phenytoin use includes phenytoin, phenytoin sodium, ethotoin, fosphenytoin, fosphenytoin sodium, and zentronal. Valproate use includes valproic acid, valproate semisodium, valproate sodium, ergenyl chrono, and valpromide.
Note: [1] The investigator text of 'VIMPAT' is displayed instead of the WHO Preferred Term of 'ANTIEPILEPTICS'.
Reference: Subject Data Listings 2.6.1 and 2.6.2

表 2.3-4　治療期間中の併用抗てんかん薬：SS（続き）

Table 5.2.1
Concomitant AED Use Summary
Population: Safety Set

WHO-DRL (Version: Q2/2004) ATC class level 4 Generic Name	N = 39 n (%)
OTHER ANTIEPILEPTICS	33 (84.6)
LAMOTRIGINE	19 (48.7)
LEVETIRACETAM	17 (43.6)
TOPIRAMATE	9 (23.1)
ZONISAMIDE	9 (23.1)
SUCCINIMIDE DERIVATIVES	1 (2.6)
ETHOSUXIMIDE	1 (2.6)

Note: Subjects reporting the same class more than once are counted once per class but may be counted under more than one generic name.
Note: Phenobarbital use includes: phenobarbital, phenobarbital sodium, methylphenobarbital, and primidone. Phenytoin use includes phenytoin, phenytoin sodium, ethotoin, fosphenytoin, fosphenytoin sodium, and zentronal. Valproate use includes valproic acid, valproate semisodium, valproate sodium, ergenyl chrono, and valpromide.
Note: [1] The investigator text of 'VIMPAT' is displayed instead of the WHO Preferred Term of 'ANTIEPILEPTICS'.
Reference: Subject Data Listings 2.6.1 and 2.6.2

2.3.3 安全性

2.3.3.1 曝露状況

本治験での治験薬の曝露期間、最高投与量及び最頻投与量を表 2.3-5 に示した。また、治験薬の曝露期間別の曝露状況を表 2.3-6 に、最頻投与量別の曝露状況を表 2.3-7 に示した。

本治験に登録された 39 例のうち、ほとんどの被験者（82.1%）が 12 ヵ月を超えて治験薬を投与された。

治験薬の最高投与量の平均値は 464.1 mg/日で、最頻投与量の平均値は 428.2 mg/日であった。最頻投与量別の被験者の割合は、400 mg/日以上 500 mg/日未満（38.5%）が最も高く、400 mg/日未満と 500 mg/日以上は同程度であった（それぞれ 28.2%及び 33.3%）。800 mg/日超を投与された被験者はいなかった。これらの結果は、強直間代発作を有するてんかん患者に対して推奨されるラコサミドの目標用量が 400 mg/日であることを支持するものであった。

表 2.3-5　治験薬の曝露期間、最高投与量及び最頻投与量：SS

Table 9.2.1

Duration of exposure, Maximum Daily Dose, and Modal Dose

Population: Safety Set

	LCM Exposure N = 39					
Parameter	n	Mean	SD	Median	Min	Max
Duration of exposure (days)	38	367.0	91.0	399.0	67	429
Maximum daily dose (mg/day)	39	464.1	144.2	400.0	300	800
Modal dose (mg/day)	39	428.2	135.6	400.0	200	800

Note: Duration of exposure (days) is calculated as the date of last dose of LCM minus the date of the first dose of LCM plus one day. The date of last dose of LCM is missing for subject [redacted] and so their duration of exposure is unknown.

Reference: Subject Data Listing 4.2.1

表 2.3-6　治験薬の曝露期間別の曝露状況：SS

Table 9.1.1
Overall Exposure Summary
Population: Safety Set

LCM Exposure	Number of Subjects N = 39 n (%)	Subject-Years Exposed Total
>0 Months	38 (97.4)	38.2
>3 Months	37 (94.9)	38.0
>6 Months	35 (89.7)	37.2
>9 Months	33 (84.6)	36.2
>12 Months	32 (82.1)	35.3

Note: Duration of exposure (days) is calculated as the date of last dose of LCM minus the date of the first dose of LCM plus one day.
Note: Subject-years of exposure is defined as the total LCM exposure in days divided by 365.25.
Note: The date of last dose of LCM is missing for subject [redacted] and so their duration of exposure is unknown.
Reference: Subject Data Listing 4.2.1

表 2.3-7　治験薬の最頻投与量別の曝露状況：SS

Table 9.1.2
Overall Exposure Summary by Modal Dose
Population: Safety Set

		LCM Modal Dose (mg/day) N = 39						
Parameter	Statistic	0 to <100	100 to <200	200 to <300	300 to <400	400 to <500	500 to 600	>600
Number of Subjects	n (%)	0	0	2 (5.1)	9 (23.1)	15 (38.5)	10 (25.6)	3 (7.7)
Subject-years exposed	Total	0.0	0.0	2.2	8.2	14.0	10.3	3.5

Note: Subject-years of exposure is defined as the total LCM exposure in days divided by 365.25.
Reference: Subject Data Listing 4.2.1

2.3.3.2 主要評価項目

2.3.3.2.1 有害事象

本治験では MedDRA version 9.1 を用いて有害事象を集計した。

治験薬との因果関係は、治験責任医師が「関連なし（Not related）」、「おそらく関連なし（Unlikely related）」、「どちらともいえない（Possibly related）」、「関連あり（Related）」の 4 段階で評価した。このうち、「どちらともいえない」、「関連あり」の有害事象を「治験薬との因果関係が否定できない有害事象」として取り扱った。

2.3.3.2.1.1 有害事象発現例数の概要

本治験の治験薬投与開始後に認められた有害事象発現例数の概要を表 2.3-8 に示した。

表 2.3-8　有害事象発現例数の概要：SS

Table 10.1.1
Incidence of Treatment-Emergent Adverse Events (TEAEs) - Overview
Population: Safety Set

Category	N = 39 n (%) [#]
Any TEAEs	37 (94.9) [263]
Serious TEAEs	3 (7.7) [4]
TEAEs leading to discontinuation	2 (5.1) [2]
Drug-related TEAEs	17 (43.6) [64]
Severe TEAEs	9 (23.1) [17]
Other Significant TEAEs	0
TEAEs with fatal outcome	0
TEAEs requiring dose change	4 (10.3) [9]

Note: n=number of subjects reporting at least one TEAE in a category.(%)=percentage of subjects among total N. #=number of individual TEAE occurrences.
Note: Drug-related TEAEs are those with relationship other than not related and unlikely (including missing relationship information).
Reference: Subject Data Listing 5.1.1

2.3.3.2.1.2 有害事象の発現状況

本治験の治験薬投与開始後に認められた重症度別の有害事象を表 2.3-9 に示した。

本治験では、多くの有害事象の重症度は軽度又は中等度であった。ほとんどの有害事象は、神経系障害（53.8%）、感染症および寄生虫症（53.8%）、胃腸障害（35.9%）及び傷害、中毒および処置合併症（35.9%）の SOC で認められた。

表 2.3-9　重症度別の有害事象：SS

Table 10.6.1
Incidence of TEAEs by Maximum Intensity
Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Intensity	N = 39 n (%) [#]
Any System Organ Class	Any	37 (94.9) [263]
	Mild	12 (30.8) [49]
	Moderate	16 (41.0) [34]
	Severe	9 (23.1) [17]
心臓障害	Any	2 (5.1) [2]
	Mild	0
	Moderate	2 (5.1) [2]
	Severe	0
動悸	Any	2 (5.1) [2]
	Mild	0
	Moderate	2 (5.1) [2]
	Severe	0
耳および迷路障害	Any	2 (5.1) [2]
	Mild	2 (5.1) [2]
	Moderate	0
	Severe	0

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term. (%)=percentage of subjects among total N. [#] is the number of individual occurrences of the TEAE.
Note: Each subject is counted once within each System Organ Class and Preferred Term according to the maximum intensity for all TEAEs within that System Organ Class or Preferred Term.
Reference: Subject Data Listings 5.1.1 and 5.1.2

表 2.3-9　重症度別の有害事象：SS（続き）

Table 10.6.1
Incidence of TEAEs by Maximum Intensity
Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Intensity	N = 39 n (%) [#]
耳痛	Any	1 (2.6) [1]
	Mild	1 (2.6) [1]
	Moderate	0
	Severe	0
回転性めまい	Any	1 (2.6) [1]
	Mild	1 (2.6) [1]
	Moderate	0
	Severe	0
内分泌障害	Any	1 (2.6) [1]
	Mild	1 (2.6) [1]
	Moderate	0
	Severe	0
甲状腺機能低下症	Any	1 (2.6) [1]
	Mild	1 (2.6) [1]
	Moderate	0
	Severe	0

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term. (%)=percentage of subjects among total N. [#] is the number of individual occurrences of the TEAE.
Note: Each subject is counted once within each System Organ Class and Preferred Term according to the maximum intensity for all TEAEs within that System Organ Class or Preferred Term.
Reference: Subject Data Listings 5.1.1 and 5.1.2

表 2.3-9　重症度別の有害事象：SS（続き）

Table 10.6.1
Incidence of TEAEs by Maximum Intensity
Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Intensity	N = 39 n (%) [#]
眼障害	Any	5 (12.8) [6]
	Mild	4 (10.3) [4]
	Moderate	1 (2.6) [2]
	Severe	0
複視	Any	3 (7.7) [4]
	Mild	2 (5.1) [2]
	Moderate	1 (2.6) [2]
	Severe	0
結膜出血	Any	1 (2.6) [1]
	Mild	1 (2.6) [1]
	Moderate	0
	Severe	0
結膜炎	Any	1 (2.6) [1]
	Mild	1 (2.6) [1]
	Moderate	0
	Severe	0

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term. (%)=percentage of subjects among total N. [#] is the number of individual occurrences of the TEAE.
Note: Each subject is counted once within each System Organ Class and Preferred Term according to the maximum intensity for all TEAEs within that System Organ Class or Preferred Term.
Reference: Subject Data Listings 5.1.1 and 5.1.2

表 2.3-9　重症度別の有害事象：SS（続き）

Table 10.6.1
Incidence of TEAEs by Maximum Intensity
Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Intensity	N = 39 n (%) [#]
胃腸障害	Any	14 (35.9) [23]
	Mild	7 (17.9) [11]
	Moderate	5 (12.8) [7]
	Severe	2 (5.1) [2]
悪心	Any	5 (12.8) [5]
	Mild	1 (2.6) [1]
	Moderate	3 (7.7) [3]
	Severe	1 (2.6) [1]
下痢	Any	2 (5.1) [2]
	Mild	1 (2.6) [1]
	Moderate	1 (2.6) [1]
	Severe	0
腹部ヘルニア	Any	1 (2.6) [1]
	Mild	1 (2.6) [1]
	Moderate	0
	Severe	0

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term. (%)=percentage of subjects among total N. [#] is the number of individual occurrences of the TEAE.
Note: Each subject is counted once within each System Organ Class and Preferred Term according to the maximum intensity for all TEAEs within that System Organ Class or Preferred Term.
Reference: Subject Data Listings 5.1.1 and 5.1.2

表 2.3-9　重症度別の有害事象：SS（続き）

Table 10.6.1
Incidence of TEAEs by Maximum Intensity
Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Intensity	N = 39 n (%) [#]
腹痛	Any	1 (2.6) [1]
	Mild	0
	Moderate	0
	Severe	1 (2.6) [1]
下腹部痛	Any	1 (2.6) [1]
	Mild	0
	Moderate	1 (2.6) [1]
	Severe	0
上腹部痛	Any	1 (2.6) [1]
	Mild	0
	Moderate	1 (2.6) [1]
	Severe	0
便秘	Any	1 (2.6) [1]
	Mild	1 (2.6) [1]
	Moderate	0
	Severe	0

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term. (%)=percentage of subjects among total N. [#] is the number of individual occurrences of the TEAE.
Note: Each subject is counted once within each System Organ Class and Preferred Term according to the maximum intensity for all TEAEs within that System Organ Class or Preferred Term.
Reference: Subject Data Listings 5.1.1 and 5.1.2

表 2.3-9　重症度別の有害事象：SS（続き）

Table 10.6.1
Incidence of TEAEs by Maximum Intensity
Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Intensity	N = 39 n (%) [#]
消化不良	Any	1 (2.6) [1]
	Mild	0
	Moderate	1 (2.6) [1]
	Severe	0
胃食道逆流性疾患	Any	1 (2.6) [1]
	Mild	0
	Moderate	1 (2.6) [1]
	Severe	0
口の感覚鈍麻	Any	1 (2.6) [1]
	Mild	1 (2.6) [1]
	Moderate	0
	Severe	0
口唇腫脹	Any	1 (2.6) [1]
	Mild	1 (2.6) [1]
	Moderate	0
	Severe	0

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term. (%)=percentage of subjects among total N. [#] is the number of individual occurrences of the TEAE.
Note: Each subject is counted once within each System Organ Class and Preferred Term according to the maximum intensity for all TEAEs within that System Organ Class or Preferred Term.
Reference: Subject Data Listings 5.1.1 and 5.1.2

表 2.3-9　重症度別の有害事象：SS（続き）

Table 10.6.1
Incidence of TEAEs by Maximum Intensity
Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Intensity	N = 39 n (%) [#]
口腔内痛	Any	1 (2.6) [3]
	Mild	1 (2.6) [3]
	Moderate	0
	Severe	0
口の錯感覚	Any	1 (2.6) [2]
	Mild	1 (2.6) [2]
	Moderate	0
	Severe	0
胃不快感	Any	1 (2.6) [1]
	Mild	0
	Moderate	1 (2.6) [1]
	Severe	0
嘔吐	Any	1 (2.6) [1]
	Mild	1 (2.6) [1]
	Moderate	0
	Severe	0

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term. (%)=percentage of subjects among total N. [#] is the number of individual occurrences of the TEAE.
Note: Each subject is counted once within each System Organ Class and Preferred Term according to the maximum intensity for all TEAEs within that System Organ Class or Preferred Term.
Reference: Subject Data Listings 5.1.1 and 5.1.2

表 2.3-9　重症度別の有害事象：SS（続き）

Table 10.6.1
Incidence of TEAEs by Maximum Intensity
Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Intensity	N = 39 n (%) [#]
全身障害および投与局所様態	Any	11 (28.2) [13]
	Mild	7 (17.9) [7]
	Moderate	4 (10.3) [5]
	Severe	0
疲労	Any	3 (7.7) [4]
	Mild	1 (2.6) [1]
	Moderate	2 (5.1) [2]
	Severe	0
歩行障害	Any	2 (5.1) [2]
	Mild	2 (5.1) [2]
	Moderate	0
	Severe	0
無力症	Any	1 (2.6) [1]
	Mild	1 (2.6) [1]
	Moderate	0
	Severe	0

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term. (%)=percentage of subjects among total N. [#] is the number of individual occurrences of the TEAE.
Note: Each subject is counted once within each System Organ Class and Preferred Term according to the maximum intensity for all TEAEs within that System Organ Class or Preferred Term.
Reference: Subject Data Listings 5.1.1 and 5.1.2

表 2.3-9　重症度別の有害事象：SS（続き）

Table 10.6.1
Incidence of TEAEs by Maximum Intensity
Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Intensity	N = 39 n (%) [#]
胸部不快感	Any	1 (2.6) [1]
	Mild	1 (2.6) [1]
	Moderate	0
	Severe	0
顔面痛	Any	1 (2.6) [1]
	Mild	1 (2.6) [1]
	Moderate	0
	Severe	0
異常感	Any	1 (2.6) [1]
	Mild	0
	Moderate	1 (2.6) [1]
	Severe	0
易刺激性	Any	1 (2.6) [1]
	Mild	1 (2.6) [1]
	Moderate	0
	Severe	0

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term. (%)=percentage of subjects among total N. [#] is the number of individual occurrences of the TEAE.
Note: Each subject is counted once within each System Organ Class and Preferred Term according to the maximum intensity for all TEAEs within that System Organ Class or Preferred Term.
Reference: Subject Data Listings 5.1.1 and 5.1.2

表 2.3-9　重症度別の有害事象：SS（続き）

Table 10.6.1
Incidence of TEAEs by Maximum Intensity
Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Intensity	N = 39 n (%) [#]
非心臓性胸痛	Any	1 (2.6) [1]
	Mild	0
	Moderate	1 (2.6) [1]
	Severe	0
疼痛	Any	1 (2.6) [1]
	Mild	0
	Moderate	1 (2.6) [1]
	Severe	0
肝胆道系障害	Any	1 (2.6) [1]
	Mild	1 (2.6) [1]
	Moderate	0
	Severe	0
胆石症	Any	1 (2.6) [1]
	Mild	1 (2.6) [1]
	Moderate	0
	Severe	0

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term. (%)=percentage of subjects among total N. [#] is the number of individual occurrences of the TEAE.
Note: Each subject is counted once within each System Organ Class and Preferred Term according to the maximum intensity for all TEAEs within that System Organ Class or Preferred Term.
Reference: Subject Data Listings 5.1.1 and 5.1.2

表 2.3-9　重症度別の有害事象：SS（続き）

Table 10.6.1
Incidence of TEAEs by Maximum Intensity
Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Intensity	N = 39 n (%) [#]
免疫系障害	Any	3 (7.7) [3]
	Mild	3 (7.7) [3]
	Moderate	0
	Severe	0
季節性アレルギー	Any	3 (7.7) [3]
	Mild	3 (7.7) [3]
	Moderate	0
	Severe	0
感染症および寄生虫症	Any	21 (53.8) [40]
	Mild	10 (25.6) [17]
	Moderate	9 (23.1) [17]
	Severe	2 (5.1) [2]
上気道感染	Any	10 (25.6) [13]
	Mild	8 (20.5) [9]
	Moderate	2 (5.1) [4]
	Severe	0

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term. (%)=percentage of subjects among total N. [#] is the number of individual occurrences of the TEAE.
Note: Each subject is counted once within each System Organ Class and Preferred Term according to the maximum intensity for all TEAEs within that System Organ Class or Preferred Term.
Reference: Subject Data Listings 5.1.1 and 5.1.2

表 2.3-9　重症度別の有害事象：SS（続き）

Table 10.6.1
Incidence of TEAEs by Maximum Intensity
Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Intensity	N = 39 n (%) [#]
副鼻腔炎	Any	3 (7.7) [3]
	Mild	1 (2.6) [1]
	Moderate	2 (5.1) [2]
	Severe	0
ウイルス性胃腸炎	Any	2 (5.1) [3]
	Mild	1 (2.6) [1]
	Moderate	1 (2.6) [1]
	Severe	0
インフルエンザ	Any	2 (5.1) [2]
	Mild	1 (2.6) [1]
	Moderate	1 (2.6) [1]
	Severe	0
肺炎	Any	2 (5.1) [2]
	Mild	0
	Moderate	1 (2.6) [1]
	Severe	1 (2.6) [1]

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term. (%)=percentage of subjects among total N. [#] is the number of individual occurrences of the TEAE.
Note: Each subject is counted once within each System Organ Class and Preferred Term according to the maximum intensity for all TEAEs within that System Organ Class or Preferred Term.
Reference: Subject Data Listings 5.1.1 and 5.1.2

表 2.3-9　重症度別の有害事象：SS（続き）

Table 10.6.1
Incidence of TEAEs by Maximum Intensity
Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Intensity	N = 39 n (%) [#]
歯膿瘍	Any	2 (5.1) [2]
	Mild	1 (2.6) [1]
	Moderate	1 (2.6) [1]
	Severe	0
気管支炎	Any	1 (2.6) [1]
	Mild	0
	Moderate	1 (2.6) [1]
	Severe	0
膀胱炎	Any	1 (2.6) [1]
	Mild	0
	Moderate	1 (2.6) [1]
	Severe	0
耳感染	Any	1 (2.6) [1]
	Mild	1 (2.6) [1]
	Moderate	0
	Severe	0

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term. (%)=percentage of subjects among total N. [#] is the number of individual occurrences of the TEAE.
Note: Each subject is counted once within each System Organ Class and Preferred Term according to the maximum intensity for all TEAEs within that System Organ Class or Preferred Term.
Reference: Subject Data Listings 5.1.1 and 5.1.2

表 2.3-9　重症度別の有害事象：SS（続き）

Table 10.6.1
Incidence of TEAEs by Maximum Intensity
Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Intensity	N = 39 n (%) [#]
真菌感染	Any	1 (2.6) [1]
	Mild	0
	Moderate	1 (2.6) [1]
	Severe	0
胃腸炎	Any	1 (2.6) [1]
	Mild	0
	Moderate	1 (2.6) [1]
	Severe	0
A型肝炎	Any	1 (2.6) [1]
	Mild	1 (2.6) [1]
	Moderate	0
	Severe	0
単純ヘルペス	Any	1 (2.6) [1]
	Mild	0
	Moderate	1 (2.6) [1]
	Severe	0

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term. (%)=percentage of subjects among total N. [#] is the number of individual occurrences of the TEAE.
Note: Each subject is counted once within each System Organ Class and Preferred Term according to the maximum intensity for all TEAEs within that System Organ Class or Preferred Term.
Reference: Subject Data Listings 5.1.1 and 5.1.2

表 2.3-9　重症度別の有害事象：SS（続き）

Table 10.6.1
Incidence of TEAEs by Maximum Intensity
Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Intensity	N = 39 n (%) [#]
鼻咽頭炎	Any	1 (2.6) [2]
	Mild	1 (2.6) [2]
	Moderate	0
	Severe	0
中耳炎	Any	1 (2.6) [1]
	Mild	0
	Moderate	0
	Severe	1 (2.6) [1]
ブドウ球菌感染	Any	1 (2.6) [1]
	Mild	1 (2.6) [1]
	Moderate	0
	Severe	0
レンサ球菌感染	Any	1 (2.6) [1]
	Mild	1 (2.6) [1]
	Moderate	0
	Severe	0

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term. (%)=percentage of subjects among total N. [#] is the number of individual occurrences of the TEAE.
Note: Each subject is counted once within each System Organ Class and Preferred Term according to the maximum intensity for all TEAEs within that System Organ Class or Preferred Term.
Reference: Subject Data Listings 5.1.1 and 5.1.2

表 2.3-9　重症度別の有害事象：SS（続き）

Table 10.6.1
Incidence of TEAEs by Maximum Intensity
Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Intensity	N = 39 n (%) [#]
白癬感染	Any	1 (2.6) [1]
	Mild	1 (2.6) [1]
	Moderate	0
	Severe	0
歯感染	Any	1 (2.6) [1]
	Mild	0
	Moderate	1 (2.6) [1]
	Severe	0
尿路感染	Any	1 (2.6) [1]
	Mild	0
	Moderate	1 (2.6) [1]
	Severe	0
傷害、中毒および処置合併症	Any	14 (35.9) [24]
	Mild	8 (20.5) [15]
	Moderate	6 (15.4) [7]
	Severe	0

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term. (%)=percentage of subjects among total N. [#] is the number of individual occurrences of the TEAE.
Note: Each subject is counted once within each System Organ Class and Preferred Term according to the maximum intensity for all TEAEs within that System Organ Class or Preferred Term.
Reference: Subject Data Listings 5.1.1 and 5.1.2

表 2.3-9　重症度別の有害事象：SS（続き）

Table 10.6.1
Incidence of TEAEs by Maximum Intensity
Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Intensity	N = 39 n (%) [#]
転倒	Any	4 (10.3) [4]
	Mild	3 (7.7) [3]
	Moderate	1 (2.6) [1]
	Severe	0
関節捻挫	Any	4 (10.3) [5]
	Mild	2 (5.1) [3]
	Moderate	2 (5.1) [2]
	Severe	0
挫傷	Any	3 (7.7) [3]
	Mild	2 (5.1) [2]
	Moderate	1 (2.6) [1]
	Severe	0
擦過傷	Any	2 (5.1) [2]
	Mild	2 (5.1) [2]
	Moderate	0
	Severe	0

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term. (%)=percentage of subjects among total N. [#] is the number of individual occurrences of the TEAE.
Note: Each subject is counted once within each System Organ Class and Preferred Term according to the maximum intensity for all TEAEs within that System Organ Class or Preferred Term.
Reference: Subject Data Listings 5.1.1 and 5.1.2

表 2.3-9　重症度別の有害事象：SS（続き）

Table 10.6.1
Incidence of TEAEs by Maximum Intensity
Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Intensity	N = 39 n (%) [#]
筋挫傷	Any	2 (5.1) [2]
	Mild	2 (5.1) [2]
	Moderate	0
	Severe	0
皮膚裂傷	Any	2 (5.1) [2]
	Mild	0
	Moderate	2 (5.1) [2]
	Severe	0
節足動物刺傷	Any	1 (2.6) [1]
	Mild	1 (2.6) [1]
	Moderate	0
	Severe	0
顔面損傷	Any	1 (2.6) [1]
	Mild	1 (2.6) [1]
	Moderate	0
	Severe	0

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term. (%)=percentage of subjects among total N. [#] is the number of individual occurrences of the TEAE.
Note: Each subject is counted once within each System Organ Class and Preferred Term according to the maximum intensity for all TEAEs within that System Organ Class or Preferred Term.
Reference: Subject Data Listings 5.1.1 and 5.1.2

表 2.3-9　重症度別の有害事象：SS（続き）

Table 10.6.1
Incidence of TEAEs by Maximum Intensity
Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Intensity	N = 39 n (%) [#]
足骨折	Any	1 (2.6) [1]
	Mild	0
	Moderate	1 (2.6) [1]
	Severe	0
四肢損傷	Any	1 (2.6) [1]
	Mild	1 (2.6) [1]
	Moderate	0
	Severe	0
骨格損傷	Any	1 (2.6) [1]
	Mild	1 (2.6) [1]
	Moderate	0
	Severe	0
熱傷	Any	1 (2.6) [1]
	Mild	1 (2.6) [1]
	Moderate	0
	Severe	0

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term. (%)=percentage of subjects among total N. [#] is the number of individual occurrences of the TEAE.
Note: Each subject is counted once within each System Organ Class and Preferred Term according to the maximum intensity for all TEAEs within that System Organ Class or Preferred Term.
Reference: Subject Data Listings 5.1.1 and 5.1.2

表 2.3-9　重症度別の有害事象：SS（続き）

Table 10.6.1
Incidence of TEAEs by Maximum Intensity
Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Intensity	N = 39 n (%) [#]
臨床検査	Any	12 (30.8) [21]
	Mild	10 (25.6) [17]
	Moderate	1 (2.6) [1]
	Severe	1 (2.6) [1]
体重増加	Any	4 (10.3) [4]
	Mild	4 (10.3) [4]
	Moderate	0
	Severe	0
アラニン・アミノトランスフェラーゼ増加	Any	2 (5.1) [2]
	Mild	2 (5.1) [2]
	Moderate	0
	Severe	0
動脈雑音	Any	2 (5.1) [2]
	Mild	2 (5.1) [2]
	Moderate	0
	Severe	0

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term. (%)=percentage of subjects among total N. [#] is the number of individual occurrences of the TEAE.
Note: Each subject is counted once within each System Organ Class and Preferred Term according to the maximum intensity for all TEAEs within that System Organ Class or Preferred Term.
Reference: Subject Data Listings 5.1.1 and 5.1.2

表 2.3-9　重症度別の有害事象：SS（続き）

Table 10.6.1
Incidence of TEAEs by Maximum Intensity
Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Intensity	N = 39 n (%) [#]
アスパラギン酸アミノトランスフェラーゼ増加	Any	2 (5.1) [2]
	Mild	2 (5.1) [2]
	Moderate	0
	Severe	0
γ－グルタミルトランスフェラーゼ増加	Any	2 (5.1) [2]
	Mild	2 (5.1) [2]
	Moderate	0
	Severe	0
血中アルカリホスファターゼ増加	Any	1 (2.6) [1]
	Mild	1 (2.6) [1]
	Moderate	0
	Severe	0
血中カルシウム減少	Any	1 (2.6) [1]
	Mild	1 (2.6) [1]
	Moderate	0
	Severe	0

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term. (%)=percentage of subjects among total N. [#] is the number of individual occurrences of the TEAE.
Note: Each subject is counted once within each System Organ Class and Preferred Term according to the maximum intensity for all TEAEs within that System Organ Class or Preferred Term.
Reference: Subject Data Listings 5.1.1 and 5.1.2

表 2.3-9　重症度別の有害事象：SS（続き）

Table 10.6.1
Incidence of TEAEs by Maximum Intensity
Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Intensity	N = 39 n (%) [#]
好酸球数異常	Any	1 (2.6) [2]
	Mild	1 (2.6) [2]
	Moderate	0
	Severe	0
胃内ｐＨ低下	Any	1 (2.6) [1]
	Mild	0
	Moderate	1 (2.6) [1]
	Severe	0
ＩＮＲ増加	Any	1 (2.6) [1]
	Mild	0
	Moderate	0
	Severe	1 (2.6) [1]
尿中赤血球	Any	1 (2.6) [1]
	Mild	1 (2.6) [1]
	Moderate	0
	Severe	0

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term. (%)=percentage of subjects among total N. [#] is the number of individual occurrences of the TEAE.
Note: Each subject is counted once within each System Organ Class and Preferred Term according to the maximum intensity for all TEAEs within that System Organ Class or Preferred Term.
Reference: Subject Data Listings 5.1.1 and 5.1.2

表 2.3-9　重症度別の有害事象：SS（続き）

Table 10.6.1
Incidence of TEAEs by Maximum Intensity
Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Intensity	N = 39 n (%) [#]
尿中赤血球陽性	Any	1 (2.6) [1]
	Mild	1 (2.6) [1]
	Moderate	0
	Severe	0
尿円柱	Any	1 (2.6) [1]
	Mild	1 (2.6) [1]
	Moderate	0
	Severe	0
代謝および栄養障害	Any	3 (7.7) [3]
	Mild	3 (7.7) [3]
	Moderate	0
	Severe	0
食欲亢進	Any	2 (5.1) [2]
	Mild	2 (5.1) [2]
	Moderate	0
	Severe	0

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term. (%)=percentage of subjects among total N. [#] is the number of individual occurrences of the TEAE.
Note: Each subject is counted once within each System Organ Class and Preferred Term according to the maximum intensity for all TEAEs within that System Organ Class or Preferred Term.
Reference: Subject Data Listings 5.1.1 and 5.1.2

表 2.3-9　重症度別の有害事象：SS（続き）

Table 10.6.1
Incidence of TEAEs by Maximum Intensity
Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Intensity	N = 39 n (%) [#]
食欲障害	Any	1 (2.6) [1]
	Mild	1 (2.6) [1]
	Moderate	0
	Severe	0
筋骨格系および結合組織障害	Any	10 (25.6) [16]
	Mild	4 (10.3) [4]
	Moderate	6 (15.4) [10]
	Severe	0
筋骨格痛	Any	3 (7.7) [3]
	Mild	0
	Moderate	3 (7.7) [3]
	Severe	0
関節痛	Any	2 (5.1) [4]
	Mild	1 (2.6) [1]
	Moderate	1 (2.6) [2]
	Severe	0

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term. (%)=percentage of subjects among total N. [#] is the number of individual occurrences of the TEAE.
Note: Each subject is counted once within each System Organ Class and Preferred Term according to the maximum intensity for all TEAEs within that System Organ Class or Preferred Term.
Reference: Subject Data Listings 5.1.1 and 5.1.2

表 2.3-9　重症度別の有害事象：SS（続き）

Table 10.6.1
Incidence of TEAEs by Maximum Intensity
Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Intensity	N = 39 n (%) [#]
背部痛	Any	1 (2.6) [1]
	Mild	0
	Moderate	1 (2.6) [1]
	Severe	0
肋軟骨炎	Any	1 (2.6) [1]
	Mild	1 (2.6) [1]
	Moderate	0
	Severe	0
側腹部痛	Any	1 (2.6) [1]
	Mild	0
	Moderate	1 (2.6) [1]
	Severe	0
関節硬直	Any	1 (2.6) [1]
	Mild	0
	Moderate	1 (2.6) [1]
	Severe	0

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term. (%)=percentage of subjects among total N. [#] is the number of individual occurrences of the TEAE.
Note: Each subject is counted once within each System Organ Class and Preferred Term according to the maximum intensity for all TEAEs within that System Organ Class or Preferred Term.
Reference: Subject Data Listings 5.1.1 and 5.1.2

表 2.3-9　重症度別の有害事象：SS（続き）

Table 10.6.1
Incidence of TEAEs by Maximum Intensity
Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Intensity	N = 39 n (%) [#]
筋痙縮	Any	1 (2.6) [1]
	Mild	0
	Moderate	1 (2.6) [1]
	Severe	0
骨関節炎	Any	1 (2.6) [1]
	Mild	1 (2.6) [1]
	Moderate	0
	Severe	0
四肢痛	Any	1 (2.6) [1]
	Mild	1 (2.6) [1]
	Moderate	0
	Severe	0
顎痛	Any	1 (2.6) [1]
	Mild	0
	Moderate	1 (2.6) [1]
	Severe	0

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term. (%)=percentage of subjects among total N. [#] is the number of individual occurrences of the TEAE.
Note: Each subject is counted once within each System Organ Class and Preferred Term according to the maximum intensity for all TEAEs within that System Organ Class or Preferred Term.
Reference: Subject Data Listings 5.1.1 and 5.1.2

表 2.3-9　重症度別の有害事象：SS（続き）

Table 10.6.1
Incidence of TEAEs by Maximum Intensity
Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Intensity	N = 39 n (%) [#]
顎関節症候群	Any	1 (2.6) [1]
	Mild	1 (2.6) [1]
	Moderate	0
	Severe	0
神経系障害	Any	21 (53.8) [54]
	Mild	11 (28.2) [15]
	Moderate	5 (12.8) [9]
	Severe	5 (12.8) [7]
浮動性めまい	Any	10 (25.6) [12]
	Mild	5 (12.8) [6]
	Moderate	5 (12.8) [6]
	Severe	0
頭痛	Any	7 (17.9) [12]
	Mild	4 (10.3) [4]
	Moderate	3 (7.7) [7]
	Severe	0

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term. (%)=percentage of subjects among total N. [#] is the number of individual occurrences of the TEAE.
Note: Each subject is counted once within each System Organ Class and Preferred Term according to the maximum intensity for all TEAEs within that System Organ Class or Preferred Term.
Reference: Subject Data Listings 5.1.1 and 5.1.2

表 2.3-9　重症度別の有害事象：SS（続き）

Table 10.6.1
Incidence of TEAEs by Maximum Intensity
Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Intensity	N = 39 n (%) [#]
振戦	Any	6 (15.4) [6]
	Mild	6 (15.4) [6]
	Moderate	0
	Severe	0
痙攣	Any	2 (5.1) [2]
	Mild	1 (2.6) [1]
	Moderate	1 (2.6) [1]
	Severe	0
発作後状態	Any	2 (5.1) [9]
	Mild	0
	Moderate	1 (2.6) [2]
	Severe	1 (2.6) [2]
平衡障害	Any	1 (2.6) [1]
	Mild	1 (2.6) [1]
	Moderate	0
	Severe	0

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term. (%)=percentage of subjects among total N. [#] is the number of individual occurrences of the TEAE.
Note: Each subject is counted once within each System Organ Class and Preferred Term according to the maximum intensity for all TEAEs within that System Organ Class or Preferred Term.
Reference: Subject Data Listings 5.1.1 and 5.1.2

表 2.3-9　重症度別の有害事象：SS（続き）

Table 10.6.1
Incidence of TEAEs by Maximum Intensity
Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Intensity	N = 39 n (%) [#]
協調運動異常	Any	1 (2.6) [1]
	Mild	1 (2.6) [1]
	Moderate	0
	Severe	0
味覚異常	Any	1 (2.6) [1]
	Mild	1 (2.6) [1]
	Moderate	0
	Severe	0
大発作痙攣	Any	1 (2.6) [1]
	Mild	0
	Moderate	0
	Severe	1 (2.6) [1]
記憶障害	Any	1 (2.6) [1]
	Mild	1 (2.6) [1]
	Moderate	0
	Severe	0

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term. (%)=percentage of subjects among total N. [#] is the number of individual occurrences of the TEAE.
Note: Each subject is counted once within each System Organ Class and Preferred Term according to the maximum intensity for all TEAEs within that System Organ Class or Preferred Term.
Reference: Subject Data Listings 5.1.1 and 5.1.2

表 2.3-9　重症度別の有害事象：SS（続き）

Table 10.6.1
Incidence of TEAEs by Maximum Intensity
Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Intensity	N = 39 n (%) [#]
片頭痛	Any	1 (2.6) [1]
	Mild	0
	Moderate	0
	Severe	1 (2.6) [1]
ミオクローヌス	Any	1 (2.6) [1]
	Mild	0
	Moderate	1 (2.6) [1]
	Severe	0
眼振	Any	1 (2.6) [1]
	Mild	1 (2.6) [1]
	Moderate	0
	Severe	0
小発作てんかん	Any	1 (2.6) [1]
	Mild	0
	Moderate	0
	Severe	1 (2.6) [1]

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term. (%)=percentage of subjects among total N. [#] is the number of individual occurrences of the TEAE.
Note: Each subject is counted once within each System Organ Class and Preferred Term according to the maximum intensity for all TEAEs within that System Organ Class or Preferred Term.
Reference: Subject Data Listings 5.1.1 and 5.1.2

表 2.3-9　重症度別の有害事象：SS（続き）

Table 10.6.1
Incidence of TEAEs by Maximum Intensity
Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Intensity	N = 39 n (%) [#]
発作後頭痛	Any	1 (2.6) [2]
	Mild	0
	Moderate	0
	Severe	1 (2.6) [2]
下肢静止不能症候群	Any	1 (2.6) [1]
	Mild	0
	Moderate	1 (2.6) [1]
	Severe	0
傾眠	Any	1 (2.6) [1]
	Mild	1 (2.6) [1]
	Moderate	0
	Severe	0
精神障害	Any	12 (30.8) [19]
	Mild	8 (20.5) [9]
	Moderate	4 (10.3) [7]
	Severe	0

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term. (%)=percentage of subjects among total N. [#] is the number of individual occurrences of the TEAE.
Note: Each subject is counted once within each System Organ Class and Preferred Term according to the maximum intensity for all TEAEs within that System Organ Class or Preferred Term.
Reference: Subject Data Listings 5.1.1 and 5.1.2

表 2.3-9　重症度別の有害事象：SS（続き）

Table 10.6.1
Incidence of TEAEs by Maximum Intensity
Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Intensity	N = 39 n (%) [#]
不安	Any	4 (10.3) [5]
	Mild	3 (7.7) [3]
	Moderate	1 (2.6) [2]
	Severe	0
錯乱状態	Any	4 (10.3) [4]
	Mild	3 (7.7) [3]
	Moderate	1 (2.6) [1]
	Severe	0
うつ病	Any	2 (5.1) [2]
	Mild	2 (5.1) [2]
	Moderate	0
	Severe	0
異常行動	Any	1 (2.6) [1]
	Mild	0
	Moderate	1 (2.6) [1]
	Severe	0

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term. (%)=percentage of subjects among total N. [#] is the number of individual occurrences of the TEAE.
Note: Each subject is counted once within each System Organ Class and Preferred Term according to the maximum intensity for all TEAEs within that System Organ Class or Preferred Term.
Reference: Subject Data Listings 5.1.1 and 5.1.2

表 2.3-9　重症度別の有害事象：SS（続き）

Table 10.6.1
Incidence of TEAEs by Maximum Intensity
Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Intensity	N = 39 n (%) [#]
注意欠陥多動性障害	Any	1 (2.6) [1]
	Mild	1 (2.6) [1]
	Moderate	0
	Severe	0
双極性障害	Any	1 (2.6) [1]
	Mild	1 (2.6) [1]
	Moderate	0
	Severe	0
初期不眠症	Any	1 (2.6) [1]
	Mild	0
	Moderate	1 (2.6) [1]
	Severe	0
不眠症	Any	1 (2.6) [1]
	Mild	1 (2.6) [1]
	Moderate	0
	Severe	0

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term. (%)=percentage of subjects among total N. [#] is the number of individual occurrences of the TEAE.
Note: Each subject is counted once within each System Organ Class and Preferred Term according to the maximum intensity for all TEAEs within that System Organ Class or Preferred Term.
Reference: Subject Data Listings 5.1.1 and 5.1.2

表 2.3-9　重症度別の有害事象：SS（続き）

Table 10.6.1
Incidence of TEAEs by Maximum Intensity
Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Intensity	N = 39 n (%) [#]
気分動揺	Any	1 (2.6) [1]
	Mild	0
	Moderate	1 (2.6) [1]
	Severe	0
パニック発作	Any	1 (2.6) [1]
	Mild	0
	Moderate	1 (2.6) [1]
	Severe	0
睡眠障害	Any	1 (2.6) [1]
	Mild	1 (2.6) [1]
	Moderate	0
	Severe	0
腎および尿路障害	Any	1 (2.6) [3]
	Mild	1 (2.6) [3]
	Moderate	0
	Severe	0

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term. (%)=percentage of subjects among total N. [#] is the number of individual occurrences of the TEAE.
Note: Each subject is counted once within each System Organ Class and Preferred Term according to the maximum intensity for all TEAEs within that System Organ Class or Preferred Term.
Reference: Subject Data Listings 5.1.1 and 5.1.2

表 2.3-9　重症度別の有害事象：SS（続き）

Table 10.6.1
Incidence of TEAEs by Maximum Intensity
Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Intensity	N = 39 n (%) [#]
尿意切迫	Any	1 (2.6) [1]
	Mild	1 (2.6) [1]
	Moderate	0
	Severe	0
蛋白尿	Any	1 (2.6) [1]
	Mild	1 (2.6) [1]
	Moderate	0
	Severe	0
腎不全	Any	1 (2.6) [1]
	Mild	1 (2.6) [1]
	Moderate	0
	Severe	0
生殖系および乳房障害	Any	3 (7.7) [6]
	Mild	0
	Moderate	2 (5.1) [4]
	Severe	1 (2.6) [2]

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term. (%)=percentage of subjects among total N. [#] is the number of individual occurrences of the TEAE.
Note: Each subject is counted once within each System Organ Class and Preferred Term according to the maximum intensity for all TEAEs within that System Organ Class or Preferred Term.
Reference: Subject Data Listings 5.1.1 and 5.1.2

表 2.3-9　重症度別の有害事象：SS（続き）

Table 10.6.1
Incidence of TEAEs by Maximum Intensity
Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Intensity	N = 39 n (%) [#]
精巣上体嚢胞	Any	1 (2.6) [1]
	Mild	0
	Moderate	1 (2.6) [1]
	Severe	0
精巣上体炎	Any	1 (2.6) [1]
	Mild	0
	Moderate	1 (2.6) [1]
	Severe	0
月経過多	Any	1 (2.6) [1]
	Mild	0
	Moderate	1 (2.6) [1]
	Severe	0
希発月経	Any	1 (2.6) [1]
	Mild	0
	Moderate	1 (2.6) [1]
	Severe	0

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term. (%)=percentage of subjects among total N. [#] is the number of individual occurrences of the TEAE.
Note: Each subject is counted once within each System Organ Class and Preferred Term according to the maximum intensity for all TEAEs within that System Organ Class or Preferred Term.
Reference: Subject Data Listings 5.1.1 and 5.1.2

表 2.3-9　重症度別の有害事象：SS（続き）

Table 10.6.1
Incidence of TEAEs by Maximum Intensity
Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Intensity	N = 39 n (%) [#]
卵巣嚢胞	Any	1 (2.6) [1]
	Mild	0
	Moderate	0
	Severe	1 (2.6) [1]
骨盤痛	Any	1 (2.6) [1]
	Mild	0
	Moderate	0
	Severe	1 (2.6) [1]
呼吸器、胸郭および縦隔障害	Any	12 (30.8) [18]
	Mild	4 (10.3) [5]
	Moderate	6 (15.4) [9]
	Severe	2 (5.1) [2]
呼吸困難	Any	4 (10.3) [4]
	Mild	0
	Moderate	3 (7.7) [3]
	Severe	1 (2.6) [1]

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term. (%)=percentage of subjects among total N. [#] is the number of individual occurrences of the TEAE.
Note: Each subject is counted once within each System Organ Class and Preferred Term according to the maximum intensity for all TEAEs within that System Organ Class or Preferred Term.
Reference: Subject Data Listings 5.1.1 and 5.1.2

表 2.3-9　重症度別の有害事象：SS（続き）

Table 10.6.1
Incidence of TEAEs by Maximum Intensity
Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Intensity	N = 39 n (%) [#]
呼吸障害	Any	2 (5.1) [2]
	Mild	0
	Moderate	2 (5.1) [2]
	Severe	0
気管支反応性亢進	Any	1 (2.6) [1]
	Mild	1 (2.6) [1]
	Moderate	0
	Severe	0
気管支痙攣	Any	1 (2.6) [1]
	Mild	0
	Moderate	1 (2.6) [1]
	Severe	0
咳嗽	Any	1 (2.6) [1]
	Mild	0
	Moderate	1 (2.6) [1]
	Severe	0

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term. (%)=percentage of subjects among total N. [#] is the number of individual occurrences of the TEAE.
Note: Each subject is counted once within each System Organ Class and Preferred Term according to the maximum intensity for all TEAEs within that System Organ Class or Preferred Term.
Reference: Subject Data Listings 5.1.1 and 5.1.2

表 2.3-9　重症度別の有害事象：SS（続き）

Table 10.6.1
Incidence of TEAEs by Maximum Intensity
Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Intensity	N = 39 n (%) [#]
鼻出血	Any	1 (2.6) [1]
	Mild	1 (2.6) [1]
	Moderate	0
	Severe	0
しゃっくり	Any	1 (2.6) [1]
	Mild	1 (2.6) [1]
	Moderate	0
	Severe	0
低換気	Any	1 (2.6) [1]
	Mild	1 (2.6) [1]
	Moderate	0
	Severe	0
肺障害	Any	1 (2.6) [1]
	Mild	1 (2.6) [1]
	Moderate	0
	Severe	0

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term. (%)=percentage of subjects among total N. [#] is the number of individual occurrences of the TEAE.
Note: Each subject is counted once within each System Organ Class and Preferred Term according to the maximum intensity for all TEAEs within that System Organ Class or Preferred Term.
Reference: Subject Data Listings 5.1.1 and 5.1.2

表 2.3-9　重症度別の有害事象：SS（続き）

Table 10.6.1
Incidence of TEAEs by Maximum Intensity
Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Intensity	N = 39 n (%) [#]
胸水	Any	1 (2.6) [1]
	Mild	0
	Moderate	0
	Severe	1 (2.6) [1]
副鼻腔うっ血	Any	1 (2.6) [2]
	Mild	0
	Moderate	1 (2.6) [2]
	Severe	0
くしゃみ	Any	1 (2.6) [1]
	Mild	1 (2.6) [1]
	Moderate	0
	Severe	0
気管狭窄	Any	1 (2.6) [1]
	Mild	1 (2.6) [1]
	Moderate	0
	Severe	0

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term. (%)=percentage of subjects among total N. [#] is the number of individual occurrences of the TEAE.
Note: Each subject is counted once within each System Organ Class and Preferred Term according to the maximum intensity for all TEAEs within that System Organ Class or Preferred Term.
Reference: Subject Data Listings 5.1.1 and 5.1.2

表 2.3-9　重症度別の有害事象：SS（続き）

Table 10.6.1
Incidence of TEAEs by Maximum Intensity
Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Intensity	N = 39 n (%) [#]
皮膚および皮下組織障害	Any	5 (12.8) [8]
	Mild	3 (7.7) [6]
	Moderate	1 (2.6) [1]
	Severe	1 (2.6) [1]
脱毛症	Any	2 (5.1) [2]
	Mild	2 (5.1) [2]
	Moderate	0
	Severe	0
ざ瘡	Any	1 (2.6) [1]
	Mild	1 (2.6) [1]
	Moderate	0
	Severe	0
皮膚嚢腫	Any	1 (2.6) [1]
	Mild	0
	Moderate	1 (2.6) [1]
	Severe	0

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term. (%)=percentage of subjects among total N. [#] is the number of individual occurrences of the TEAE.
Note: Each subject is counted once within each System Organ Class and Preferred Term according to the maximum intensity for all TEAEs within that System Organ Class or Preferred Term.
Reference: Subject Data Listings 5.1.1 and 5.1.2

表 2.3-9　重症度別の有害事象：SS（続き）

Table 10.6.1
Incidence of TEAEs by Maximum Intensity
Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Intensity	N = 39 n (%) [#]
寝汗	Any	1 (2.6) [1]
	Mild	0
	Moderate	0
	Severe	1 (2.6) [1]
そう痒症	Any	1 (2.6) [1]
	Mild	1 (2.6) [1]
	Moderate	0
	Severe	0
発疹	Any	1 (2.6) [1]
	Mild	1 (2.6) [1]
	Moderate	0
	Severe	0
皮膚障害	Any	1 (2.6) [1]
	Mild	1 (2.6) [1]
	Moderate	0
	Severe	0

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term. (%)=percentage of subjects among total N. [#] is the number of individual occurrences of the TEAE.
Note: Each subject is counted once within each System Organ Class and Preferred Term according to the maximum intensity for all TEAEs within that System Organ Class or Preferred Term.
Reference: Subject Data Listings 5.1.1 and 5.1.2

2.3.3.2.1.3 治験薬との因果関係が否定できない有害事象

本治験の治験薬投与開始後に認められた治験薬との因果関係別の有害事象を表 2.3-10 に示した。

表 2.3-10　治験薬との因果関係別の有害事象：SS

Table 10.7.1

Incidence of TEAEs by Relationship to Study Medication per the Investigator

Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Drug Relationship	N = 39 n (%) [#]
Any System Organ Class	Any	37 (94.9) [263]
	Related	17 (43.6) [64]
	Not Related	36 (92.3) [199]
心臓障害	Any	2 (5.1) [2]
	Related	0
	Not Related	2 (5.1) [2]
動悸	Any	2 (5.1) [2]
	Related	0
	Not Related	2 (5.1) [2]
耳および迷路障害	Any	2 (5.1) [2]
	Related	1 (2.6) [1]
	Not Related	1 (2.6) [1]
耳痛	Any	1 (2.6) [1]
	Related	0
	Not Related	1 (2.6) [1]

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term. (%)=percentage of subjects among total N. [#] is the number of individual occurrences of the TEAE.

Note: A subject may be counted more than once according to the relationship of the TEAEs.

Note: Drug-related TEAEs are those with relationship other than not related and unlikely (including missing relationship information).

Reference: Subject Data Listings 5.1.1 and 5.1.2

表 2.3-10　治験薬との因果関係別の有害事象：SS（続き）

Table 10.7.1
Incidence of TEAEs by Relationship to Study Medication per the Investigator
Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Drug Relationship	N = 39 n (%) [#]
回転性めまい	Any	1 (2.6) [1]
	Related	1 (2.6) [1]
	Not Related	0
内分泌障害	Any	1 (2.6) [1]
	Related	0
	Not Related	1 (2.6) [1]
甲状腺機能低下症	Any	1 (2.6) [1]
	Related	0
	Not Related	1 (2.6) [1]
眼障害	Any	5 (12.8) [6]
	Related	2 (5.1) [3]
	Not Related	3 (7.7) [3]
複視	Any	3 (7.7) [4]
	Related	2 (5.1) [3]
	Not Related	1 (2.6) [1]

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term. (%)=percentage of subjects among total N. [#] is the number of individual occurrences of the TEAE.
Note: A subject may be counted more than once according to the relationship of the TEAEs.
Note: Drug-related TEAEs are those with relationship other than not related and unlikely (including missing relationship information).
Reference: Subject Data Listings 5.1.1 and 5.1.2

表 2.3-10　治験薬との因果関係別の有害事象：SS（続き）

Table 10.7.1

Incidence of TEAEs by Relationship to Study Medication per the Investigator

Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Drug Relationship	N = 39 n (%) [#]
結膜出血	Any	1 (2.6) [1]
	Related	0
	Not Related	1 (2.6) [1]
結膜炎	Any	1 (2.6) [1]
	Related	0
	Not Related	1 (2.6) [1]
胃腸障害	Any	14 (35.9) [23]
	Related	4 (10.3) [6]
	Not Related	10 (25.6) [17]
悪心	Any	5 (12.8) [5]
	Related	1 (2.6) [1]
	Not Related	4 (10.3) [4]
下痢	Any	2 (5.1) [2]
	Related	0
	Not Related	2 (5.1) [2]

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term. (%)=percentage of subjects among total N. [#] is the number of individual occurrences of the TEAE.

Note: A subject may be counted more than once according to the relationship of the TEAEs.

Note: Drug-related TEAEs are those with relationship other than not related and unlikely (including missing relationship information).

Reference: Subject Data Listings 5.1.1 and 5.1.2

表 2.3-10　治験薬との因果関係別の有害事象：SS（続き）

Table 10.7.1

Incidence of TEAEs by Relationship to Study Medication per the Investigator

Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Drug Relationship	N = 39 n (%) [#]
腹部ヘルニア	Any	1 (2.6) [1]
	Related	0
	Not Related	1 (2.6) [1]
腹痛	Any	1 (2.6) [1]
	Related	0
	Not Related	1 (2.6) [1]
下腹部痛	Any	1 (2.6) [1]
	Related	0
	Not Related	1 (2.6) [1]
上腹部痛	Any	1 (2.6) [1]
	Related	0
	Not Related	1 (2.6) [1]
便秘	Any	1 (2.6) [1]
	Related	0
	Not Related	1 (2.6) [1]

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term. (%)=percentage of subjects among total N. [#] is the number of individual occurrences of the TEAE.

Note: A subject may be counted more than once according to the relationship of the TEAEs.

Note: Drug-related TEAEs are those with relationship other than not related and unlikely (including missing relationship information).

Reference: Subject Data Listings 5.1.1 and 5.1.2

表 2.3-10　治験薬との因果関係別の有害事象：SS（続き）

Table 10.7.1
Incidence of TEAEs by Relationship to Study Medication per the Investigator
Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Drug Relationship	N = 39 n (%) [#]
消化不良	Any	1 (2.6) [1]
	Related	1 (2.6) [1]
	Not Related	0
胃食道逆流性疾患	Any	1 (2.6) [1]
	Related	0
	Not Related	1 (2.6) [1]
口の感覚鈍麻	Any	1 (2.6) [1]
	Related	1 (2.6) [1]
	Not Related	0
口唇腫脹	Any	1 (2.6) [1]
	Related	0
	Not Related	1 (2.6) [1]
口腔内痛	Any	1 (2.6) [3]
	Related	0
	Not Related	1 (2.6) [3]

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term. (%)=percentage of subjects among total N. [#] is the number of individual occurrences of the TEAE.
Note: A subject may be counted more than once according to the relationship of the TEAEs.
Note: Drug-related TEAEs are those with relationship other than not related and unlikely (including missing relationship information).
Reference: Subject Data Listings 5.1.1 and 5.1.2

表 2.3-10　治験薬との因果関係別の有害事象：SS（続き）

Table 10.7.1
Incidence of TEAEs by Relationship to Study Medication per the Investigator
Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Drug Relationship	N = 39 n (%) [#]
口の錯感覚	Any	1 (2.6) [2]
	Related	1 (2.6) [2]
	Not Related	0
胃不快感	Any	1 (2.6) [1]
	Related	0
	Not Related	1 (2.6) [1]
嘔吐	Any	1 (2.6) [1]
	Related	1 (2.6) [1]
	Not Related	0
全身障害および投与局所様態	Any	11 (28.2) [13]
	Related	3 (7.7) [4]
	Not Related	8 (20.5) [9]
疲労	Any	3 (7.7) [4]
	Related	2 (5.1) [3]
	Not Related	1 (2.6) [1]

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term. (%)=percentage of subjects among total N. [#] is the number of individual occurrences of the TEAE.
Note: A subject may be counted more than once according to the relationship of the TEAEs.
Note: Drug-related TEAEs are those with relationship other than not related and unlikely (including missing relationship information).
Reference: Subject Data Listings 5.1.1 and 5.1.2

表 2.3-10　治験薬との因果関係別の有害事象：SS（続き）

Table 10.7.1

Incidence of TEAEs by Relationship to Study Medication per the Investigator

Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Drug Relationship	N = 39 n (%) [#]
歩行障害	Any	2 (5.1) [2]
	Related	1 (2.6) [1]
	Not Related	1 (2.6) [1]
無力症	Any	1 (2.6) [1]
	Related	0
	Not Related	1 (2.6) [1]
胸部不快感	Any	1 (2.6) [1]
	Related	0
	Not Related	1 (2.6) [1]
顔面痛	Any	1 (2.6) [1]
	Related	0
	Not Related	1 (2.6) [1]
異常感	Any	1 (2.6) [1]
	Related	0
	Not Related	1 (2.6) [1]

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term. (%)=percentage of subjects among total N. [#] is the number of individual occurrences of the TEAE.

Note: A subject may be counted more than once according to the relationship of the TEAEs.

Note: Drug-related TEAEs are those with relationship other than not related and unlikely (including missing relationship information).

Reference: Subject Data Listings 5.1.1 and 5.1.2

表 2.3-10　治験薬との因果関係別の有害事象：SS（続き）

Table 10.7.1

Incidence of TEAEs by Relationship to Study Medication per the Investigator

Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Drug Relationship	N = 39 n (%) [#]
易刺激性	Any	1 (2.6) [1]
	Related	0
	Not Related	1 (2.6) [1]
非心臓性胸痛	Any	1 (2.6) [1]
	Related	0
	Not Related	1 (2.6) [1]
疼痛	Any	1 (2.6) [1]
	Related	0
	Not Related	1 (2.6) [1]
肝胆道系障害	Any	1 (2.6) [1]
	Related	0
	Not Related	1 (2.6) [1]
胆石症	Any	1 (2.6) [1]
	Related	0
	Not Related	1 (2.6) [1]

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term. (%)=percentage of subjects among total N. [#] is the number of individual occurrences of the TEAE.

Note: A subject may be counted more than once according to the relationship of the TEAEs.

Note: Drug-related TEAEs are those with relationship other than not related and unlikely (including missing relationship information).

Reference: Subject Data Listings 5.1.1 and 5.1.2

表 2.3-10　治験薬との因果関係別の有害事象：SS（続き）

Table 10.7.1
Incidence of TEAEs by Relationship to Study Medication per the Investigator
Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Drug Relationship	N = 39 n (%) [#]
免疫系障害	Any	3 (7.7) [3]
	Related	0
	Not Related	3 (7.7) [3]
季節性アレルギー	Any	3 (7.7) [3]
	Related	0
	Not Related	3 (7.7) [3]
感染症および寄生虫症	Any	21 (53.8) [40]
	Related	0
	Not Related	21 (53.8) [40]
上気道感染	Any	10 (25.6) [13]
	Related	0
	Not Related	10 (25.6) [13]
副鼻腔炎	Any	3 (7.7) [3]
	Related	0
	Not Related	3 (7.7) [3]

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term. (%)=percentage of subjects among total N. [#] is the number of individual occurrences of the TEAE.
Note: A subject may be counted more than once according to the relationship of the TEAEs.
Note: Drug-related TEAEs are those with relationship other than not related and unlikely (including missing relationship information).
Reference: Subject Data Listings 5.1.1 and 5.1.2

表 2.3-10　治験薬との因果関係別の有害事象：SS（続き）

Table 10.7.1
Incidence of TEAEs by Relationship to Study Medication per the Investigator
Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Drug Relationship	N = 39 n (%) [#]
ウイルス性胃腸炎	Any	2 (5.1) [3]
	Related	0
	Not Related	2 (5.1) [3]
インフルエンザ	Any	2 (5.1) [2]
	Related	0
	Not Related	2 (5.1) [2]
肺炎	Any	2 (5.1) [2]
	Related	0
	Not Related	2 (5.1) [2]
歯膿瘍	Any	2 (5.1) [2]
	Related	0
	Not Related	2 (5.1) [2]
気管支炎	Any	1 (2.6) [1]
	Related	0
	Not Related	1 (2.6) [1]

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term. (%)=percentage of subjects among total N. [#] is the number of individual occurrences of the TEAE.
Note: A subject may be counted more than once according to the relationship of the TEAEs.
Note: Drug-related TEAEs are those with relationship other than not related and unlikely (including missing relationship information).
Reference: Subject Data Listings 5.1.1 and 5.1.2

表 2.3-10　治験薬との因果関係別の有害事象：SS（続き）

Table 10.7.1

Incidence of TEAEs by Relationship to Study Medication per the Investigator

Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Drug Relationship	N = 39 n (%) [#]
膀胱炎	Any	1 (2.6) [1]
	Related	0
	Not Related	1 (2.6) [1]
耳感染	Any	1 (2.6) [1]
	Related	0
	Not Related	1 (2.6) [1]
真菌感染	Any	1 (2.6) [1]
	Related	0
	Not Related	1 (2.6) [1]
胃腸炎	Any	1 (2.6) [1]
	Related	0
	Not Related	1 (2.6) [1]
A型肝炎	Any	1 (2.6) [1]
	Related	0
	Not Related	1 (2.6) [1]

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term. (%)=percentage of subjects among total N. [#] is the number of individual occurrences of the TEAE.

Note: A subject may be counted more than once according to the relationship of the TEAEs.

Note: Drug-related TEAEs are those with relationship other than not related and unlikely (including missing relationship information).

Reference: Subject Data Listings 5.1.1 and 5.1.2

表 2.3-10　治験薬との因果関係別の有害事象：SS（続き）

Table 10.7.1
Incidence of TEAEs by Relationship to Study Medication per the Investigator
Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Drug Relationship	N = 39 n (%) [#]
単純ヘルペス	Any	1 (2.6) [1]
	Related	0
	Not Related	1 (2.6) [1]
鼻咽頭炎	Any	1 (2.6) [2]
	Related	0
	Not Related	1 (2.6) [2]
中耳炎	Any	1 (2.6) [1]
	Related	0
	Not Related	1 (2.6) [1]
ブドウ球菌感染	Any	1 (2.6) [1]
	Related	0
	Not Related	1 (2.6) [1]
レンサ球菌感染	Any	1 (2.6) [1]
	Related	0
	Not Related	1 (2.6) [1]

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term. (%)=percentage of subjects among total N. [#] is the number of individual occurrences of the TEAE.
Note: A subject may be counted more than once according to the relationship of the TEAEs.
Note: Drug-related TEAEs are those with relationship other than not related and unlikely (including missing relationship information).
Reference: Subject Data Listings 5.1.1 and 5.1.2

表 2.3-10　治験薬との因果関係別の有害事象：SS（続き）

Table 10.7.1
Incidence of TEAEs by Relationship to Study Medication per the Investigator
Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Drug Relationship	N = 39 n (%) [#]
白癬感染	Any	1 (2.6) [1]
	Related	0
	Not Related	1 (2.6) [1]
歯感染	Any	1 (2.6) [1]
	Related	0
	Not Related	1 (2.6) [1]
尿路感染	Any	1 (2.6) [1]
	Related	0
	Not Related	1 (2.6) [1]
傷害、中毒および処置合併症	Any	14 (35.9) [24]
	Related	1 (2.6) [1]
	Not Related	13 (33.3) [23]
転倒	Any	4 (10.3) [4]
	Related	1 (2.6) [1]
	Not Related	3 (7.7) [3]

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term. (%)=percentage of subjects among total N. [#] is the number of individual occurrences of the TEAE.
Note: A subject may be counted more than once according to the relationship of the TEAEs.
Note: Drug-related TEAEs are those with relationship other than not related and unlikely (including missing relationship information).
Reference: Subject Data Listings 5.1.1 and 5.1.2

表 2.3-10　治験薬との因果関係別の有害事象：SS（続き）

Table 10.7.1

Incidence of TEAEs by Relationship to Study Medication per the Investigator

Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Drug Relationship	N = 39 n (%) [#]
関節捻挫	Any	4 (10.3) [5]
	Related	0
	Not Related	4 (10.3) [5]
挫傷	Any	3 (7.7) [3]
	Related	0
	Not Related	3 (7.7) [3]
擦過傷	Any	2 (5.1) [2]
	Related	0
	Not Related	2 (5.1) [2]
筋挫傷	Any	2 (5.1) [2]
	Related	0
	Not Related	2 (5.1) [2]
皮膚裂傷	Any	2 (5.1) [2]
	Related	0
	Not Related	2 (5.1) [2]

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term. (%)=percentage of subjects among total N. [#] is the number of individual occurrences of the TEAE.

Note: A subject may be counted more than once according to the relationship of the TEAEs.

Note: Drug-related TEAEs are those with relationship other than not related and unlikely (including missing relationship information).

Reference: Subject Data Listings 5.1.1 and 5.1.2

表 2.3-10　治験薬との因果関係別の有害事象：SS（続き）

Table 10.7.1

Incidence of TEAEs by Relationship to Study Medication per the Investigator

Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Drug Relationship	N = 39 n (%) [#]
節足動物刺傷	Any	1 (2.6) [1]
	Related	0
	Not Related	1 (2.6) [1]
顔面損傷	Any	1 (2.6) [1]
	Related	0
	Not Related	1 (2.6) [1]
足骨折	Any	1 (2.6) [1]
	Related	0
	Not Related	1 (2.6) [1]
四肢損傷	Any	1 (2.6) [1]
	Related	0
	Not Related	1 (2.6) [1]
骨格損傷	Any	1 (2.6) [1]
	Related	0
	Not Related	1 (2.6) [1]

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term. (%)=percentage of subjects among total N. [#] is the number of individual occurrences of the TEAE.

Note: A subject may be counted more than once according to the relationship of the TEAEs.

Note: Drug-related TEAEs are those with relationship other than not related and unlikely (including missing relationship information).

Reference: Subject Data Listings 5.1.1 and 5.1.2

表 2.3-10　治験薬との因果関係別の有害事象：SS（続き）

Table 10.7.1
Incidence of TEAEs by Relationship to Study Medication per the Investigator
Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Drug Relationship	N = 39 n (%) [#]
熱傷	Any	1 (2.6) [1]
	Related	0
	Not Related	1 (2.6) [1]
臨床検査	Any	12 (30.8) [21]
	Related	2 (5.1) [3]
	Not Related	10 (25.6) [18]
体重増加	Any	4 (10.3) [4]
	Related	1 (2.6) [1]
	Not Related	3 (7.7) [3]
アラニン・アミノトランスフェラーゼ増加	Any	2 (5.1) [2]
	Related	0
	Not Related	2 (5.1) [2]
動脈雑音	Any	2 (5.1) [2]
	Related	0
	Not Related	2 (5.1) [2]

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term. (%)=percentage of subjects among total N. [#] is the number of individual occurrences of the TEAE.
Note: A subject may be counted more than once according to the relationship of the TEAEs.
Note: Drug-related TEAEs are those with relationship other than not related and unlikely (including missing relationship information).
Reference: Subject Data Listings 5.1.1 and 5.1.2

表 2.3-10　治験薬との因果関係別の有害事象：SS（続き）

Table 10.7.1
Incidence of TEAEs by Relationship to Study Medication per the Investigator
Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Drug Relationship	N = 39 n (%) [#]
アスパラギン酸アミノトランスフェラーゼ増加	Any	2 (5.1) [2]
	Related	0
	Not Related	2 (5.1) [2]
γ－グルタミルトランスフェラーゼ増加	Any	2 (5.1) [2]
	Related	0
	Not Related	2 (5.1) [2]
血中アルカリホスファターゼ増加	Any	1 (2.6) [1]
	Related	0
	Not Related	1 (2.6) [1]
血中カルシウム減少	Any	1 (2.6) [1]
	Related	0
	Not Related	1 (2.6) [1]
好酸球数異常	Any	1 (2.6) [2]
	Related	0
	Not Related	1 (2.6) [2]

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term. (%)=percentage of subjects among total N. [#] is the number of individual occurrences of the TEAE.
Note: A subject may be counted more than once according to the relationship of the TEAEs.
Note: Drug-related TEAEs are those with relationship other than not related and unlikely (including missing relationship information).
Reference: Subject Data Listings 5.1.1 and 5.1.2

表 2.3-10　治験薬との因果関係別の有害事象：SS（続き）

Table 10.7.1

Incidence of TEAEs by Relationship to Study Medication per the Investigator

Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Drug Relationship	N = 39 n (%) [#]
胃内ｐＨ低下	Any	1 (2.6) [1]
	Related	0
	Not Related	1 (2.6) [1]
ＩＮＲ増加	Any	1 (2.6) [1]
	Related	0
	Not Related	1 (2.6) [1]
尿中赤血球	Any	1 (2.6) [1]
	Related	0
	Not Related	1 (2.6) [1]
尿中赤血球陽性	Any	1 (2.6) [1]
	Related	1 (2.6) [1]
	Not Related	0
尿円柱	Any	1 (2.6) [1]
	Related	1 (2.6) [1]
	Not Related	0

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term. (%)=percentage of subjects among total N. [#] is the number of individual occurrences of the TEAE.

Note: A subject may be counted more than once according to the relationship of the TEAEs.

Note: Drug-related TEAEs are those with relationship other than not related and unlikely (including missing relationship information).

Reference: Subject Data Listings 5.1.1 and 5.1.2

表 2.3-10　治験薬との因果関係別の有害事象：SS（続き）

Table 10.7.1

Incidence of TEAEs by Relationship to Study Medication per the Investigator

Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Drug Relationship	N = 39 n (%) [#]
代謝および栄養障害	Any	3 (7.7) [3]
	Related	2 (5.1) [2]
	Not Related	1 (2.6) [1]
食欲亢進	Any	2 (5.1) [2]
	Related	1 (2.6) [1]
	Not Related	1 (2.6) [1]
食欲障害	Any	1 (2.6) [1]
	Related	1 (2.6) [1]
	Not Related	0
筋骨格系および結合組織障害	Any	10 (25.6) [16]
	Related	1 (2.6) [1]
	Not Related	9 (23.1) [15]
筋骨格痛	Any	3 (7.7) [3]
	Related	1 (2.6) [1]
	Not Related	2 (5.1) [2]

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term. (%)=percentage of subjects among total N. [#] is the number of individual occurrences of the TEAE.

Note: A subject may be counted more than once according to the relationship of the TEAEs.

Note: Drug-related TEAEs are those with relationship other than not related and unlikely (including missing relationship information).

Reference: Subject Data Listings 5.1.1 and 5.1.2

表 2.3-10　治験薬との因果関係別の有害事象：SS（続き）

Table 10.7.1

Incidence of TEAEs by Relationship to Study Medication per the Investigator

Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Drug Relationship	N = 39 n (%) [#]
関節痛	Any	2 (5.1) [4]
	Related	0
	Not Related	2 (5.1) [4]
背部痛	Any	1 (2.6) [1]
	Related	0
	Not Related	1 (2.6) [1]
肋軟骨炎	Any	1 (2.6) [1]
	Related	0
	Not Related	1 (2.6) [1]
側腹部痛	Any	1 (2.6) [1]
	Related	0
	Not Related	1 (2.6) [1]
関節硬直	Any	1 (2.6) [1]
	Related	0
	Not Related	1 (2.6) [1]

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term. (%)=percentage of subjects among total N. [#] is the number of individual occurrences of the TEAE.

Note: A subject may be counted more than once according to the relationship of the TEAEs.

Note: Drug-related TEAEs are those with relationship other than not related and unlikely (including missing relationship information).

Reference: Subject Data Listings 5.1.1 and 5.1.2

表 2.3-10　治験薬との因果関係別の有害事象：SS（続き）

Table 10.7.1

Incidence of TEAEs by Relationship to Study Medication per the Investigator

Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Drug Relationship	N = 39 n (%) [#]
筋痙縮	Any	1 (2.6) [1]
	Related	0
	Not Related	1 (2.6) [1]
骨関節炎	Any	1 (2.6) [1]
	Related	0
	Not Related	1 (2.6) [1]
四肢痛	Any	1 (2.6) [1]
	Related	0
	Not Related	1 (2.6) [1]
顎痛	Any	1 (2.6) [1]
	Related	0
	Not Related	1 (2.6) [1]
顎関節症候群	Any	1 (2.6) [1]
	Related	0
	Not Related	1 (2.6) [1]

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term. (%)=percentage of subjects among total N. [#] is the number of individual occurrences of the TEAE.

Note: A subject may be counted more than once according to the relationship of the TEAEs.

Note: Drug-related TEAEs are those with relationship other than not related and unlikely (including missing relationship information).

Reference: Subject Data Listings 5.1.1 and 5.1.2

表 2.3-10　治験薬との因果関係別の有害事象：SS（続き）

Table 10.7.1

Incidence of TEAEs by Relationship to Study Medication per the Investigator

Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Drug Relationship	N = 39 n (%) [#]
神経系障害	Any	21 (53.8) [54]
	Related	11 (28.2) [27]
	Not Related	12 (30.8) [27]
浮動性めまい	Any	10 (25.6) [12]
	Related	7 (17.9) [8]
	Not Related	4 (10.3) [4]
頭痛	Any	7 (17.9) [12]
	Related	2 (5.1) [2]
	Not Related	5 (12.8) [10]
振戦	Any	6 (15.4) [6]
	Related	3 (7.7) [3]
	Not Related	3 (7.7) [3]
痙攣	Any	2 (5.1) [2]
	Related	1 (2.6) [1]
	Not Related	1 (2.6) [1]

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term. (%)=percentage of subjects among total N. [#] is the number of individual occurrences of the TEAE.

Note: A subject may be counted more than once according to the relationship of the TEAEs.

Note: Drug-related TEAEs are those with relationship other than not related and unlikely (including missing relationship information).

Reference: Subject Data Listings 5.1.1 and 5.1.2

表 2.3-10　治験薬との因果関係別の有害事象：SS（続き）

Table 10.7.1

Incidence of TEAEs by Relationship to Study Medication per the Investigator

Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Drug Relationship	N = 39 n (%) [#]
発作後状態	Any	2 (5.1) [9]
	Related	1 (2.6) [7]
	Not Related	1 (2.6) [2]
平衡障害	Any	1 (2.6) [1]
	Related	1 (2.6) [1]
	Not Related	0
協調運動異常	Any	1 (2.6) [1]
	Related	1 (2.6) [1]
	Not Related	0
味覚異常	Any	1 (2.6) [1]
	Related	0
	Not Related	1 (2.6) [1]
大発作痙攣	Any	1 (2.6) [1]
	Related	0
	Not Related	1 (2.6) [1]

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term. (%)=percentage of subjects among total N. [#] is the number of individual occurrences of the TEAE.

Note: A subject may be counted more than once according to the relationship of the TEAEs.

Note: Drug-related TEAEs are those with relationship other than not related and unlikely (including missing relationship information).

Reference: Subject Data Listings 5.1.1 and 5.1.2

表 2.3-10　治験薬との因果関係別の有害事象：SS（続き）

Table 10.7.1
Incidence of TEAEs by Relationship to Study Medication per the Investigator
Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Drug Relationship	N = 39 n (%) [#]
記憶障害	Any	1 (2.6) [1]
	Related	1 (2.6) [1]
	Not Related	0
片頭痛	Any	1 (2.6) [1]
	Related	0
	Not Related	1 (2.6) [1]
ミオクローヌス	Any	1 (2.6) [1]
	Related	0
	Not Related	1 (2.6) [1]
眼振	Any	1 (2.6) [1]
	Related	1 (2.6) [1]
	Not Related	0
小発作てんかん	Any	1 (2.6) [1]
	Related	1 (2.6) [1]
	Not Related	0

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term. (%)=percentage of subjects among total N. [#] is the number of individual occurrences of the TEAE.
Note: A subject may be counted more than once according to the relationship of the TEAEs.
Note: Drug-related TEAEs are those with relationship other than not related and unlikely (including missing relationship information).
Reference: Subject Data Listings 5.1.1 and 5.1.2

表 2.3-10　治験薬との因果関係別の有害事象：SS（続き）

Table 10.7.1

Incidence of TEAEs by Relationship to Study Medication per the Investigator

Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Drug Relationship	N = 39 n (%) [#]
発作後頭痛	Any	1 (2.6) [2]
	Related	0
	Not Related	1 (2.6) [2]
下肢静止不能症候群	Any	1 (2.6) [1]
	Related	0
	Not Related	1 (2.6) [1]
傾眠	Any	1 (2.6) [1]
	Related	1 (2.6) [1]
	Not Related	0
精神障害	Any	12 (30.8) [19]
	Related	6 (15.4) [9]
	Not Related	7 (17.9) [10]
不安	Any	4 (10.3) [5]
	Related	1 (2.6) [1]
	Not Related	3 (7.7) [4]

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term. (%)=percentage of subjects among total N. [#] is the number of individual occurrences of the TEAE.

Note: A subject may be counted more than once according to the relationship of the TEAEs.

Note: Drug-related TEAEs are those with relationship other than not related and unlikely (including missing relationship information).

Reference: Subject Data Listings 5.1.1 and 5.1.2

表 2.3-10　治験薬との因果関係別の有害事象：SS（続き）

Table 10.7.1

Incidence of TEAEs by Relationship to Study Medication per the Investigator

Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Drug Relationship	N = 39 n (%) [#]
錯乱状態	Any	4 (10.3) [4]
	Related	3 (7.7) [3]
	Not Related	1 (2.6) [1]
うつ病	Any	2 (5.1) [2]
	Related	1 (2.6) [1]
	Not Related	1 (2.6) [1]
異常行動	Any	1 (2.6) [1]
	Related	1 (2.6) [1]
	Not Related	0
注意欠陥多動性障害	Any	1 (2.6) [1]
	Related	1 (2.6) [1]
	Not Related	0
双極性障害	Any	1 (2.6) [1]
	Related	0
	Not Related	1 (2.6) [1]

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term. (%)=percentage of subjects among total N. [#] is the number of individual occurrences of the TEAE.

Note: A subject may be counted more than once according to the relationship of the TEAEs.

Note: Drug-related TEAEs are those with relationship other than not related and unlikely (including missing relationship information).

Reference: Subject Data Listings 5.1.1 and 5.1.2

表 2.3-10　治験薬との因果関係別の有害事象：SS（続き）

Table 10.7.1

Incidence of TEAEs by Relationship to Study Medication per the Investigator

Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Drug Relationship	N = 39 n (%) [#]
初期不眠症	Any	1 (2.6) [1]
	Related	1 (2.6) [1]
	Not Related	0
不眠症	Any	1 (2.6) [1]
	Related	0
	Not Related	1 (2.6) [1]
気分動揺	Any	1 (2.6) [1]
	Related	0
	Not Related	1 (2.6) [1]
パニック発作	Any	1 (2.6) [1]
	Related	0
	Not Related	1 (2.6) [1]
睡眠障害	Any	1 (2.6) [1]
	Related	1 (2.6) [1]
	Not Related	0

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term. (%)=percentage of subjects among total N. [#] is the number of individual occurrences of the TEAE.

Note: A subject may be counted more than once according to the relationship of the TEAEs.

Note: Drug-related TEAEs are those with relationship other than not related and unlikely (including missing relationship information).

Reference: Subject Data Listings 5.1.1 and 5.1.2

表 2.3-10　治験薬との因果関係別の有害事象：SS（続き）

Table 10.7.1
Incidence of TEAEs by Relationship to Study Medication per the Investigator
Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Drug Relationship	N = 39 n (%) [#]
腎および尿路障害	Any	1 (2.6) [3]
	Related	1 (2.6) [2]
	Not Related	1 (2.6) [1]
尿意切迫	Any	1 (2.6) [1]
	Related	0
	Not Related	1 (2.6) [1]
蛋白尿	Any	1 (2.6) [1]
	Related	1 (2.6) [1]
	Not Related	0
腎不全	Any	1 (2.6) [1]
	Related	1 (2.6) [1]
	Not Related	0
生殖系および乳房障害	Any	3 (7.7) [6]
	Related	0
	Not Related	3 (7.7) [6]

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term. (%)=percentage of subjects among total N. [#] is the number of individual occurrences of the TEAE.
Note: A subject may be counted more than once according to the relationship of the TEAEs.
Note: Drug-related TEAEs are those with relationship other than not related and unlikely (including missing relationship information).
Reference: Subject Data Listings 5.1.1 and 5.1.2

表 2.3-10　治験薬との因果関係別の有害事象：SS（続き）

Table 10.7.1

Incidence of TEAEs by Relationship to Study Medication per the Investigator

Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Drug Relationship	N = 39 n (%) [#]
精巣上体嚢胞	Any	1 (2.6) [1]
	Related	0
	Not Related	1 (2.6) [1]
精巣上体炎	Any	1 (2.6) [1]
	Related	0
	Not Related	1 (2.6) [1]
月経過多	Any	1 (2.6) [1]
	Related	0
	Not Related	1 (2.6) [1]
希発月経	Any	1 (2.6) [1]
	Related	0
	Not Related	1 (2.6) [1]
卵巣嚢胞	Any	1 (2.6) [1]
	Related	0
	Not Related	1 (2.6) [1]

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term. (%)=percentage of subjects among total N. [#] is the number of individual occurrences of the TEAE.

Note: A subject may be counted more than once according to the relationship of the TEAEs.

Note: Drug-related TEAEs are those with relationship other than not related and unlikely (including missing relationship information).

Reference: Subject Data Listings 5.1.1 and 5.1.2

表 2.3-10　治験薬との因果関係別の有害事象：SS（続き）

Table 10.7.1
Incidence of TEAEs by Relationship to Study Medication per the Investigator
Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Drug Relationship	N = 39 n (%) [#]
骨盤痛	Any	1 (2.6) [1]
	Related	0
	Not Related	1 (2.6) [1]
呼吸器、胸郭および縦隔障害	Any	12 (30.8) [18]
	Related	1 (2.6) [1]
	Not Related	11 (28.2) [17]
呼吸困難	Any	4 (10.3) [4]
	Related	0
	Not Related	4 (10.3) [4]
呼吸障害	Any	2 (5.1) [2]
	Related	0
	Not Related	2 (5.1) [2]
気管支反応性亢進	Any	1 (2.6) [1]
	Related	0
	Not Related	1 (2.6) [1]

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term. (%)=percentage of subjects among total N. [#] is the number of individual occurrences of the TEAE.
Note: A subject may be counted more than once according to the relationship of the TEAEs.
Note: Drug-related TEAEs are those with relationship other than not related and unlikely (including missing relationship information).
Reference: Subject Data Listings 5.1.1 and 5.1.2

表 2.3-10　治験薬との因果関係別の有害事象：SS（続き）

Table 10.7.1

Incidence of TEAEs by Relationship to Study Medication per the Investigator

Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Drug Relationship	N = 39 n (%) [#]
気管支痙攣	Any	1 (2.6) [1]
	Related	0
	Not Related	1 (2.6) [1]
咳嗽	Any	1 (2.6) [1]
	Related	0
	Not Related	1 (2.6) [1]
鼻出血	Any	1 (2.6) [1]
	Related	0
	Not Related	1 (2.6) [1]
しゃっくり	Any	1 (2.6) [1]
	Related	1 (2.6) [1]
	Not Related	0
低換気	Any	1 (2.6) [1]
	Related	0
	Not Related	1 (2.6) [1]

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term. (%)=percentage of subjects among total N. [#] is the number of individual occurrences of the TEAE.

Note: A subject may be counted more than once according to the relationship of the TEAEs.

Note: Drug-related TEAEs are those with relationship other than not related and unlikely (including missing relationship information).

Reference: Subject Data Listings 5.1.1 and 5.1.2

表 2.3-10　治験薬との因果関係別の有害事象：SS（続き）

Table 10.7.1

Incidence of TEAEs by Relationship to Study Medication per the Investigator

Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Drug Relationship	N = 39 n (%) [#]
肺障害	Any	1 (2.6) [1]
	Related	0
	Not Related	1 (2.6) [1]
胸水	Any	1 (2.6) [1]
	Related	0
	Not Related	1 (2.6) [1]
副鼻腔うっ血	Any	1 (2.6) [2]
	Related	0
	Not Related	1 (2.6) [2]
くしゃみ	Any	1 (2.6) [1]
	Related	0
	Not Related	1 (2.6) [1]
気管狭窄	Any	1 (2.6) [1]
	Related	0
	Not Related	1 (2.6) [1]

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term. (%)=percentage of subjects among total N. [#] is the number of individual occurrences of the TEAE.

Note: A subject may be counted more than once according to the relationship of the TEAEs.

Note: Drug-related TEAEs are those with relationship other than not related and unlikely (including missing relationship information).

Reference: Subject Data Listings 5.1.1 and 5.1.2

表 2.3-10　治験薬との因果関係別の有害事象：SS（続き）

Table 10.7.1

Incidence of TEAEs by Relationship to Study Medication per the Investigator

Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Drug Relationship	N = 39 n (%) [#]
皮膚および皮下組織障害	Any	5 (12.8) [8]
	Related	2 (5.1) [4]
	Not Related	4 (10.3) [4]
脱毛症	Any	2 (5.1) [2]
	Related	1 (2.6) [1]
	Not Related	1 (2.6) [1]
ざ瘡	Any	1 (2.6) [1]
	Related	0
	Not Related	1 (2.6) [1]
皮膚嚢腫	Any	1 (2.6) [1]
	Related	0
	Not Related	1 (2.6) [1]
寝汗	Any	1 (2.6) [1]
	Related	0
	Not Related	1 (2.6) [1]

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term. (%)=percentage of subjects among total N. [#] is the number of individual occurrences of the TEAE.

Note: A subject may be counted more than once according to the relationship of the TEAEs.

Note: Drug-related TEAEs are those with relationship other than not related and unlikely (including missing relationship information).

Reference: Subject Data Listings 5.1.1 and 5.1.2

表 2.3-10　治験薬との因果関係別の有害事象：SS（続き）

Table 10.7.1

Incidence of TEAEs by Relationship to Study Medication per the Investigator

Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	Drug Relationship	N = 39 n (%) [#]
そう痒症	Any	1 (2.6) [1]
	Related	1 (2.6) [1]
	Not Related	0
発疹	Any	1 (2.6) [1]
	Related	1 (2.6) [1]
	Not Related	0
皮膚障害	Any	1 (2.6) [1]
	Related	1 (2.6) [1]
	Not Related	0

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term. (%)=percentage of subjects among total N. [#] is the number of individual occurrences of the TEAE.

Note: A subject may be counted more than once according to the relationship of the TEAEs.

Note: Drug-related TEAEs are those with relationship other than not related and unlikely (including missing relationship information).

Reference: Subject Data Listings 5.1.1 and 5.1.2

2.3.3.2.1.4 死亡

本治験では、死亡は認められなかった。

2.3.3.2.1.5 重篤な有害事象

本治験の治験薬投与開始後に認められた重篤な有害事象を表 2.3-11 に示した。

本治験では、治験薬投与開始後に重篤な有害事象が 3 例（7.7%）に認められた。

表 2.3-11　重篤な有害事象：SS

Table 10.4.1
Incidence of Serious TEAEs
Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	N = 39 n (%) [#]
Any System Organ Class	3 (7.7) [4]
感染症および寄生虫症	1 (2.6) [1]
肺炎	1 (2.6) [1]
神経系障害	2 (5.1) [2]
痙攣	1 (2.6) [1]
片頭痛	1 (2.6) [1]
精神障害	1 (2.6) [1]
異常行動	1 (2.6) [1]

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term. (%)=percentage of subjects among total N. [#] is the number of individual occurrences of the TEAE.
Reference: Subject Data Listings 5.1.1 and 5.1.2

2.3.3.2.1.6 治験薬の投与中止に至った有害事象

本治験で認められた治験薬の投与中止に至った有害事象を表 2.3-12 に示した。

本治験では、治験薬の投与中止に至った有害事象が 2 例（異常行動及び錯乱状態、各 1 例）に認められた。いずれの事象も発作増加との関連は認められなかった。

表 2.3-12　治験薬の投与中止に至った有害事象：SS

Table 10.5.1
Incidence of TEAEs Leading to Discontinuation
Population: Safety Set

MedDRA (Version 9.1) System Organ Class Preferred Term	N = 39 n (%) [#]
Any System Organ Class	2 (5.1) [2]
精神障害	2 (5.1) [2]
異常行動	1 (2.6) [1]
錯乱状態	1 (2.6) [1]

Note: n=number of subjects reporting at least one TEAE within System Organ Class/Preferred Term. (%)=percentage of subjects among total N. [#] is the number of individual occurrences of the TEAE.
Reference: Subject Data Listings 5.2.1 and 5.1.2

2.3.3.2.1.7 その他の注目すべき有害事象

本治験では、治験薬投与開始後に認められた有害事象のうち、その他の注目すべき有害事象として肝毒性関連、自殺関連、心臓障害関連、並びに失神及び意識消失の有害事象の有無を確認した。

本治験では、その他の注目すべき有害事象は認められなかった。

2.3.3.2.1.8 発作に関連する有害事象

強直間代発作に関連する有害事象（医師記載用語：小発作てんかん及びミオクロニー発作）を除き、本治験で認められた有害事象は、部分発作を有するてんかん患者を対象とした臨床試験で認められた有害事象と類似していた。

本治験では、全体的に欠神発作又はミオクロニー発作の増加に関連する有害事象の発現は少なく、小発作てんかん（医師記載用語：欠神発作増加）及びミオクローヌス（医師記載用語：ミオクロニー性単収縮増加）が各 1 例のみに認められた。小発作てんかんは、800 mg/日投与時に発現し、投与量を減量して消失した。本被験者は、Prospective ベースライン期間の 28 日あたりの欠神発作発現日数が 14 日であった。ミオクローヌスは、300 mg/日投与時に発現した。本被験者は、Prospective ベースライン期間に対する治療期間の 28 日あたりのミオクロニー発作発現日数が大幅に減少した（Prospective ベースライン期間 : 27 日、治療期間 : 0.49 日）。いずれの事象も非重篤な有害事象で、消失した。また、治験薬の投与中止に至った有害事象ではなかった。

2.3.3.3 その他の評価項目

本治験でのベースライン及び各来院時の測定値、並びにベースラインからの変化量について、血液学的検査を表 2.3-13 に、血液生化学検査を表 2.3-14 に示した。また、バイタルサイン（体重を含む）のベースライン及び各来院時の測定値、並びにベースラインからの変化量を表 2.3-15 に示した。

臨床検査値、12 誘導心電図、バイタルサイン、並びに身体所見及び神経学的検査の結果から、ラコサミド投与に起因すると考えられる臨床的に重要な所見は認められなかった。

本治験では、4 例に体重増加の有害事象が認められた。いずれの事象も非重篤な有害事象で、治験薬の投与中止に至った有害事象ではなかった。体重が減少した被験者よりも増加した被験者が多く認められたが、本治験は非盲検及び非対照の臨床試験であることから、臨床的な関連性は不明である。

表 2.3-13　血液学的検査の測定値及びベースラインからの変化量：SS

Table 11.1.1
Laboratory Parameters (Hematology) Summary
Population: Safety Set

		Actual Value						Change From Baseline				
Visit	n	Mean	SD	Median	Min	Max	n	Mean	SD	Median	Min	Max
Lab Parameter: Erythrocytes (T/L)												
Baseline	39	4.55	0.35	4.57	3.7	5.5						
Visit 3 (Week 8)	37	4.47	0.36	4.51	3.6	5.3	37	-0.10	0.19	-0.15	-0.5	0.4
Visit 5 (Week 24)	35	4.52	0.37	4.56	3.6	5.2	35	-0.02	0.16	-0.01	-0.4	0.5
Termination Visit	38	4.58	0.40	4.52	3.6	5.5	38	0.04	0.20	0.05	-0.4	0.5
Final Clinic Visit	36	4.63	0.38	4.62	3.9	5.6	36	0.07	0.24	0.07	-0.5	0.6
Min Post-BL	39	4.36	0.35	4.39	3.6	5.1	39	-0.18	0.15	-0.20	-0.5	0.1
Max Post-BL	39	4.72	0.36	4.69	3.9	5.6	39	0.17	0.20	0.16	-0.3	0.6

Note: Baseline = last non-missing value prior to LCM treatment in study SP0961.
Note: Minimum (Maximum) Post-BL=Minimum (Maximum) of all reported values during the Treatment Period.
Reference: Subject Data Listing 6.1.1

表 2.3-13　血液学的検査の測定値及びベースラインからの変化量：SS（続き）

Table 11.1.1
Laboratory Parameters (Hematology) Summary
Population: Safety Set

	Actual Value					Change From Baseline				
Visit	n	Mean	SD	Median	Min	Max	n	Mean	SD	Median	Min	Max
Lab Parameter: Hematocrit (%)												
Baseline	39	42.15	3.74	41.80	34.1	50.2						
Visit 3 (Week 8)	37	41.66	3.64	41.00	34.6	49.2	37	-0.67	2.34	-0.80	-7.0	3.2
Visit 5 (Week 24)	35	41.34	3.91	41.10	34.4	48.8	35	-0.64	2.20	-0.70	-5.7	4.6
Termination Visit	38	42.48	4.33	42.00	35.1	55.5	38	0.29	2.59	0.30	-4.5	7.2
Final Clinic Visit	36	42.62	4.03	42.60	36.5	52.9	36	0.27	2.81	0.00	-4.9	6.5
Min Post-BL	39	40.10	3.30	40.10	34.4	47.3	39	-2.05	1.99	-1.50	-7.0	1.7
Max Post-BL	39	43.84	4.07	43.70	36.5	55.5	39	1.69	2.24	1.40	-2.1	7.2

Note: Baseline = last non-missing value prior to LCM treatment in study SP0961.
Note: Minimum (Maximum) Post-BL=Minimum (Maximum) of all reported values during the Treatment Period.
Reference: Subject Data Listing 6.1.1

表 2.3-13　血液学的検査の測定値及びベースラインからの変化量：SS（続き）

Table 11.1.1
Laboratory Parameters (Hematology) Summary
Population: Safety Set

		Actual Value						Change From Baseline				
Visit	n	Mean	SD	Median	Min	Max	n	Mean	SD	Median	Min	Max
Lab Parameter: Hemoglobin (g/L)												
Baseline	39	141.28	12.90	140.00	113.0	173.0						
Visit 3 (Week 8)	37	139.30	12.73	137.00	114.0	168.0	37	-2.51	7.10	-2.00	-21.0	10.0
Visit 5 (Week 24)	35	139.37	12.43	139.00	116.0	164.0	35	-1.29	6.04	0.00	-13.0	14.0
Termination Visit	38	139.89	13.58	138.00	116.0	170.0	38	-1.55	6.82	-1.00	-17.0	12.0
Final Clinic Visit	36	141.08	13.77	141.50	121.0	172.0	36	-0.86	8.18	-2.50	-19.0	15.0
Min Post-BL	39	134.85	11.82	135.00	114.0	158.0	39	-6.44	6.08	-6.00	-21.0	3.0
Max Post-BL	39	143.95	13.10	143.00	122.0	172.0	39	2.67	6.41	2.00	-13.0	15.0

Note: Baseline = last non-missing value prior to LCM treatment in study SP0961.
Note: Minimum (Maximum) Post-BL=Minimum (Maximum) of all reported values during the Treatment Period.
Reference: Subject Data Listing 6.1.1

表 2.3-13　血液学的検査の測定値及びベースラインからの変化量：SS（続き）

Table 11.1.1
Laboratory Parameters (Hematology) Summary
Population: Safety Set

	Actual Value					Change From Baseline				
Visit	n	Mean	SD	Median	Min	Max	n	Mean	SD	Median	Min	Max
Lab Parameter: Leukocytes (G/L)												
Baseline	39	6.73	2.12	6.40	3.1	12.0						
Visit 3 (Week 8)	37	6.42	1.81	6.20	3.6	11.8	37	-0.35	1.54	-0.40	-4.5	2.8
Visit 5 (Week 24)	35	6.41	1.57	6.30	3.4	10.1	35	-0.11	1.47	0.00	-5.4	2.8
Termination Visit	38	6.84	2.14	6.45	3.8	13.0	38	0.17	1.79	-0.05	-3.1	3.9
Final Clinic Visit	36	6.71	1.95	6.40	4.1	12.7	36	-0.11	1.53	-0.20	-4.1	2.9
Min Post-BL	39	5.75	1.55	5.90	3.4	10.7	39	-0.98	1.54	-1.10	-5.4	2.5
Max Post-BL	39	7.66	1.98	7.30	4.1	13.0	39	0.93	1.44	0.60	-2.4	3.9

Note: Baseline = last non-missing value prior to LCM treatment in study SP0961.
Note: Minimum (Maximum) Post-BL=Minimum (Maximum) of all reported values during the Treatment Period.
Reference: Subject Data Listing 6.1.1

表 2.3-13　血液学的検査の測定値及びベースラインからの変化量：SS（続き）

Table 11.1.1
Laboratory Parameters (Hematology) Summary
Population: Safety Set

		Actual Value						Change From Baseline				
Visit	n	Mean	SD	Median	Min	Max	n	Mean	SD	Median	Min	Max
Lab Parameter: Lymphocytes/Leukocytes (%)												
Baseline	39	32.35	10.84	32.80	12.2	67.1						
Visit 3 (Week 8)	37	33.61	8.23	32.80	19.8	53.4	37	0.28	7.31	0.10	-21.3	15.5
Visit 5 (Week 24)	35	30.96	7.50	31.00	13.9	45.8	35	-1.61	9.62	1.10	-28.1	15.1
Termination Visit	37	31.39	7.94	31.10	17.0	47.7	37	-1.09	9.23	0.40	-27.4	15.8
Final Clinic Visit	36	31.87	6.73	31.50	18.0	46.2	36	-0.46	9.28	-0.80	-31.7	18.1
Min Post-BL	39	26.65	6.94	25.90	13.9	41.9	39	-5.70	8.14	-4.30	-31.7	11.8
Max Post-BL	39	36.70	7.59	35.80	19.8	53.4	39	4.35	7.56	4.90	-21.3	18.1

Note: Baseline = last non-missing value prior to LCM treatment in study SP0961.
Note: Minimum (Maximum) Post-BL=Minimum (Maximum) of all reported values during the Treatment Period.
Reference: Subject Data Listing 6.1.1

表 2.3-13　血液学的検査の測定値及びベースラインからの変化量：SS（続き）

Table 11.1.1
Laboratory Parameters (Hematology) Summary
Population: Safety Set

		Actual Value						Change From Baseline				
Visit	n	Mean	SD	Median	Min	Max	n	Mean	SD	Median	Min	Max
Lab Parameter: Basophils/Leukocytes (%)												
Baseline	39	0.35	0.17	0.40	0.1	0.8						
Visit 3 (Week 8)	37	0.36	0.17	0.30	0.1	0.8	37	0.01	0.21	0.00	-0.5	0.5
Visit 5 (Week 24)	35	0.38	0.16	0.40	0.1	0.9	35	0.04	0.21	0.00	-0.4	0.5
Termination Visit	37	0.41	0.22	0.40	0.0	1.1	37	0.05	0.22	0.10	-0.4	0.5
Final Clinic Visit	36	0.39	0.29	0.30	0.1	1.5	36	0.05	0.24	0.00	-0.4	0.9
Min Post-BL	39	0.24	0.15	0.20	0.0	0.8	39	-0.11	0.17	-0.10	-0.6	0.2
Max Post-BL	39	0.54	0.26	0.50	0.2	1.5	39	0.18	0.24	0.20	-0.4	0.9

Note: Baseline = last non-missing value prior to LCM treatment in study SP0961.
Note: Minimum (Maximum) Post-BL=Minimum (Maximum) of all reported values during the Treatment Period.
Reference: Subject Data Listing 6.1.1

表 2.3-13　血液学的検査の測定値及びベースラインからの変化量：SS（続き）

Table 11.1.1
Laboratory Parameters (Hematology) Summary
Population: Safety Set

	Actual Value					Change From Baseline				
Visit	n	Mean	SD	Median	Min	Max	n	Mean	SD	Median	Min	Max
Lab Parameter: Eosinophils (G/L)												
Baseline	39	0.16	0.20	0.10	0.0	1.0						
Visit 3 (Week 8)	37	0.13	0.15	0.10	0.0	0.7	37	-0.03	0.11	0.00	-0.3	0.2
Visit 5 (Week 24)	35	0.16	0.21	0.10	0.0	1.1	35	0.02	0.13	0.00	-0.2	0.6
Termination Visit	38	0.13	0.15	0.10	0.0	0.7	38	-0.02	0.12	0.00	-0.4	0.4
Final Clinic Visit	36	0.17	0.26	0.10	0.0	1.5	36	0.01	0.17	0.00	-0.4	0.7
Min Post-BL	39	0.09	0.13	0.10	0.0	0.6	39	-0.07	0.10	-0.10	-0.4	0.1
Max Post-BL	39	0.24	0.28	0.20	0.0	1.5	39	0.08	0.17	0.10	-0.2	0.7

Note: Baseline = last non-missing value prior to LCM treatment in study SP0961.
Note: Minimum (Maximum) Post-BL=Minimum (Maximum) of all reported values during the Treatment Period.
Reference: Subject Data Listing 6.1.1

表 2.3-13　血液学的検査の測定値及びベースラインからの変化量：SS（続き）

Table 11.1.1
Laboratory Parameters (Hematology) Summary
Population: Safety Set

		Actual Value						Change From Baseline				
Visit	n	Mean	SD	Median	Min	Max	n	Mean	SD	Median	Min	Max
Lab Parameter: Eosinophils/Leukocytes (%)												
Baseline	39	2.26	2.48	1.50	0.0	12.5						
Visit 3 (Week 8)	37	2.16	2.19	1.40	0.1	10.5	37	-0.09	1.12	0.00	-2.3	2.9
Visit 5 (Week 24)	35	2.11	2.33	1.40	0.0	11.7	35	0.02	1.59	0.10	-3.0	7.1
Termination Visit	37	1.97	2.05	1.30	0.3	9.5	37	-0.38	1.71	-0.30	-6.2	5.4
Final Clinic Visit	36	2.42	2.57	1.60	0.0	13.9	36	0.14	2.03	0.10	-5.3	5.1
Min Post-BL	39	1.26	1.48	0.90	0.0	7.4	39	-1.00	1.40	-0.60	-6.2	0.8
Max Post-BL	39	3.17	2.89	2.30	0.1	13.9	39	0.91	1.83	0.70	-2.1	7.1

Note: Baseline = last non-missing value prior to LCM treatment in study SP0961.
Note: Minimum (Maximum) Post-BL=Minimum (Maximum) of all reported values during the Treatment Period.
Reference: Subject Data Listing 6.1.1

表 2.3-13　血液学的検査の測定値及びベースラインからの変化量：SS（続き）

Table 11.1.1
Laboratory Parameters (Hematology) Summary
Population: Safety Set

		Actual Value						Change From Baseline				
Visit	n	Mean	SD	Median	Min	Max	n	Mean	SD	Median	Min	Max
Lab Parameter: Monocytes/Leukocytes (%)												
Baseline	39	6.08	3.24	5.40	2.2	18.9						
Visit 3 (Week 8)	37	6.17	2.91	5.70	2.0	14.1	37	0.07	2.08	0.10	-4.8	5.7
Visit 5 (Week 24)	35	5.81	2.55	5.30	1.9	11.5	35	-0.06	1.54	-0.10	-3.1	3.1
Termination Visit	37	6.54	3.01	5.90	1.7	14.4	37	0.35	3.05	0.70	-11.8	6.4
Final Clinic Visit	36	6.55	2.96	6.30	0.6	12.8	36	0.81	2.46	0.55	-3.5	5.6
Min Post-BL	39	4.78	2.36	4.30	0.6	10.8	39	-1.30	2.33	-1.10	-11.8	2.3
Max Post-BL	39	7.92	3.01	7.60	2.6	14.4	39	1.84	2.26	1.90	-4.8	6.4

Note: Baseline = last non-missing value prior to LCM treatment in study SP0961.
Note: Minimum (Maximum) Post-BL=Minimum (Maximum) of all reported values during the Treatment Period.
Reference: Subject Data Listing 6.1.1

表 2.3-13　血液学的検査の測定値及びベースラインからの変化量：SS（続き）

Table 11.1.1
Laboratory Parameters (Hematology) Summary
Population: Safety Set

		Actual Value						Change From Baseline				
Visit	n	Mean	SD	Median	Min	Max	n	Mean	SD	Median	Min	Max
Lab Parameter: Neutrophils (G/L)												
Baseline	39	4.13	1.91	3.80	0.6	9.9						
Visit 3 (Week 8)	37	3.81	1.57	3.70	1.7	8.7	37	-0.30	1.45	-0.30	-4.5	2.4
Visit 5 (Week 24)	35	3.97	1.38	3.70	1.8	8.1	35	-0.03	1.54	0.10	-5.3	2.6
Termination Visit	38	4.21	1.75	3.90	1.8	7.8	38	0.13	1.65	-0.05	-2.9	4.3
Final Clinic Visit	36	4.00	1.42	3.75	2.1	7.9	36	-0.20	1.45	-0.20	-4.4	2.9
Min Post-BL	39	3.28	1.19	3.20	1.7	6.6	39	-0.85	1.39	-0.70	-5.3	2.1
Max Post-BL	39	4.93	1.62	4.80	2.5	8.7	39	0.80	1.41	0.80	-2.7	4.3

Note: Baseline = last non-missing value prior to LCM treatment in study SP0961.
Note: Minimum (Maximum) Post-BL=Minimum (Maximum) of all reported values during the Treatment Period.
Reference: Subject Data Listing 6.1.1

表 2.3-13　血液学的検査の測定値及びベースラインからの変化量：SS（続き）

Table 11.1.1
Laboratory Parameters (Hematology) Summary
Population: Safety Set

		Actual Value						Change From Baseline				
Visit	n	Mean	SD	Median	Min	Max	n	Mean	SD	Median	Min	Max
Lab Parameter: Neutrophils/Leukocytes (%)												
Baseline	39	58.96	13.04	61.60	17.1	84.2						
Visit 3 (Week 8)	37	57.70	9.82	57.10	38.5	76.0	37	-0.27	8.96	-0.90	-16.7	25.3
Visit 5 (Week 24)	35	60.73	8.64	61.10	44.4	80.8	35	1.62	10.97	-2.00	-17.0	32.3
Termination Visit	37	59.70	9.52	58.70	42.6	77.2	37	1.08	11.41	0.80	-22.6	35.6
Final Clinic Visit	36	58.77	8.28	58.45	40.5	77.9	36	-0.53	11.90	0.50	-22.4	40.9
Min Post-BL	39	53.64	8.52	53.80	38.5	76.0	39	-5.32	9.58	-6.00	-22.6	25.3
Max Post-BL	39	65.63	8.54	66.20	45.7	80.8	39	6.67	9.98	7.20	-15.9	40.9

Note: Baseline = last non-missing value prior to LCM treatment in study SP0961.
Note: Minimum (Maximum) Post-BL=Minimum (Maximum) of all reported values during the Treatment Period.
Reference: Subject Data Listing 6.1.1

表 2.3-13　血液学的検査の測定値及びベースラインからの変化量：SS（続き）

Table 11.1.1
Laboratory Parameters (Hematology) Summary
Population: Safety Set

		Actual Value						Change From Baseline				
Visit	n	Mean	SD	Median	Min	Max	n	Mean	SD	Median	Min	Max
Lab Parameter: Platelets (G/L)												
Baseline	39	229.26	62.48	223.00	113.0	400.0						
Visit 3 (Week 8)	37	230.38	60.29	233.00	126.0	362.0	37	-1.86	32.15	-3.00	-58.0	74.0
Visit 5 (Week 24)	35	235.31	82.35	226.00	121.0	572.0	35	9.26	62.62	8.00	-75.0	315.0
Termination Visit	38	240.50	60.44	233.50	136.0	381.0	38	10.68	47.48	19.00	-131.0	107.0
Final Clinic Visit	36	238.03	57.70	231.00	158.0	405.0	36	6.47	44.69	3.00	-76.0	131.0
Min Post-BL	39	208.54	49.80	201.00	121.0	290.0	39	-20.72	33.32	-20.00	-131.0	45.0
Max Post-BL	39	266.64	79.54	261.00	163.0	572.0	39	37.38	58.46	32.00	-42.0	315.0

Note: Baseline = last non-missing value prior to LCM treatment in study SP0961.
Note: Minimum (Maximum) Post-BL=Minimum (Maximum) of all reported values during the Treatment Period.
Reference: Subject Data Listing 6.1.1

表 2.3-14　血液生化学検査の測定値及びベースラインからの変化量：SS

Table 11.2.1
Laboratory Parameters (Chemistry) Summary
Population: Safety Set

	Actual Value					Change From Baseline				
Visit	n	Mean	SD	Median	Min	Max	n	Mean	SD	Median	Min	Max
Lab Parameter: Alanine Aminotransferase (U/L)												
Baseline	39	24.67	17.35	19.00	9.0	96.0						
Visit 3 (Week 8)	38	24.24	17.08	19.50	9.0	95.0	38	-0.37	9.24	0.00	-30.0	19.0
Visit 5 (Week 24)	34	22.59	13.57	20.00	8.0	72.0	34	-2.85	9.13	-1.00	-27.0	12.0
Termination Visit	39	30.54	40.73	19.00	9.0	258.0	39	5.87	40.52	1.00	-46.0	242.0
Final Clinic Visit	36	23.36	16.95	18.00	8.0	97.0	36	-2.14	13.16	-1.50	-34.0	31.0
Min Post-BL	39	18.31	11.14	15.00	8.0	64.0	39	-6.36	11.04	-3.00	-46.0	12.0
Max Post-BL	39	35.44	41.40	24.00	11.0	258.0	39	10.77	39.03	3.00	-15.0	242.0

Note: Baseline = last non-missing value prior to LCM treatment in study SP0961.
Note: Minimum (Maximum) Post-BL=Minimum (Maximum) of all reported values during the Treatment Period.
Reference: Subject Data Listing 6.2.1

表 2.3-14　血液生化学検査の測定値及びベースラインからの変化量：SS（続き）

Table 11.2.1
Laboratory Parameters (Chemistry) Summary
Population: Safety Set

	Actual Value					Change From Baseline				
Visit	n	Mean	SD	Median	Min	Max	n	Mean	SD	Median	Min	Max
Lab Parameter: Aspartate Aminotransferase (U/L)												
Baseline	39	24.62	13.30	22.00	7.0	86.0						
Visit 3 (Week 8)	38	24.08	12.02	21.00	12.0	68.0	38	-0.37	6.91	1.00	-18.0	13.0
Visit 5 (Week 24)	34	23.21	9.47	21.00	13.0	52.0	34	-1.97	9.37	-1.00	-40.0	19.0
Termination Visit	39	26.05	19.85	20.00	8.0	126.0	39	1.44	19.60	0.00	-37.0	107.0
Final Clinic Visit	36	22.33	11.35	20.50	7.0	71.0	36	-2.72	10.10	-0.50	-40.0	21.0
Min Post-BL	39	19.41	8.71	17.00	7.0	52.0	39	-5.21	8.36	-3.00	-40.0	6.0
Max Post-BL	39	30.77	20.50	24.00	14.0	126.0	39	6.15	18.30	5.00	-18.0	107.0

Note: Baseline = last non-missing value prior to LCM treatment in study SP0961.
Note: Minimum (Maximum) Post-BL=Minimum (Maximum) of all reported values during the Treatment Period.
Reference: Subject Data Listing 6.2.1

表 2.3-14　血液生化学検査の測定値及びベースラインからの変化量：SS（続き）

Table 11.2.1
Laboratory Parameters (Chemistry) Summary
Population: Safety Set

		Actual Value						Change From Baseline				
Visit	n	Mean	SD	Median	Min	Max	n	Mean	SD	Median	Min	Max
Lab Parameter: Alkaline Phosphatase (U/L)												
Baseline	39	88.28	34.14	80.00	38.0	230.0						
Visit 3 (Week 8)	38	86.55	36.80	77.00	45.0	252.0	38	-1.92	10.58	-4.00	-32.0	22.0
Visit 5 (Week 24)	35	86.31	34.62	80.00	41.0	235.0	35	-1.94	12.97	-2.00	-41.0	21.0
Termination Visit	39	90.15	34.69	81.00	44.0	224.0	39	1.87	18.66	0.00	-50.0	63.0
Final Clinic Visit	36	89.64	34.18	82.00	44.0	223.0	36	-0.17	16.67	-2.00	-42.0	58.0
Min Post-BL	39	79.08	31.19	74.00	41.0	223.0	39	-9.21	11.16	-8.00	-50.0	14.0
Max Post-BL	39	96.82	37.17	90.00	50.0	252.0	39	8.54	15.44	6.00	-26.0	63.0

Note: Baseline = last non-missing value prior to LCM treatment in study SP0961.
Note: Minimum (Maximum) Post-BL=Minimum (Maximum) of all reported values during the Treatment Period.
Reference: Subject Data Listing 6.2.1

表 2.3-14　血液生化学検査の測定値及びベースラインからの変化量：SS（続き）

Table 11.2.1
Laboratory Parameters (Chemistry) Summary
Population: Safety Set

	Actual Value					Change From Baseline				
Visit	n	Mean	SD	Median	Min	Max	n	Mean	SD	Median	Min	Max
Lab Parameter: Gamma Glutamyl Transferase (U/L)												
Baseline	39	45.69	58.52	25.00	6.0	304.0						
Visit 3 (Week 8)	38	48.00	62.63	27.00	5.0	368.0	38	1.87	22.69	3.00	-113.0	64.0
Visit 5 (Week 24)	35	40.71	56.35	24.00	8.0	323.0	35	-6.14	32.39	1.00	-179.0	19.0
Termination Visit	39	47.18	60.61	26.00	8.0	337.0	39	1.49	35.53	3.00	-179.0	67.0
Final Clinic Visit	36	46.22	57.65	26.50	7.0	320.0	36	-2.42	33.94	0.50	-178.0	44.0
Min Post-BL	39	36.95	53.28	20.00	5.0	320.0	39	-8.74	30.53	-2.00	-179.0	17.0
Max Post-BL	39	56.33	64.08	31.00	9.0	368.0	39	10.64	27.92	7.00	-113.0	67.0

Note: Baseline = last non-missing value prior to LCM treatment in study SP0961.
Note: Minimum (Maximum) Post-BL=Minimum (Maximum) of all reported values during the Treatment Period.
Reference: Subject Data Listing 6.2.1

表 2.3-14　血液生化学検査の測定値及びベースラインからの変化量：SS（続き）

Table 11.2.1
Laboratory Parameters (Chemistry) Summary
Population: Safety Set

	Actual Value					Change From Baseline				
Visit	n	Mean	SD	Median	Min	Max	n	Mean	SD	Median	Min	Max
Lab Parameter: Bilirubin (umol/L)												
Baseline	39	6.40	3.72	5.13	1.7	22.2						
Visit 3 (Week 8)	38	6.12	3.22	5.13	1.7	17.1	38	-0.32	2.14	0.00	-5.1	3.4
Visit 5 (Week 24)	35	5.82	2.69	5.13	1.7	12.0	35	-0.73	2.88	0.00	-10.3	3.4
Termination Visit	39	5.39	2.90	5.13	1.7	17.1	39	-1.01	2.77	-1.71	-12.0	5.1
Final Clinic Visit	36	6.56	3.74	5.99	3.4	23.9	36	0.38	2.17	0.00	-3.4	5.1
Min Post-BL	39	4.39	2.28	3.42	1.7	12.0	39	-2.02	2.71	-1.71	-12.0	1.7
Max Post-BL	39	7.46	3.69	6.84	3.4	23.9	39	1.05	1.95	1.71	-3.4	5.1

Note: Baseline = last non-missing value prior to LCM treatment in study SP0961.
Note: Minimum (Maximum) Post-BL=Minimum (Maximum) of all reported values during the Treatment Period.
Reference: Subject Data Listing 6.2.1

表 2.3-14　血液生化学検査の測定値及びベースラインからの変化量：SS（続き）

Table 11.2.1
Laboratory Parameters (Chemistry) Summary
Population: Safety Set

		Actual Value						Change From Baseline				
Visit	n	Mean	SD	Median	Min	Max	n	Mean	SD	Median	Min	Max
Lab Parameter: Protein (g/L)												
Baseline	39	70.69	4.21	70.00	61.0	80.0						
Visit 3 (Week 8)	38	70.61	4.04	71.00	63.0	82.0	38	-0.08	4.33	0.00	-9.0	10.0
Visit 5 (Week 24)	35	70.86	4.75	71.00	61.0	84.0	35	0.23	3.66	0.00	-8.0	7.0
Termination Visit	39	70.64	3.55	71.00	62.0	77.0	39	-0.05	4.24	0.00	-9.0	10.0
Final Clinic Visit	36	70.92	3.83	70.50	63.0	79.0	36	0.39	4.16	0.00	-8.0	9.0
Min Post-BL	39	68.23	3.31	68.00	61.0	74.0	39	-2.46	3.55	-3.00	-9.0	4.0
Max Post-BL	39	73.69	3.73	74.00	65.0	84.0	39	3.00	3.60	3.00	-6.0	10.0

Note: Baseline = last non-missing value prior to LCM treatment in study SP0961.
Note: Minimum (Maximum) Post-BL=Minimum (Maximum) of all reported values during the Treatment Period.
Reference: Subject Data Listing 6.2.1

表 2.3-14　血液生化学検査の測定値及びベースラインからの変化量：SS（続き）

Table 11.2.1
Laboratory Parameters (Chemistry) Summary
Population: Safety Set

	Actual Value					Change From Baseline				
Visit	n	Mean	SD	Median	Min	Max	n	Mean	SD	Median	Min	Max
Lab Parameter: Albumin (g/L)												
Baseline	39	45.08	2.65	44.00	41.0	51.0						
Visit 3 (Week 8)	38	45.50	2.26	45.50	41.0	50.0	38	0.37	2.45	0.00	-5.0	5.0
Visit 5 (Week 24)	35	45.31	2.89	45.00	39.0	51.0	35	0.34	2.39	0.00	-5.0	7.0
Termination Visit	39	45.03	2.51	45.00	41.0	49.0	39	-0.05	2.51	0.00	-4.0	5.0
Final Clinic Visit	36	44.97	2.60	45.00	38.0	50.0	36	-0.06	2.54	0.00	-6.0	5.0
Min Post-BL	39	43.59	2.30	44.00	38.0	48.0	39	-1.49	2.08	-2.00	-6.0	3.0
Max Post-BL	39	47.00	2.05	47.00	43.0	51.0	39	1.92	2.18	1.00	-4.0	7.0

Note: Baseline = last non-missing value prior to LCM treatment in study SP0961.
Note: Minimum (Maximum) Post-BL=Minimum (Maximum) of all reported values during the Treatment Period.
Reference: Subject Data Listing 6.2.1

表 2.3-14　血液生化学検査の測定値及びベースラインからの変化量：SS（続き）

Table 11.2.1
Laboratory Parameters (Chemistry) Summary
Population: Safety Set

	Actual Value					Change From Baseline				
Visit	n	Mean	SD	Median	Min	Max	n	Mean	SD	Median	Min	Max
Lab Parameter: Blood Urea Nitrogen (mmol/L)												
Baseline	39	4.71	1.45	4.64	2.9	10.4						
Visit 3 (Week 8)	38	4.62	1.22	4.64	2.1	7.9	38	0.06	1.26	0.00	-2.1	3.9
Visit 5 (Week 24)	35	4.82	1.73	4.64	2.5	11.8	35	0.12	1.34	0.00	-2.9	4.6
Termination Visit	39	4.54	1.05	4.64	2.9	6.4	39	-0.17	1.52	0.00	-5.7	2.5
Final Clinic Visit	36	4.66	1.44	4.28	2.5	9.3	36	-0.10	1.47	0.00	-4.3	2.5
Min Post-BL	39	3.84	0.90	3.57	2.1	5.7	39	-0.88	1.30	-0.71	-5.7	1.1
Max Post-BL	39	5.53	1.57	5.36	2.9	11.8	39	0.81	1.38	0.71	-1.8	4.6

Note: Baseline = last non-missing value prior to LCM treatment in study SP0961.
Note: Minimum (Maximum) Post-BL=Minimum (Maximum) of all reported values during the Treatment Period.
Reference: Subject Data Listing 6.2.1

表 2.3-14　血液生化学検査の測定値及びベースラインからの変化量：SS（続き）

Table 11.2.1
Laboratory Parameters (Chemistry) Summary
Population: Safety Set

	Actual Value					Change From Baseline				
Visit	n	Mean	SD	Median	Min	Max	n	Mean	SD	Median	Min	Max
Lab Parameter: Creatinine (umol/L)												
Baseline	39	78.06	16.90	79.56	44.2	120.2						
Visit 3 (Week 8)	38	77.65	14.35	79.56	44.2	114.9	38	-0.14	13.37	0.00	-44.2	26.5
Visit 5 (Week 24)	35	75.72	14.86	72.49	41.5	106.1	35	-1.92	11.29	-1.77	-35.4	17.7
Termination Visit	39	79.47	12.52	79.56	59.2	106.1	39	1.41	13.14	0.88	-43.3	28.3
Final Clinic Visit	36	79.29	14.09	77.79	53.9	117.6	36	0.86	13.52	3.54	-40.7	29.2
Min Post-BL	39	71.60	12.89	70.72	41.5	97.2	39	-6.46	11.26	-4.42	-44.2	8.8
Max Post-BL	39	84.82	13.62	83.98	59.2	117.6	39	6.75	12.38	7.07	-35.4	29.2

Note: Baseline = last non-missing value prior to LCM treatment in study SP0961.
Note: Minimum (Maximum) Post-BL=Minimum (Maximum) of all reported values during the Treatment Period.
Reference: Subject Data Listing 6.2.1

表 2.3-14　血液生化学検査の測定値及びベースラインからの変化量：SS（続き）

Table 11.2.1
Laboratory Parameters (Chemistry) Summary
Population: Safety Set

		Actual Value						Change From Baseline				
Visit	n	Mean	SD	Median	Min	Max	n	Mean	SD	Median	Min	Max
Lab Parameter: Bicarbonate (mmol/L)												
Baseline	39	27.46	3.73	28.00	17.0	35.0						
Visit 3 (Week 8)	38	27.11	3.51	27.50	20.0	33.0	38	-0.29	2.83	0.00	-8.0	7.0
Visit 5 (Week 24)	35	26.29	3.18	26.00	18.0	34.0	35	-1.37	3.00	-1.00	-7.0	9.0
Termination Visit	39	26.44	3.52	26.00	18.0	33.0	39	-1.03	2.95	-1.00	-10.0	9.0
Final Clinic Visit	36	26.22	3.41	27.00	16.0	34.0	36	-1.08	3.29	-1.00	-7.0	10.0
Min Post-BL	39	24.64	3.37	24.00	16.0	32.0	39	-2.82	2.92	-3.00	-10.0	7.0
Max Post-BL	39	28.38	2.98	28.00	21.0	34.0	39	0.92	2.54	1.00	-4.0	10.0

Note: Baseline = last non-missing value prior to LCM treatment in study SP0961.
Note: Minimum (Maximum) Post-BL=Minimum (Maximum) of all reported values during the Treatment Period.
Reference: Subject Data Listing 6.2.1

表 2.3-14　血液生化学検査の測定値及びベースラインからの変化量：SS（続き）

Table 11.2.1
Laboratory Parameters (Chemistry) Summary
Population: Safety Set

	Actual Value					Change From Baseline				
Visit	n	Mean	SD	Median	Min	Max	n	Mean	SD	Median	Min	Max
Lab Parameter: Calcium (mmol/L)												
Baseline	39	2.33	0.10	2.33	2.1	2.6						
Visit 3 (Week 8)	38	2.35	0.10	2.35	2.2	2.6	38	0.03	0.11	0.05	-0.2	0.3
Visit 5 (Week 24)	35	2.37	0.10	2.35	2.2	2.6	35	0.05	0.08	0.03	-0.1	0.2
Termination Visit	39	2.38	0.13	2.35	2.0	2.6	39	0.05	0.13	0.05	-0.4	0.3
Final Clinic Visit	36	2.39	0.12	2.35	2.2	2.7	36	0.06	0.10	0.05	-0.1	0.3
Min Post-BL	39	2.30	0.10	2.30	2.0	2.5	39	-0.03	0.11	-0.03	-0.4	0.3
Max Post-BL	39	2.44	0.10	2.43	2.3	2.7	39	0.11	0.09	0.13	-0.1	0.3

Note: Baseline = last non-missing value prior to LCM treatment in study SP0961.
Note: Minimum (Maximum) Post-BL=Minimum (Maximum) of all reported values during the Treatment Period.
Reference: Subject Data Listing 6.2.1

表 2.3-14　血液生化学検査の測定値及びベースラインからの変化量：SS（続き）

Table 11.2.1
Laboratory Parameters (Chemistry) Summary
Population: Safety Set

	Actual Value					Change From Baseline				
Visit	n	Mean	SD	Median	Min	Max	n	Mean	SD	Median	Min	Max
Lab Parameter: Chloride (mmol/L)												
Baseline	39	106.38	3.13	106.00	101.0	113.0						
Visit 3 (Week 8)	38	106.87	3.13	106.00	101.0	114.0	38	0.55	2.53	0.00	-4.0	5.0
Visit 5 (Week 24)	35	106.51	3.43	107.00	95.0	113.0	35	0.26	3.00	0.00	-8.0	7.0
Termination Visit	39	106.05	3.32	106.00	97.0	111.0	39	-0.33	2.80	0.00	-8.0	5.0
Final Clinic Visit	36	106.31	3.53	106.00	100.0	115.0	36	-0.19	2.77	-0.50	-6.0	5.0
Min Post-BL	39	104.56	3.44	105.00	95.0	111.0	39	-1.82	2.63	-2.00	-8.0	3.0
Max Post-BL	39	108.23	2.89	108.00	102.0	115.0	39	1.85	2.25	2.00	-3.0	7.0

Note: Baseline = last non-missing value prior to LCM treatment in study SP0961.
Note: Minimum (Maximum) Post-BL=Minimum (Maximum) of all reported values during the Treatment Period.
Reference: Subject Data Listing 6.2.1

表 2.3-14　血液生化学検査の測定値及びベースラインからの変化量：SS（続き）

Table 11.2.1
Laboratory Parameters (Chemistry) Summary
Population: Safety Set

	Actual Value					Change From Baseline				
Visit	n	Mean	SD	Median	Min	Max	n	Mean	SD	Median	Min	Max
Lab Parameter: Phosphate (mmol/L)												
Baseline	39	1.21	0.18	1.20	0.9	1.7						
Visit 3 (Week 8)	38	1.12	0.18	1.13	0.8	1.5	38	-0.09	0.23	-0.10	-0.5	0.5
Visit 5 (Week 24)	34	1.19	0.23	1.21	0.6	1.8	34	-0.04	0.20	-0.03	-0.5	0.5
Termination Visit	37	1.15	0.16	1.10	0.8	1.5	37	-0.06	0.24	-0.10	-0.6	0.5
Final Clinic Visit	36	1.17	0.17	1.16	0.9	1.6	36	-0.04	0.22	-0.06	-0.5	0.4
Min Post-BL	39	1.01	0.15	1.00	0.6	1.3	39	-0.20	0.20	-0.23	-0.6	0.3
Max Post-BL	39	1.30	0.17	1.32	0.9	1.8	39	0.09	0.21	0.10	-0.3	0.5

Note: Baseline = last non-missing value prior to LCM treatment in study SP0961.
Note: Minimum (Maximum) Post-BL=Minimum (Maximum) of all reported values during the Treatment Period.
Reference: Subject Data Listing 6.2.1

表 2.3-14　血液生化学検査の測定値及びベースラインからの変化量：SS（続き）

Table 11.2.1
Laboratory Parameters (Chemistry) Summary
Population: Safety Set

	Actual Value					Change From Baseline				
Visit	n	Mean	SD	Median	Min	Max	n	Mean	SD	Median	Min	Max
Lab Parameter: Potassium (mmol/L)												
Baseline	39	4.29	0.36	4.30	3.0	5.0						
Visit 3 (Week 8)	38	4.22	0.35	4.20	3.5	5.0	38	-0.06	0.41	-0.10	-0.7	1.4
Visit 5 (Week 24)	34	4.28	0.32	4.30	3.6	5.0	34	-0.03	0.34	-0.05	-0.6	0.6
Termination Visit	37	4.32	0.46	4.50	3.3	5.2	37	0.02	0.44	0.00	-0.9	0.8
Final Clinic Visit	36	4.28	0.40	4.20	3.4	5.0	36	-0.03	0.34	-0.05	-0.7	0.6
Min Post-BL	39	3.99	0.32	3.90	3.3	4.7	39	-0.30	0.30	-0.30	-0.9	0.4
Max Post-BL	39	4.54	0.33	4.50	3.9	5.2	39	0.24	0.36	0.20	-0.3	1.4

Note: Baseline = last non-missing value prior to LCM treatment in study SP0961.
Note: Minimum (Maximum) Post-BL=Minimum (Maximum) of all reported values during the Treatment Period.
Reference: Subject Data Listing 6.2.1

表 2.3-14　血液生化学検査の測定値及びベースラインからの変化量：SS（続き）

Table 11.2.1
Laboratory Parameters (Chemistry) Summary
Population: Safety Set

	Actual Value					Change From Baseline				
Visit	n	Mean	SD	Median	Min	Max	n	Mean	SD	Median	Min	Max
Lab Parameter: Sodium (mmol/L)												
Baseline	39	141.23	1.95	141.00	137.0	146.0						
Visit 3 (Week 8)	38	141.47	1.81	141.50	138.0	145.0	38	0.32	2.16	0.00	-6.0	4.0
Visit 5 (Week 24)	35	141.49	2.37	142.00	134.0	145.0	35	0.31	2.52	0.00	-4.0	8.0
Termination Visit	39	141.36	1.68	141.00	137.0	144.0	39	0.13	2.10	0.00	-5.0	4.0
Final Clinic Visit	36	141.17	1.95	141.00	137.0	145.0	36	-0.14	2.44	-0.50	-5.0	6.0
Min Post-BL	39	139.92	1.77	140.00	134.0	143.0	39	-1.31	1.98	-1.00	-6.0	4.0
Max Post-BL	39	142.82	1.59	143.00	140.0	145.0	39	1.59	2.34	2.00	-4.0	8.0

Note: Baseline = last non-missing value prior to LCM treatment in study SP0961.
Note: Minimum (Maximum) Post-BL=Minimum (Maximum) of all reported values during the Treatment Period.
Reference: Subject Data Listing 6.2.1

表 2.3-14　血液生化学検査の測定値及びベースラインからの変化量：SS（続き）

Table 11.2.1
Laboratory Parameters (Chemistry) Summary
Population: Safety Set

	Actual Value					Change From Baseline				
Visit	n	Mean	SD	Median	Min	Max	n	Mean	SD	Median	Min	Max
Lab Parameter: Glucose (mmol/L)												
Baseline	39	5.14	2.21	4.77	3.6	18.0						
Visit 3 (Week 8)	38	5.49	2.06	4.94	3.8	15.6	38	0.36	1.34	0.28	-2.4	4.9
Visit 5 (Week 24)	35	5.01	0.97	4.94	3.3	8.9	35	-0.14	1.76	0.11	-9.2	1.8
Termination Visit	37	5.32	1.83	5.00	3.1	15.0	37	0.11	1.12	0.06	-3.1	2.2
Final Clinic Visit	36	5.50	2.48	4.91	3.9	19.0	36	0.31	1.21	0.28	-1.7	5.3
Min Post-BL	39	4.45	0.89	4.44	3.1	8.9	39	-0.69	1.57	-0.50	-9.2	1.3
Max Post-BL	39	6.34	2.35	5.72	4.8	19.0	39	1.20	1.27	0.94	-1.1	5.3

Note: Baseline = last non-missing value prior to LCM treatment in study SP0961.
Note: Minimum (Maximum) Post-BL=Minimum (Maximum) of all reported values during the Treatment Period.
Reference: Subject Data Listing 6.2.1

表 2.3-14　血液生化学検査の測定値及びベースラインからの変化量：SS（続き）

Table 11.2.1
Laboratory Parameters (Chemistry) Summary
Population: Safety Set

	Actual Value					Change From Baseline				
Visit	n	Mean	SD	Median	Min	Max	n	Mean	SD	Median	Min	Max
Lab Parameter: Urate (umol/L)												
Baseline	39	275.29	75.41	273.61	142.8	434.2						
Visit 3 (Week 8)	38	286.29	86.24	270.63	166.5	493.7	38	11.74	43.92	8.92	-113.0	130.9
Visit 5 (Week 24)	35	300.97	101.40	297.40	89.2	594.8	35	23.45	78.50	17.84	-83.3	279.6
Termination Visit	39	278.64	72.25	279.56	130.9	452.0	39	3.36	42.95	-5.95	-101.1	83.3
Final Clinic Visit	36	286.50	80.43	273.61	160.6	547.2	36	7.44	48.16	11.90	-119.0	119.0
Min Post-BL	39	248.29	69.39	231.97	89.2	422.3	39	-26.99	43.02	-11.90	-119.0	41.6
Max Post-BL	39	334.16	96.77	321.19	184.4	594.8	39	58.87	62.42	47.58	-11.9	279.6

Note: Baseline = last non-missing value prior to LCM treatment in study SP0961.
Note: Minimum (Maximum) Post-BL=Minimum (Maximum) of all reported values during the Treatment Period.
Reference: Subject Data Listing 6.2.1

表 2.3-15　バイタルサインの測定値及びベースラインからの変化量：SS

Table 12.1.1
Vital Signs Summary
Population: Safety Set

	Actual Value						Change From Baseline					
Visit	n	Mean	SD	Median	Min	Max	n	Mean	SD	Median	Min	Max
Systolic Blood Pressure (mmHg)												
Baseline	39	116.0	13.31	115.0	89.0	143.0						
Visit 5 (Week 24)	35	116.3	10.61	114.0	99.0	146.0	35	2.3	9.48	2.0	-22.0	18.0
Termination Visit	39	118.3	13.11	118.0	96.0	158.0	39	2.3	12.62	1.0	-21.0	31.0
Final Clinic Visit	37	117.9	12.72	118.0	86.0	143.0	37	2.4	12.21	2.0	-28.0	23.0
Minimum Post-BL	39	114.1	11.28	112.0	92.0	146.0	39	-1.9	9.73	-3.0	-22.0	18.0
Maximum Post-BL	39	121.2	12.20	120.0	100.0	158.0	39	5.2	11.78	2.0	-21.0	31.0
Diastolic Blood Pressure (mmHg)												
Baseline	39	74.6	8.99	73.0	58.0	96.0						
Visit 5 (Week 24)	35	76.3	10.02	76.0	58.0	92.0	35	2.8	10.15	0.0	-11.0	32.0
Termination Visit	39	74.9	9.04	74.0	57.0	92.0	39	0.4	10.99	-2.0	-20.0	30.0
Final Clinic Visit	37	78.3	10.25	78.0	54.0	101.0	37	3.7	10.78	4.0	-14.0	28.0
Minimum Post-BL	39	72.2	8.74	72.0	57.0	90.0	39	-2.3	9.65	-4.0	-20.0	20.0
Maximum Post-BL	39	78.9	9.22	78.0	60.0	92.0	39	4.3	11.39	4.0	-20.0	32.0

Note: Baseline = last non-missing value prior to LCM treatment in study SP0961.
Note: Minimum (Maximum) Post-BL=Minimum (Maximum) of all reported values during the Treatment Period.
Reference: Subject Data Listing 7.1.1

表 2.3-15　バイタルサインの測定値及びベースラインからの変化量：SS（続き）

Table 12.1.1
Vital Signs Summary
Population: Safety Set

	Actual Value						Change From Baseline					
Visit	n	Mean	SD	Median	Min	Max	n	Mean	SD	Median	Min	Max
Pulse Rate (bpm)												
Baseline	39	72.3	11.71	68.0	50.0	100.0						
Visit 5 (Week 24)	35	76.8	10.51	76.0	56.0	101.0	35	5.1	10.36	5.0	-18.0	22.0
Termination Visit	39	77.0	11.43	78.0	54.0	106.0	39	4.7	8.90	2.0	-18.0	24.0
Final Clinic Visit	37	75.8	11.34	75.0	51.0	103.0	37	3.3	12.57	2.0	-22.0	36.0
Minimum Post-BL	39	72.5	9.48	72.0	54.0	92.0	39	0.2	8.56	0.0	-18.0	18.0
Maximum Post-BL	39	81.2	10.16	80.0	60.0	101.0	39	8.9	8.26	8.0	-4.0	24.0
Weight (kg)												
Baseline	39	77.7	17.58	74.4	42.2	113.4						
Visit 5 (Week 24)	34	80.0	19.40	73.8	47.6	110.2	34	2.4	5.15	2.3	-8.8	18.2
Termination Visit	39	81.5	18.35	78.7	49.4	118.8	39	3.9	7.15	5.0	-15.2	25.0
Final Clinic Visit	37	82.1	18.91	81.6	49.4	118.4	37	4.2	7.13	5.9	-13.6	22.7
Minimum Post-BL	39	79.2	17.87	76.3	47.6	110.2	39	1.5	5.70	2.2	-15.2	18.2
Maximum Post-BL	39	82.3	18.62	78.7	49.4	118.8	39	4.6	6.50	5.2	-7.5	25.0

Note: Baseline = last non-missing value prior to LCM treatment in study SP0961.
Note: Minimum (Maximum) Post-BL=Minimum (Maximum) of all reported values during the Treatment Period.
Reference: Subject Data Listing 7.1.1

2.3.4 有効性関連

2.3.4.1 発作回数

2.3.4.1.1 欠神発作発現日数の変化量及び変化率

本治験の FAS での治療期間における 28 日あたりの欠神発作発現日数及び Prospective ベースライン期間に対する変化量を表 2.3-16 に、治療期間における 28 日あたりの欠神発作発現日数の変化率を表 2.3-17 に示した。

28 日あたりの欠神発作発現日数は、全体的に維持又は減少した。28 日あたりの欠神発作発現日数の平均値は、Prospective ベースライン期間では 4.94 日、治療期間では 2.56 日であり、変化量の平均値は−2.38 日であった。また、Prospective ベースライン期間中に欠神発作を発現した被験者での治療期間の 28 日あたりの欠神発作発現日数の変化率の中央値は−66.7%であった。

表 2.3-16　治療期間における 28 日あたりの欠神発作発現日数及び Prospective ベースライン期間に対する変化量：FAS

Table 6.1.1

Change in the Number of Days with Absence Seizures per 28 days by Time Interval During the Treatment Period

Population: Full Analysis Set

		Actual Value						Change From Baseline				
Time Interval	n	Mean	SD	Med	Min	Max	n	Mean	SD	Med	Min	Max
Prospective Baseline	39	4.94	9.08	0.00	0.0	28.0						
0 to 6 months	39	2.62	6.23	0.00	0.0	27.2	39	-2.32	5.22	0.00	-19.3	4.3
>6 to 12 months	36	2.01	5.26	0.00	0.0	20.8	36	-2.56	5.95	0.00	-22.3	4.3
0 to 12 months	39	2.59	6.28	0.00	0.0	27.2	39	-2.35	5.40	0.00	-20.8	2.3
Treatment Period	39	2.56	6.32	0.00	0.0	27.2	39	-2.38	5.54	0.00	-21.7	2.7

Note: One month corresponds to 28 days.
Note: Prospective Baseline = the 4-week Baseline Phase of study SP0961.
Reference: Subject Data Listings 3.1.1 and 3.2.1

表 2.3-17　治療期間における 28 日あたりの欠神発作発現日数の変化率：FAS

Table 6.3.1

Percent Change in the Number of Days with Absence Seizures per 28 days by Time Interval During the Treatment Period

Population: Full Analysis Set

Time Interval	n	Mean	SD	Med	Min	Max
0 to 6 months	13	-43.2	56.3	-62.5	-100	111
>6 to 12 months	12	-61.1	44.9	-81.5	-100	30
0 to 12 months	13	-49.4	43.6	-66.7	-100	23
Treatment Period	13	-51.6	41.3	-66.7	-100	19

Note: One month corresponds to 28 days.

Reference: Subject Data Listings 3.1.1 and 3.2.1

2.3.4.1.2 ミオクロニー発作発現日数の変化量及び変化率

本治験の FAS での治療期間における 28 日あたりのミオクロニー発作発現日数及び Prospective ベースライン期間に対する変化量を表 2.3-18 に、治療期間における 28 日あたりのミオクロニー発作発現日数の変化率を表 2.3-19 に示した。

28 日あたりのミオクロニー発作発現日数は、維持又は減少した。28 日あたりのミオクロニー発作発現日数の平均値は、Prospective ベースライン期間では 4.32 日、治療期間では 1.54 日であり、変化量の平均値は−2.78 日であった。また、Prospective ベースライン期間中にミオクロニー発作を発現した被験者での治療期間の 28 日あたりのミオクロニー発作発現日数の変化率の中央値は−84.7%であった。

表 2.3-18　治療期間における 28 日あたりのミオクロニー発作発現日数及び Prospective ベースライン期間に対する変化量：FAS

Table 6.2.1

Change in the Number of Days with Myoclonic Seizures per 28 days by Time Interval During the Treatment Period

Population: Full Analysis Set

		Actual Value						Change From Baseline				
Time Interval	n	Mean	SD	Med	Min	Max	n	Mean	SD	Med	Min	Max
Prospective Baseline	39	4.32	7.69	0.00	0.0	27.0						
0 to 6 months	39	1.68	5.05	0.00	0.0	28.0	39	-2.63	6.40	0.00	-26.5	4.0
>6 to 12 months	36	1.68	5.23	0.00	0.0	28.0	36	-2.39	5.97	0.00	-26.5	4.2
0 to 12 months	39	1.63	4.97	0.00	0.0	28.0	39	-2.69	6.39	0.00	-26.5	4.0
Treatment Period	39	1.54	4.82	0.00	0.0	27.5	39	-2.78	6.43	0.00	-26.5	3.5

Note: One month corresponds to 28 days.
Note: Prospective Baseline = the 4-week Baseline Phase of study SP0961.
Reference: Subject Data Listings 3.1.1 and 3.2.1

表 2.3-19　治療期間における 28 日あたりのミオクロニー発作発現日数の変化率：FAS

Table 6.4.1

Percent Change in the Number of Days with Myoclonic Seizures per 28 days by Time Interval During the Treatment Period

Population: Full Analysis Set

Time Interval	n	Mean	SD	Med	Min	Max
0 to 6 months	13	-63.1	43.5	-75.1	-100	17
>6 to 12 months	12	-71.0	44.1	-91.9	-100	17
0 to 12 months	13	-66.9	40.7	-80.6	-100	17
Treatment Period	13	-68.9	39.9	-84.7	-100	15

Note: One month corresponds to 28 days.

Reference: Subject Data Listings 3.1.1 and 3.2.1

2.3.4.1.3 強直間代発作

本治験の FAS での Combined ベースライン期間に対する治療期間の 28 日あたりの強直間代発作回数の変化率を期間別に表 2.3-20 に、Prospective ベースライン期間に対する治療期間の 28 日あたりの強直間代発作回数の変化率を期間別に表 2.3-21 に示した。また、治療期間における 6 及び 12 ヵ月間の強直間代発作の消失状態を表 2.3-22 に示した。

Combined ベースライン期間及び Prospective ベースライン期間に対する治療期間の 28 日あたりの強直間代発作回数の変化率の中央値は、それぞれ−72.3%及び−89.3%であった。強直間代発作を 6 及び 12 ヵ月間消失状態であった被験者は、それぞれ 25 例（64.1%）及び 14 例（35.9%）であった。

表 2.3-20　Combined ベースライン期間に対する治療期間の 28 日あたりの強直間代発作回数の変化率：FAS

Table 6.5.1

Percent Change in PGTC Seizure Frequency per 28 Days from the Combined Baseline Phase by Time Interval

Population: Full Analysis Set

Time Interval	n	Mean	SD	Med	Min	Max
0 to 6 months	39	-46.6	80.7	-100.0	-100	234
>6 to 12 months	36	-58.0	68.5	-100.0	-100	167
0 to 12 months	39	-44.0	80.5	-80.0	-100	234
Treatment Period	39	-45.8	76.7	-72.3	-100	234

Note: One month corresponds to 28 days.

Note: Combined Baseline = the 16-week Combined Historical and Baseline Phases of study SP0961.

Reference: Subject Data Listings 3.1.1 and 3.3.1

表 2.3-21　Prospective ベースライン期間に対する治療期間の 28 日あたりの強直間代発作回数の変化率：FAS

Table 6.6.1

Percent Change in PGTC Seizure Frequency per 28 Days from the Prospective Baseline Phase by Time Interval

Population: Full Analysis Set

Time Interval	n	Mean	SD	Med	Min	Max
0 to 6 months	23	-71.9	40.6	-100.0	-100	37
>6 to 12 months	21	-72.0	40.2	-87.9	-100	33
0 to 12 months	23	-70.1	39.7	-92.0	-100	25
Treatment Period	23	-70.7	37.9	-89.3	-100	30

Note: One month corresponds to 28 days.
Note: Prospective Baseline = the 4-week Baseline Phase of study SP0961.
Reference: Subject Data Listings 3.1.1 and 3.3.1

表 2.3-22　治療期間における強直間代発作の消失状態：FAS

Table 7.1.1
Summary of PGTC Seizure-Free Status During the Treatment Period
Population: Full Analysis Set

		Seizure-Free Status	
		Yes	No
Period	n	n %	n %
6 Months	39	25 (64.1)	14 (35.9)
1 Year	39	14 (35.9)	25 (64.1)

Note: One month corresponds to 28 days.
Note: Percentages are based on the number of subjects in the FAS.
Reference: Subject Data Listings 3.1.1 and 3.4.1

2.3.4.2 探索的評価項目

2.3.4.2.1 臨床全般評価の変化／被験者による全般評価の変化

本治験の FAS での第 5 回来院時及び最終の規定来院時における臨床全般評価の変化を表 2.3-23 に、被験者による全般評価の変化を表 2.3-24 に示した。

臨床全般評価及び被験者による全般評価は、いずれも治療期間を通じて、ほとんどの被験者で改善が認められた（第 5 回来院時：各 94.3%）。これは、強直間代発作を有するてんかん患者に対するラコサミド投与が有効であることを支持するものであった。

表 2.3-23　臨床全般評価の変化：FAS

Table 8.1.1
Clinical Global Impression of Change Summary
Population: Full Analysis Set

Visit	Impression of Change	N = 39 n (%)
Visit 5	Total	35 (100)
	Very Much Improved	13 (37.1)
	Much Improved	13 (37.1)
	Minimally Improved	7 (20.0)
	No Change	2 (5.7)
	Minimally Worse	0
	Much Worse	0
	Very Much Worse	0
	Improved	33 (94.3)
	No Change	2 (5.7)
	Worsened	0

Note: Percentages are based on the number of subjects with available data at a given visit.
Note: The category of Worsened represents the sum of Minimally Worse, Much Worse, and Very Much Worse. The category of Improved represents the sum of Very Much Improved, Much Improved, and Minimally Improved.
Reference: Subject Data Listing 3.5.1

表 2.3-23　臨床全般評価の変化：FAS（続き）

Table 8.1.1
Clinical Global Impression of Change Summary
Population: Full Analysis Set

Visit	Impression of Change	N = 39 n (%)
Termination Visit	Total	39 (100)
	Very Much Improved	11 (28.2)
	Much Improved	17 (43.6)
	Minimally Improved	6 (15.4)
	No Change	5 (12.8)
	Minimally Worse	0
	Much Worse	0
	Very Much Worse	0
	Improved	34 (87.2)
	No Change	5 (12.8)
	Worsened	0

Note: Percentages are based on the number of subjects with available data at a given visit.
Note: The category of Worsened represents the sum of Minimally Worse, Much Worse, and Very Much Worse. The category of Improved represents the sum of Very Much Improved, Much Improved, and Minimally Improved.
Reference: Subject Data Listing 3.5.1

表 2.3-24　被験者による全般評価の変化：FAS

Table 8.2.1
Patient Global Impression of Change Summary
Population: Full Analysis Set

Visit	Impression of Change	N = 39 n (%)
Visit 5	Total	35 (100)
	Very Much Improved	16 (45.7)
	Much Improved	10 (28.6)
	Minimally Improved	7 (20.0)
	No Change	2 (5.7)
	Minimally Worse	0
	Much Worse	0
	Very Much Worse	0
	Improved	33 (94.3)
	No Change	2 (5.7)
	Worsened	0

Note: Percentages are based on the number of subjects with available data at a given visit.
Note: The category of Worsened represents the sum of Minimally Worse, Much Worse, and Very Much Worse. The category of Improved represents the sum of Very Much Improved, Much Improved, and Minimally Improved.
Reference: Subject Data Listing 3.5.1

表 2.3-24　被験者による全般評価の変化：FAS（続き）

Table 8.2.1
Patient Global Impression of Change Summary
Population: Full Analysis Set

Visit	Impression of Change	N = 39 n (%)
Termination Visit	Total	39 (100)
	Very Much Improved	20 (51.3)
	Much Improved	11 (28.2)
	Minimally Improved	2 (5.1)
	No Change	3 (7.7)
	Minimally Worse	3 (7.7)
	Much Worse	0
	Very Much Worse	0
	Improved	33 (84.6)
	No Change	3 (7.7)
	Worsened	3 (7.7)

Note: Percentages are based on the number of subjects with available data at a given visit.
Note: The category of Worsened represents the sum of Minimally Worse, Much Worse, and Very Much Worse. The category of Improved represents the sum of Very Much Improved, Much Improved, and Minimally Improved.
Reference: Subject Data Listing 3.5.1

2.3.5 結論

発作コントロールが得られていない強直間代発作を有するてんかん患者にラコサミドを長期（12ヵ月超）投与した結果、安全性上の重大な懸念事項は認められなかった。強直間代発作に関連する有害事象（医師記載用語：小発作てんかん及びミオクロニー発作）を除き、本治験の有害事象のプロファイルは、部分発作を有するてんかん患者を対象としたラコサミド併用療法の臨床試験の有害事象のプロファイルと類似していた。

強直間代発作を有するてんかん患者にラコサミドを 12 ヵ月超投与した結果、欠神発作及びミオクロニー発作発現日数の増加は認められなかった。本治験の被験者は、短期投与試験である SP0961 試験に登録しており、本治験では全体的に欠神発作及びミオクロニー発作発現日数の維持又は減少が認められた。